<SEC-DOCUMENT>0001654954-22-001491.txt : 20220211
<SEC-HEADER>0001654954-22-001491.hdr.sgml : 20220211
<ACCEPTANCE-DATETIME>20220211161635
ACCESSION NUMBER:		0001654954-22-001491
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220211
DATE AS OF CHANGE:		20220211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		22621168

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:cvm="http://cvm.com/20211231"><head><title>cvm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:left;font:10pt times new roman"><div style='display:none;text-align:left;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2021-10-01to2021-12-31">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2021-10-01to2021-12-31" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2021-10-01to2021-12-31">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2021-10-01to2021-12-31">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2021-10-01to2021-12-31">2022</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">2000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">43207183</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" unitRef="Shares" decimals="0">43259013</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-10-01to2021-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:FairValueOfSeriesZwarrants" contextRef="AsOf2021-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:FairValueOfSeriesCcWarrants" contextRef="AsOf2021-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:GainLossSeriesWWarrants" contextRef="From2021-10-01to2021-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:GainLossSeriesZzWarrants" contextRef="From2021-10-01to2021-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:GainLossSeriesBbWarrants" contextRef="From2021-10-01to2021-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:DerivativeVariableInterestRate" contextRef="AsOf2021-12-31_cvm_LandlordMember" unitRef="Pure" decimals="INF">0.000845</ix:nonFraction><ix:nonFraction name="cvm:CurrentBalance" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" unitRef="USD" decimals="0">600000.0</ix:nonFraction><ix:nonFraction name="cvm:CurrentBalance" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" unitRef="USD" decimals="0">100000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" unitRef="USD" decimals="0">2100000.0</ix:nonFraction><ix:nonFraction name="cvm:CashPaidRelatedToFinanceLeasesInterest" contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" unitRef="USD" decimals="0">300000.0</ix:nonFraction><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="From2021-10-01to2021-12-31_cvm_ErgomedMember">P7Y1M6D</ix:nonNumeric><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-10-01to2021-12-31" unitRef="USD" decimals="0">14000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='cvm-20211231.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2021-10-01to2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-08-01to2020-08-31_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_srt_OfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-07_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesXWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-07_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesUUWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesNWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_ConsultantsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-10-28_cvm_SeriesWWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:SeriesWWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-10-28_cvm_SeriesWWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:SeriesWWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_DecemberTwoThousandTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:DecemberTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_DecemberTwoThousandTwentyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:DecemberTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-08-21to2021-08-22_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-21</xbrli:startDate><xbrli:endDate>2021-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-08-22_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-11-23_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-11-22to2021-11-23_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_cvm_SeriesCcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesCcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-12-01to2021-12-08_cvm_SeriesCcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_srt_MaximumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_srt_MinimumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesAaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesHhMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_srt_MaximumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_srt_MinimumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesAaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesHhMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-10-01to2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-02-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">December 31, 2021</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For the transition period from _______________ to ______________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Commission File Number <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityFileNumber">001-11889</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityRegistrantName">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160; <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">84-0916344</ix:nonNumeric> </strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;State or other jurisdiction incorporation</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;(IRS) Employer Identification Number</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;<strong><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressAddressLine1">8229 Boone Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressAddressLine2">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;<span style="text-decoration:underline"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressCityOrTown">Vienna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric> <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressPostalZipCode">22182</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Address of principal executive offices</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;<span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:CityAreaCode">703</ix:nonNumeric>) <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:LocalPhoneNumber">506-9460</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Registrant's telephone number, including area code</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading Symbol(s)</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of Each Exchange on Which Registered</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:TradingSymbol">CVM</ix:nonNumeric> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#9746; </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Yes <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Class of Stock</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;No. Shares Outstanding</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Common </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonFraction contextRef="AsOf2022-02-02" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,275,738</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">February 2, 2022</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="toc">TABLE OF CONTENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>PART I FINANCIAL INFORMATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Item 1.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Page</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#bs">Condensed Balance Sheets at December 31, 2021 (unaudited) and September 30, 2021 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#sto">Condensed Statements of Operations for the three months ended December 31, 2021 and 2020 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#eqt">Condensed Statement of Stockholders&#8217; Equity for the three months ended December 31, 2021 and 2020 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#cf">Condensed Statements of Cash Flows for the three months ended December 31, 2021 and 2020 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#cf">Notes to Condensed Financial Statements<strong>&#160;</strong>(unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i2">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i3">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i3">Quantitative and Qualitative Disclosures about Market Risks</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">23</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i4">Item 4.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i4">Controls and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">23</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><a href="#p2">PART II</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i2n">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i2n">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">24</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i6">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#i6">Exhibits</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">25</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="#sig">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">26</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="bs">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">CONDENSED BALANCE SHEETS</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>DECEMBER 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SEPTEMBER 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">ASSETS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>(UNAUDITED)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_847" contextRef="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,109,917</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_848" contextRef="AsOf2021-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,060,148</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">U.S. Treasury Bills</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_849" contextRef="AsOf2021-12-31" name="us-gaap:ShortTermInvestments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_850" contextRef="AsOf2021-09-30" name="us-gaap:ShortTermInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,151,385</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_851" contextRef="AsOf2021-12-31" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,922</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_852" contextRef="AsOf2021-09-30" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,922</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_853" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">723,782</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_854" contextRef="AsOf2021-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,482</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_855" contextRef="AsOf2021-12-31" name="cvm:SuppliesUsedForRdAndManufacturing" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,067,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_856" contextRef="AsOf2021-09-30" name="cvm:SuppliesUsedForRdAndManufacturing" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,006,584</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Short-term deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1165" contextRef="AsOf2021-12-31" name="cvm:ShortTermDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,910,917</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1166" contextRef="AsOf2021-09-30" name="cvm:ShortTermDeposits" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_859" contextRef="AsOf2021-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,867,261</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_860" contextRef="AsOf2021-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,271,521</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Finance lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_861" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,252,663</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_862" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,691,921</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_863" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,014,185</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_864" contextRef="AsOf2021-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,056,178</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_865" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,290,109</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_866" contextRef="AsOf2021-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,663,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,521</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_868" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,866</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_869" contextRef="AsOf2021-12-31" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_870" contextRef="AsOf2021-09-30" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,910,917</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_871" contextRef="AsOf2021-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,671,739</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_872" contextRef="AsOf2021-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,869,965</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_875" contextRef="AsOf2021-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,192,825</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_876" contextRef="AsOf2021-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,675,813</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_877" contextRef="AsOf2021-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">899,901</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_878" contextRef="AsOf2021-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,216</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_879" contextRef="AsOf2021-12-31" name="us-gaap:DueToOfficersOrStockholdersCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">475,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_880" contextRef="AsOf2021-09-30" name="us-gaap:DueToOfficersOrStockholdersCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,993</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Derivative instruments, current portion </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_881" contextRef="AsOf2021-12-31" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_882" contextRef="AsOf2021-09-30" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease liabilities, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_883" contextRef="AsOf2021-12-31" name="cvm:LeaseLiabilitiesCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">763,535</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_884" contextRef="AsOf2021-09-30" name="cvm:LeaseLiabilitiesCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">698,665</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_885" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,333,495</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_886" contextRef="AsOf2021-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,937,067</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_913" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,880,449</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_914" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,252,364</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_921" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,981,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_922" contextRef="AsOf2021-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,021,308</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_889" contextRef="AsOf2021-12-31" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_890" contextRef="AsOf2021-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_891" contextRef="AsOf2021-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,320,284</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_892" contextRef="AsOf2021-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,335,739</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Commitments and contingencies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_1184" contextRef="AsOf2021-12-31" name="us-gaap:CommitmentsAndContingencies" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_1185" contextRef="AsOf2021-09-30" name="us-gaap:CommitmentsAndContingencies" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_578" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction>par value-<ix:nonFraction id="fid_580" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction>shares authorized; -<ix:nonFraction id="fid_582" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction>- shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_917" contextRef="AsOf2021-12-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_918" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_909" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction>par value - <ix:nonFraction id="fid_910" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600,000,000</ix:nonFraction>shares authorized; <ix:nonFraction id="fid_911" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,259,013</ix:nonFraction>and <ix:nonFraction id="fid_595" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,207,183</ix:nonFraction>shares issued and outstanding at December 31, 2021 and September 30, 2021, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_919" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,590</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_920" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_896" contextRef="AsOf2021-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,897,883</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_897" contextRef="AsOf2021-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,298,566</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_898" contextRef="AsOf2021-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">426,979,018</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_899" contextRef="AsOf2021-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">418,196,412</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_900" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,351,455</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_901" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,534,226</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_902" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,671,739</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_903" contextRef="AsOf2021-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,869,965</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="sto">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">CONDENSED STATEMENTS OF OPERATIONS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2021 and 2020</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_924" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,083,167</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_925" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,414,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_926" contextRef="From2021-10-01to2021-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,760,208</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_927" contextRef="From2020-10-01to2020-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,316,156</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_928" contextRef="From2021-10-01to2021-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,843,375</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_929" contextRef="From2020-10-01to2020-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,730,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_930" contextRef="From2021-10-01to2021-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,843,375</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_931" contextRef="From2020-10-01to2020-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,730,916</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gain on derivative instruments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_932" contextRef="From2021-10-01to2021-12-31" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,596</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_933" contextRef="From2020-10-01to2020-12-31" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">932,836</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other non-operating gains</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_934" contextRef="From2021-10-01to2021-12-31" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,793</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_935" contextRef="From2020-10-01to2020-12-31" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,606</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_936" contextRef="From2021-10-01to2021-12-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">273,034</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_937" contextRef="From2020-10-01to2020-12-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">260,390</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_938" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_939" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,936,864</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_941" contextRef="From2020-10-01to2020-12-31" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">85,779</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_942" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_943" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,022,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">BASIC and DILUTED</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_945" contextRef="From2021-10-01to2021-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_946" contextRef="From2020-10-01to2020-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.21</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Weighted average common shares outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">BASIC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_948" contextRef="From2021-10-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,077,961</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_949" contextRef="From2020-10-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,670,247</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">DILUTED</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_950" contextRef="From2021-10-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,083,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_951" contextRef="From2020-10-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,767,286</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">See notes to condensed financial statements.</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="eqt">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">STATEMENTS OF STOCKHOLDERS' EQUITY</p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-In</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">BALANCES AT OCTOBER 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1176" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,207,183</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_990" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1177" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,298,566</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1178" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">418,196,412</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1179" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,534,226</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_957" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">19,705</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_958" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_959" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,757</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1015" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_961" contextRef="From2021-10-01to2021-12-31" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,954</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_962" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_963" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,262,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1020" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_965" contextRef="From2021-10-01to2021-12-31" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,262,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_966" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,605</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_967" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_968" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,479</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_970" contextRef="From2021-10-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,555</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock and options issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_971" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">18,020</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_972" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_973" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1030" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_975" contextRef="From2021-10-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,160</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_976" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_977" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_978" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,770</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_980" contextRef="From2021-10-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,835</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1041" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_982" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">45,965</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1043" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_984" contextRef="From2021-10-01to2021-12-31" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">45,965</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1045" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_987" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_988" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">BALANCES AT DECEMBER 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_989" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,259,013</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1170" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,590</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_991" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,897,883</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_992" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">426,979,018</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_993" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,351,455</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-In</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Shares </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">BALANCES AT OCTOBER 1, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1171" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,730,150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1050" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,302</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1172" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,174,675</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1173" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">381,835,303</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1174" contextRef="AsOf2020-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,726,674</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1007" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:ProceedsFromTheSaleOfCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1008" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:ProceedsFromTheSaleOfCommonStockAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1009" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ProceedsFromTheSaleOfCommonStockAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,549,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1010" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="cvm:ProceedsFromTheSaleOfCommonStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1011" contextRef="From2020-10-01to2020-12-31" name="cvm:ProceedsFromTheSaleOfCommonStockAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,559,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1012" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1013" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1014" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_960" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1016" contextRef="From2020-10-01to2020-12-31" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1017" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:EquityBasedCompensationEmployeesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1018" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1019" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,329</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_964" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1021" contextRef="From2020-10-01to2020-12-31" name="cvm:EquityBasedCompensationEmployeesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,309</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1022" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,564</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1023" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1024" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_969" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" contextRef="From2020-10-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,671</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock and options issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,044</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1028" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1029" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_974" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1031" contextRef="From2020-10-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,450</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1032" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1033" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1034" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,458</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_979" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1036" contextRef="From2020-10-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,511</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1037" contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="cvm:ModificationOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1040" contextRef="From2020-10-01to2020-12-31" name="cvm:ModificationOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_981" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1042" contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">117,021</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_983" contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1044" contextRef="From2020-10-01to2020-12-31" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">117,021</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_985" contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_986" contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1047" contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,936,864</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1048" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,936,864</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">BALANCES AT DECEMBER 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">39,767,058</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1168" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">397,671</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1051" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,210,168</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1052" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">389,772,167</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,835,672</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;&#160; &#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="cf">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2021 and 2020</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1054" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1055" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,936,864</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1058" contextRef="From2021-10-01to2021-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">887,930</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1059" contextRef="From2020-10-01to2020-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,682</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1060" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,318</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1061" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,660</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,262,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1063" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,309</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1064" contextRef="From2021-10-01to2021-12-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,555</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1065" contextRef="From2020-10-01to2020-12-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,671</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Gain on short-term investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1066" contextRef="From2021-10-01to2021-12-31" name="us-gaap:GainLossOnInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">615</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss on patent impairment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1068" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ImpairmentOfOngoingProject" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,793</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Gain on derivative instruments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1070" contextRef="From2021-10-01to2021-12-31" name="us-gaap:GainLossOnSaleOfDerivatives" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">364,596</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1071" contextRef="From2020-10-01to2020-12-31" name="us-gaap:GainLossOnSaleOfDerivatives" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">932,836</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1073" contextRef="From2020-10-01to2020-12-31" name="cvm:ModificationOfWarrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1076" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,328</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Prepaid expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1077" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1078" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">332,785</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1079" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncreaseDecreaseInMaterialsAndSupplies" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">61,139</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1082" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">523,152</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1083" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,685</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1085" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1086" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,718</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px;text-indent:8pt">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1088" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,997</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,319</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1090" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,805,946</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1091" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,827,899</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from maturity of US treasury bills</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1093" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,152,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1095" contextRef="From2021-10-01to2021-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,036</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1096" contextRef="From2020-10-01to2020-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,149,820</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1097" contextRef="From2021-10-01to2021-12-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,741</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Net cash provided by (used in) investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1099" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,112,223</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1100" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,149,820</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1103" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,559,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1104" contextRef="From2021-10-01to2021-12-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,800</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1105" contextRef="From2020-10-01to2020-12-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,499</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from exercises of warrants and options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1106" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1107" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments on obligations under finance lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1108" contextRef="From2021-10-01to2021-12-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,908</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1109" contextRef="From2020-10-01to2020-12-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,620</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Net cash (used in) provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1110" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">256,508</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1111" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,329,292</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET INCREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1112" contextRef="From2021-10-01to2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,769</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1113" contextRef="From2020-10-01to2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,351,573</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1114" contextRef="AsOf2021-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,060,148</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1115" contextRef="AsOf2020-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,508,909</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH AND CASH EQUIVALENTS, END OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1116" contextRef="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,109,917</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1117" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,860,482</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">See notes to condensed financial statements.</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2021 and 2020</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Property and equipment included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1119" contextRef="From2021-10-01to2021-12-31" name="cvm:PropertyPlantEquipmentIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,005</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1120" contextRef="From2020-10-01to2020-12-31" name="cvm:PropertyPlantEquipmentIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,700,969</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Capitalizable patent costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1122" contextRef="From2020-10-01to2020-12-31" name="cvm:CapitalizablePatentCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Finance lease obligation included in accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1123" contextRef="From2021-10-01to2021-12-31" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">771</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1124" contextRef="From2020-10-01to2020-12-31" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Prepaid consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1125" contextRef="From2021-10-01to2021-12-31" name="cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">233,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1126" contextRef="From2020-10-01to2020-12-31" name="cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercise of derivative liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1127" contextRef="From2021-10-01to2021-12-31" name="cvm:ExerciseOfDerivativeLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,589</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1128" contextRef="From2020-10-01to2020-12-31" name="cvm:ExerciseOfDerivativeLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,850</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1129" contextRef="From2021-10-01to2021-12-31" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,165</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1130" contextRef="From2020-10-01to2020-12-31" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,021</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160; Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1131" contextRef="From2021-10-01to2021-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,212</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1132" contextRef="From2020-10-01to2020-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,618</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">See notes to condensed financial statements.</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="nots">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>NOTES TO CONDENSED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>THREE MONTHS ENDED DECEMBER 31, 2021 AND 2020 (UNAUDITED)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1133" contextRef="From2021-10-01to2021-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_145de5"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2021 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2021 is derived from the September 30, 2021 audited financial statements.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1134" contextRef="From2021-10-01to2021-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1135" contextRef="From2021-10-01to2021-12-31" name="cvm:USTreasuryBills" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1136" contextRef="From2021-10-01to2021-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1145" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Patents</em> - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (<ix:nonNumeric id="fid_488" contextRef="From2021-10-01to2021-12-31_us-gaap_PatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear">17</ix:nonNumeric> years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1137" contextRef="From2021-10-01to2021-12-31" name="cvm:LeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p></ix:nonNumeric></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_145de5" continuedAt="cont_abc81a"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1138" contextRef="From2021-10-01to2021-12-31" name="us-gaap:DerivativesPolicyTextBlock" escape="true" continuedAt="cont_7b24c8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_7b24c8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company adopted Accounting Standards Update (ASU) 2020-06, <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </em>effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.</p></ix:continuation></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1139" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="cont_8aea38"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 <em>Compensation &#8211; Stock Compensation</em>. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_8aea38" continuedAt="cont_94eed8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p></ix:continuation></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_94eed8" continuedAt="cont_f1c770"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p></ix:continuation></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_f1c770"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:continuation></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1140" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1141" contextRef="From2021-10-01to2021-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_abc81a"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1142" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="cont_377908"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2021 and September 30, 2021.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_377908"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company adopted ASU No. 2019-12, <em>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </em>effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#8217;s financial statements.</p></ix:continuation></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1143" contextRef="From2021-10-01to2021-12-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.</p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:nonNumeric id="fid_1144" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="cont_52b3c7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>New Accounting Pronouncements</em></p></ix:nonNumeric></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_52b3c7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p></ix:continuation></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1146" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NatureOfOperations" escape="true" continuedAt="cont_50df4a"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">OPERATIONS AND FINANCING</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5 year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5 years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_50df4a"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Primarily as a result of the Company&#8217;s losses incurred to date, the Company&#8217;s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that here is sufficient cash on hand to meet the Company&#8217;s budgeted cash requirements, substantial doubt about the Company&#8217;s ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impact of the COVID-19 Pandemic</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In response to the global outbreak of COVID-19 and the World Health Organization&#8217;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention&#8217;s (&#8220;CDC&#8221;) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#8217;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1147" contextRef="From2021-10-01to2021-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_0a72de"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2020, the Company sold <ix:nonFraction id="fid_343" contextRef="From2021-10-01to2021-12-31_cvm_DecemberTwoThousandTwentyMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction>shares of common stock at a public offering price of $<ix:nonFraction id="fid_346" contextRef="AsOf2021-12-31_cvm_DecemberTwoThousandTwentyMember" name="us-gaap:SaleOfStockPricePerShare" decimals="INF" unitRef="USDPShares">14.65</ix:nonFraction> per share and received aggregate proceeds of approximately $<ix:nonFraction id="fid_391" contextRef="From2021-10-01to2021-12-31_cvm_DecemberTwoThousandTwentyMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.6</ix:nonFraction> million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Equity Compensation</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Underlying share information for equity compensation plans as of December 31, 2021 is as follows:</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_0a72de" continuedAt="cont_af1baa"><ix:nonNumeric id="fid_1154" contextRef="From2021-10-01to2021-12-31" name="cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" escape="true" continuedAt="cont_03d23d"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"><strong>Total Shares Reserved <br />Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"><strong>Shares <br />Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_160" contextRef="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_165" contextRef="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">76,829</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_167" contextRef="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">213</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_161" contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,787,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_166" contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,204,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_168" contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">172,592</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_162" contextRef="AsOf2021-12-31_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">783,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_172" contextRef="AsOf2021-12-31_cvm_StockBonusPlansMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">370,691</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_169" contextRef="AsOf2021-12-31_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">413,036</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_163" contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_173" contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">153,195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_170" contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">462,395</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_164" contextRef="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_174" contextRef="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">614,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_171" contextRef="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_af1baa" continuedAt="cont_45b02b"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Underlying share information for equity compensation plans as of September 30, 2021 is as follows:</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_45b02b" continuedAt="cont_e7677a"><ix:continuation id="cont_03d23d"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"><strong>Total Shares Reserved <br />Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"><strong>Shares <br />Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_175" contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_176" contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">76,829</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_177" contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">213</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_178" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,787,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_182" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,972,880</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_183" contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">410,592</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_179" contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">783,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_184" contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">363,086</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_185" contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">420,641</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_180" contextRef="AsOf2021-09-30_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_186" contextRef="AsOf2021-09-30_us-gaap_StockCompensationPlanMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">153,195</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_187" contextRef="AsOf2021-09-30_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">462,395</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_181" contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_188" contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">614,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_189" contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><ix:continuation id="cont_e7677a" continuedAt="cont_d92a75"><ix:nonNumeric id="fid_1155" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Stock option activity:</span></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended December31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_193" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">251,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_192" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_197" contextRef="From2021-10-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_196" contextRef="From2020-10-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_204" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_200" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">42,166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_202" contextRef="From2020-10-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">55</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_d92a75" continuedAt="cont_8d414a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the quarter ended December 31, 2021, the Company granted <ix:nonFraction id="fid_398" contextRef="From2021-10-01to2021-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:GrantPerformanceBasedStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">250,000</ix:nonFraction>performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction id="fid_400" contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:CommonStockPrice" decimals="INF" unitRef="USDPShares">10.48</ix:nonFraction>per share, the fair value on the date of issuance. The stock options will vest <ix:nonFraction id="fid_401" contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:StockOptionsVest" decimals="INF" unitRef="Pure" scale="-2">100</ix:nonFraction>% upon approval of the first marketing application for any pharmaceutical based upon the Company&#8217;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. All options which have not vested as of November 18, 2031 will be canceled. On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost is recognized relating to these options as of December 31, 2021. Management will re-assess the probability of achieving the performance condition at each reporting date.</p></ix:continuation></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_8d414a" continuedAt="cont_e72ec7"><ix:nonNumeric id="fid_1156" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Stock-Based Compensation Expense</span></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Three months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_207" contextRef="From2021-10-01to2021-12-31" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,262,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_205" contextRef="From2020-10-01to2020-12-31" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,309</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_211" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,318</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_209" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,660</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_e72ec7" continuedAt="cont_5b55f4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.</p></ix:continuation></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_5b55f4" continuedAt="cont_1cba5d"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><em>Warrants and Non-Employee Options</em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The following chart represents the warrants and non-employee options outstanding at December 31, 2021:</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_1cba5d" continuedAt="cont_4f7d5a"><ix:nonNumeric id="fid_1157" contextRef="From2021-10-01to2021-12-31" name="cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Warrant/Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>Shares Issuable upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"><strong>Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Reference</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_243" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNMember" name="cvm:IssueDate1">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_212" contextRef="AsOf2021-12-31_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_227" contextRef="AsOf2021-12-31_cvm_SeriesNMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"><ix:nonNumeric id="fid_261" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNMember" name="cvm:ExpirationDate">8/18/2022</ix:nonNumeric>&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_244" contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUMember" name="cvm:IssueDate1">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_213" contextRef="AsOf2021-12-31_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_228" contextRef="AsOf2021-12-31_cvm_SeriesUUMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"><ix:nonNumeric id="fid_262" contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUMember" name="cvm:ExpirationDate">6/30/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_245" contextRef="From2021-10-01to2021-12-31_cvm_SeriesXMember" name="cvm:IssueDate1">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_214" contextRef="AsOf2021-12-31_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_229" contextRef="AsOf2021-12-31_cvm_SeriesXMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"><ix:nonNumeric id="fid_260" contextRef="From2021-10-01to2021-12-31_cvm_SeriesXMember" name="cvm:ExpirationDate">7/13/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_246" contextRef="From2021-10-01to2021-12-31_cvm_SeriesYMember" name="cvm:IssueDate1">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_215" contextRef="AsOf2021-12-31_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_230" contextRef="AsOf2021-12-31_cvm_SeriesYMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"><ix:nonNumeric id="fid_263" contextRef="From2021-10-01to2021-12-31_cvm_SeriesYMember" name="cvm:ExpirationDate">8/15/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_250" contextRef="From2021-10-01to2021-12-31_cvm_SeriesHhMember" name="cvm:IssueDate1">2/23/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_219" contextRef="AsOf2021-12-31_cvm_SeriesHhMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_234" contextRef="AsOf2021-12-31_cvm_SeriesHhMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 8.1pt; text-align:right;"><ix:nonNumeric id="fid_267" contextRef="From2021-10-01to2021-12-31_cvm_SeriesHhMember" name="cvm:ExpirationDate">2/16/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_251" contextRef="From2021-10-01to2021-12-31_cvm_SeriesAaMember" name="cvm:IssueDate1">8/26/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_220" contextRef="AsOf2021-12-31_cvm_SeriesAaMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_235" contextRef="AsOf2021-12-31_cvm_SeriesAaMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_268" contextRef="From2021-10-01to2021-12-31_cvm_SeriesAaMember" name="cvm:ExpirationDate">2/22/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_252" contextRef="From2021-10-01to2021-12-31_cvm_SeriesMMMember" name="cvm:IssueDate1">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_221" contextRef="AsOf2021-12-31_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_236" contextRef="AsOf2021-12-31_cvm_SeriesMMMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_269" contextRef="From2021-10-01to2021-12-31_cvm_SeriesMMMember" name="cvm:ExpirationDate">6/22/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_253" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember" name="cvm:IssueDate1">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_222" contextRef="AsOf2021-12-31_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">205,587</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_237" contextRef="AsOf2021-12-31_cvm_SeriesNNMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_270" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember" name="cvm:ExpirationDate">7/24/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_254" contextRef="From2021-10-01to2021-12-31_cvm_SeriesRRMember" name="cvm:IssueDate1">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_223" contextRef="AsOf2021-12-31_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">251,761</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_238" contextRef="AsOf2021-12-31_cvm_SeriesRRMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_271" contextRef="From2021-10-01to2021-12-31_cvm_SeriesRRMember" name="cvm:ExpirationDate">10/30/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_255" contextRef="From2021-10-01to2021-12-31_cvm_SeriesSSMember" name="cvm:IssueDate1">12/19/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_224" contextRef="AsOf2021-12-31_cvm_SeriesSSMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_239" contextRef="AsOf2021-12-31_cvm_SeriesSSMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_272" contextRef="From2021-10-01to2021-12-31_cvm_SeriesSSMember" name="cvm:ExpirationDate">12/18/2022</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_256" contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember" name="cvm:IssueDate1">2/5/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_225" contextRef="AsOf2021-12-31_cvm_SeriesTTMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_240" contextRef="AsOf2021-12-31_cvm_SeriesTTMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_273" contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember" name="cvm:ExpirationDate">2/5/2023</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_257" contextRef="From2021-10-01to2021-12-31_srt_MinimumMember_cvm_ConsultantsMember" name="cvm:IssueDate1">7/28/2017</ix:nonNumeric> - <ix:nonNumeric id="fid_258" contextRef="From2021-10-01to2021-12-31_srt_MaximumMember_cvm_ConsultantsMember" name="cvm:IssueDate1">11/18/2020</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_226" contextRef="AsOf2021-12-31_cvm_ConsultantsMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">$<ix:nonFraction id="fid_241" contextRef="AsOf2021-12-31_srt_MinimumMember_cvm_ConsultantsMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction> $<ix:nonFraction id="fid_242" contextRef="AsOf2021-12-31_srt_MaximumMember_cvm_ConsultantsMember" name="cvm:ExercisePrice" decimals="INF" unitRef="USDPShares">11.61</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_274" contextRef="From2021-10-01to2021-12-31_srt_MinimumMember_cvm_ConsultantsMember" name="cvm:ExpirationDate">11/17/2022</ix:nonNumeric> - <ix:nonNumeric id="fid_275" contextRef="From2021-10-01to2021-12-31_srt_MaximumMember_cvm_ConsultantsMember" name="cvm:ExpirationDate">7/27/2027</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_4f7d5a" continuedAt="cont_ecff30"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* No current period changes to these warrants</p></ix:continuation><ix:continuation id="cont_ecff30" continuedAt="cont_569ebc"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1. </p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Derivative Liabilities</span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The table below presents the fair value of the warrant liabilities at the balance sheet dates:</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_569ebc" continuedAt="cont_1f2f21"><ix:nonNumeric id="fid_1158" contextRef="From2021-10-01to2021-12-31" name="cvm:ScheduleOfFairValueOfWarrantLiabilitestabletextblock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>September 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" contextRef="AsOf2020-12-31" name="cvm:FairValueOfSeriesZwarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,787</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" contextRef="AsOf2021-12-31" name="cvm:FairValueOfSeriesAaWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" contextRef="AsOf2020-12-31" name="cvm:FairValueOfSeriesAaWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,035</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_286" contextRef="AsOf2020-12-31" name="cvm:FairValueOfSeriesCcWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,961</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_287" contextRef="AsOf2021-12-31" name="cvm:FairValueOfSeriesHhWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" contextRef="AsOf2020-12-31" name="cvm:FairValueOfSeriesHhWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,597</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_289" contextRef="AsOf2021-12-31" name="cvm:TotalFairValueOfDerivativeLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,195</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_290" contextRef="AsOf2020-12-31" name="cvm:TotalFairValueOfDerivativeLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><ix:continuation id="cont_1f2f21" continuedAt="cont_eaa667"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The table below presents the gains on the warrant liabilities for the three months ended December 31:</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_eaa667" continuedAt="cont_32760a"><ix:nonNumeric id="fid_1159" contextRef="From2021-10-01to2021-12-31" name="cvm:ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series W warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_295" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesWWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,570</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_302" contextRef="From2021-10-01to2021-12-31" name="cvm:GainLossSeriesZWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,787</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_301" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesZWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,363</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series ZZ warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_303" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesZzWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,867</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" contextRef="From2021-10-01to2021-12-31" name="cvm:GainLossSeriesAaWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesAaWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,808</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series BB warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesBbWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,632</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_318" contextRef="From2021-10-01to2021-12-31" name="cvm:GainLossSeriesCcWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,372</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesCcWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,345</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_326" contextRef="From2021-10-01to2021-12-31" name="cvm:GainLossSeriesHhWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">802</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_325" contextRef="From2020-10-01to2020-12-31" name="cvm:GainLossSeriesHhWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net gain on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_338" contextRef="From2021-10-01to2021-12-31" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,596</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_337" contextRef="From2020-10-01to2020-12-31" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:numdotdecimal" decimals="0" unitRef="USD">932,836</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_32760a" continuedAt="cont_e954e3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</p></ix:continuation></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_e954e3" continuedAt="cont_ae3a6b"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Changes in Warrant Liabilities</span></em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021, <ix:nonFraction id="fid_1187" contextRef="From2021-10-01to2021-12-31_cvm_SeriesCcMember" name="cvm:WarrantsExpiredDuringPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,205</ix:nonFraction> Series CC warrants were exercised at an exercise price of $<ix:nonFraction id="fid_1197" contextRef="From2021-10-01to2021-12-31_cvm_SeriesCcMember" name="cvm:ExercisePricePerShare" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction>for gross proceeds of $<ix:nonFraction id="fid_436" contextRef="From2021-10-01to2021-12-31_cvm_SeriesCcMember" name="cvm:ProceedsFromWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,000</ix:nonFraction>. During the three months ended December 31, 2020, <ix:nonFraction id="fid_1188" contextRef="From2020-10-01to2020-12-31_cvm_SeriesCcMember" name="cvm:WarrantsExpiredDuringPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction> Series CC warrants were exercised at an exercise price of $<ix:nonFraction id="fid_1198" contextRef="From2020-10-01to2020-12-31_cvm_SeriesCcMember" name="cvm:ExercisePricePerShare" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction>for gross proceeds of $<ix:nonFraction id="fid_440" contextRef="From2020-10-01to2020-12-31_cvm_SeriesCcMember" name="cvm:ProceedsFromWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction>.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 8, 2021, <ix:nonFraction id="fid_1186" contextRef="From2021-12-01to2021-12-08_cvm_SeriesCcMember" name="cvm:WarrantsExpiredDuringPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640</ix:nonFraction> Series CC warrants, with an exercise price of $<ix:nonFraction id="fid_1196" contextRef="From2021-12-01to2021-12-08_cvm_SeriesCcMember" name="cvm:ExercisePricePerShare" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction>, expired. On November 23, 2021, <ix:nonFraction id="fid_452" contextRef="From2021-11-22to2021-11-23_cvm_SeriesZMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">184,800</ix:nonFraction> Series Z warrants, with an exercise price of $<ix:nonFraction id="fid_453" contextRef="AsOf2021-11-23_cvm_SeriesZMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction>, expired.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 22, 2021, <ix:nonFraction id="fid_1192" contextRef="From2021-08-21to2021-08-22_cvm_SeriesBBMember" name="cvm:WarrantsExpiredDuringPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">16,000</ix:nonFraction> Series BB warrants, with an exercise price of $<ix:nonFraction id="fid_459" contextRef="AsOf2021-08-22_cvm_SeriesBBMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction>, expired. On October 28, 2020, <ix:nonFraction id="fid_370" contextRef="From2020-10-01to2020-10-28_cvm_SeriesWWarrantsMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">688,930</ix:nonFraction> Series W warrants, with an exercise price of $<ix:nonFraction id="fid_427" contextRef="AsOf2020-10-28_cvm_SeriesWWarrantsMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" decimals="INF" unitRef="USDPShares">16.75</ix:nonFraction>, expired.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Equity Warrants</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Equity Warrants</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021, <ix:nonFraction id="fid_473" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,500</ix:nonFraction> Series NN warrants were exercised at an exercise price of $<ix:nonFraction id="fid_470" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember" name="cvm:ExercisePricePer" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction> for gross proceeds of $<ix:nonFraction id="fid_461" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember" name="cvm:ProceedsFromWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,340</ix:nonFraction>.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2020, <ix:nonFraction id="fid_476" contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction> Series TT warrants were exercised at an exercise price of $<ix:nonFraction id="fid_467" contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember" name="cvm:ExercisePricePer" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction> for gross proceeds of $<ix:nonFraction id="fid_478" contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember" name="cvm:ProceedsFromWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,400</ix:nonFraction>.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, <ix:nonNumeric id="fid_417" contextRef="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember" name="cvm:ExpirationDateDescription">the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021</ix:nonNumeric>. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_410" contextRef="From2021-10-01to2021-12-31_cvm_SeriesNWarrantsMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series N warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, <ix:nonNumeric id="fid_418" contextRef="From2020-12-01to2020-12-07_cvm_SeriesXMember" name="cvm:ExpirationDateDescription">the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021</ix:nonNumeric>. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_412" contextRef="From2021-10-01to2021-12-31_cvm_SeriesXMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series X warrants are also held by the de Clara Trust.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of the Series Y warrants, which were issued in connection with a financing, was extended six months from February 15, 2021 to August 15, 2021. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_414" contextRef="From2021-10-01to2021-12-31_cvm_SeriesYMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction> and was recorded as additional paid-in capital.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, <ix:nonNumeric id="fid_419" contextRef="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember" name="cvm:ExpirationDateDescription">the expiration date of Series UU warrants was extended six months from December 31, 2020 to June 30, 2021</ix:nonNumeric>. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was $<ix:nonFraction id="fid_411" contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUWarrantsMember" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction> and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021 and 2020, the Company issued <ix:nonFraction id="fid_384" contextRef="From2021-10-01to2021-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">18,020</ix:nonFraction> and <ix:nonFraction id="fid_481" contextRef="From2020-10-01to2020-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,044</ix:nonFraction> shares of restricted common stock, respectively, to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_360" contextRef="From2021-10-01to2021-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">9.93</ix:nonFraction> and $<ix:nonFraction id="fid_480" contextRef="From2020-10-01to2020-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">12.45</ix:nonFraction> per share, respectively, during the three months ended December 31, 2021 and 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2020, the Company issued to a consultant <ix:nonFraction id="fid_429" contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsMember" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction> options to purchase common stock with an exercise price of $11.61. The options are exercisable beginning May 18, 2021 and expire on <ix:nonNumeric id="fid_422" contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsMember" name="cvm:ExpirationDate">November 17, 2022</ix:nonNumeric>. The options were expensed on a straight-line basis over the six month vesting period at a fair value of approximately $<ix:nonFraction id="fid_365" contextRef="From2021-10-01to2021-12-31" name="cvm:FairValueOfStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction> or $<ix:nonFraction id="fid_364" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">5.65</ix:nonFraction> per option.</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_ae3a6b"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2021 and September 30, 2021, <ix:nonFraction id="fid_395" contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsOneMember" name="cvm:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction> options issued to consultants remained outstanding, all of which were issued from the Non-Qualified Stock Option plans. All <ix:nonFraction id="fid_397" contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsOneMember" name="cvm:NonQualifiedStockOptionSharesVest" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction> options are vested as of December 31, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021 and 2020, the Company recorded total expense of approximately $<ix:nonFraction id="fid_431" contextRef="From2021-10-01to2021-12-31_cvm_ConsultingAgreementsMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,000</ix:nonFraction> and $<ix:nonFraction id="fid_482" contextRef="From2020-10-01to2020-12-31_cvm_ConsultingAgreementsMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,000</ix:nonFraction>, respectively, relating to the share based compensation under&#160;these consulting agreements. At December 31, 2021 and September 30, 2021, approximately $<ix:nonFraction id="fid_1181" contextRef="AsOf2021-12-31_cvm_ConsultingAgreementsMember" name="cvm:ExpenseIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,000</ix:nonFraction>and $<ix:nonFraction id="fid_1183" contextRef="AsOf2021-09-30_cvm_ConsultingAgreementsMember" name="cvm:ExpenseIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,000</ix:nonFraction>, respectively, are included in prepaid expenses.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Securities Purchase Agreement</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into a Securities Purchase Agreement with Ergomed plc (Ergomed), one of the Company&#8217;s CROs responsible for managing the Company&#8217;s Phase 3 clinical trial, to facilitate payment of amounts due to Ergomed. Under the Agreement, the Company issued Ergomed shares of common stock and the net proceeds from&#160;Ergomed's sales of those shares would reduce outstanding amounts due to&#160;Ergomed. Upon issuance, the Company expensed the full value of the shares as other non-operating gain/loss and subsequently offset the gain/loss as amounts were realized through the sale by Ergomed and reduced accounts payable to Ergomed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No sales were made by Ergomed during the three months ended December 31, 2021. As of December 31, 2021, Ergomed had no shares for resale. During the three months ended December 31, 2020, the Company realized approximately $<ix:nonFraction id="fid_487" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million through the sale by Ergomed of 9,000 shares of the Company&#8217;s common stock and the Company reduced the payables to Ergomed and credited Other Operating Gain by that amount. No shares were issued to Ergomed during the three months ended December 31, 2021 and 2020.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1148" contextRef="From2021-10-01to2021-12-31" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="cont_6bc56f"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">FAIR VALUE MEASUREMENTS</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 820-10, <em>&#8220;Fair Value Measurements,&#8221;</em> the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_6bc56f" continuedAt="cont_0200bf"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions. Assumptions from market participants are used when pricing the asset or liabilities, given there is no readily available market information.</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_0200bf" continuedAt="cont_c6d122"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company&#8217;s assessment of the significance of an input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p></ix:continuation></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_c6d122" continuedAt="cont_4db405"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company purchased short-term U.S. Treasury bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments; therefore, they were categorized as Level 1 in the fair value hierarchy. The Treasury bills matured in December 2021 and yielded a weighted average interest rate of <ix:nonFraction id="fid_503" contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel1Member" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.10</ix:nonFraction>%.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2021 and September 30, 2021, all of the Company&#8217;s derivative instruments are classified as Level 3 on the fair value hierarchy.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following sets forth a reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2021 and the year ended September 30, 2021:</p></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_4db405" continuedAt="cont_506ca2"><ix:nonNumeric id="fid_1160" contextRef="From2021-10-01to2021-12-31" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>3 months ended December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>12 months ended September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_498" contextRef="AsOf2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_512" contextRef="AsOf2020-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,765,613</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_492" contextRef="From2021-10-01to2021-12-31" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_493" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_494" contextRef="From2021-10-01to2021-12-31" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,589</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_495" contextRef="From2020-10-01to2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,023,091</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Realized and unrealized (gains) and losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_496" contextRef="From2021-10-01to2021-12-31" name="cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">364,596</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_497" contextRef="From2020-10-01to2021-09-30" name="cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,858</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_491" contextRef="AsOf2021-12-31" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,195</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_489" contextRef="AsOf2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_506ca2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair values of the Company&#8217;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#8217;s stock, as well as U.S. Treasury Bill rates, are observable in active markets. At December 31, 2021, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $<ix:nonFraction id="fid_502" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageFairValueDerivativeInstruments" decimals="INF" unitRef="USDPShares">0.02</ix:nonFraction> per share and a weighted average exercise price of $<ix:nonFraction id="fid_504" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageExercisePriceDerivativeInstruments" decimals="INF" unitRef="USDPShares">13.73</ix:nonFraction> per share. Fair values were determined using a weighted average risk-free interest rate of <ix:nonFraction id="fid_505" contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.06</ix:nonFraction>% and weighted average volatility of <ix:nonFraction id="fid_506" contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member" name="cvm:VolatilityRate" decimals="INF" unitRef="Pure" scale="-2">79</ix:nonFraction>%. The instruments have a weighted average time to maturity of <ix:nonNumeric id="fid_507" contextRef="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageTimeToMaturityYear" format="ixt-sec:duryear">0.14</ix:nonNumeric> years. At September 30, 2021, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $<ix:nonFraction id="fid_500" contextRef="AsOf2021-09-30_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageFairValueDerivativeInstruments" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction> per share and a weighted average exercise price of $<ix:nonFraction id="fid_501" contextRef="AsOf2021-09-30_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageExercisePriceDerivativeInstruments" decimals="INF" unitRef="USDPShares">13.28</ix:nonFraction> per share. Fair values were determined using a weighted average risk-free interest rate of <ix:nonFraction id="fid_508" contextRef="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.05</ix:nonFraction>% and volatility of <ix:nonFraction id="fid_509" contextRef="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member" name="cvm:VolatilityRate" decimals="INF" unitRef="Pure" scale="-2">109</ix:nonFraction>%. The instruments have a weighted average time to maturity of <ix:nonNumeric id="fid_510" contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member" name="cvm:WeightedAverageTimeToMaturityYear" format="ixt-sec:duryear">0.3</ix:nonNumeric> years.</p></ix:continuation></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1149" contextRef="From2021-10-01to2021-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the quarter ended December 31, 2021, the Company issued officers <ix:nonFraction id="fid_159" contextRef="From2021-10-01to2021-12-31_srt_OfficerMember" name="cvm:OptionsIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">250,000</ix:nonFraction> options that vest upon FDA approval of the marketing application. See Note C for more information about the options.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust were extended by six months (Note C). The incremental cost of these modifications was approximately $<ix:nonFraction id="fid_147" contextRef="From2021-10-01to2021-12-31_cvm_SeriesXWarrantsMember" name="cvm:DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction> and was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of <ix:nonFraction id="fid_152" contextRef="AsOf2020-12-07_cvm_SeriesUUWarrantsMember" name="cvm:WarrantsIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction> Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $<ix:nonFraction id="fid_155" contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUWarrantsMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction> and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1150" contextRef="From2021-10-01to2021-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_0cd2b9"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">F. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Clinical Research Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $<ix:nonFraction id="fid_126" contextRef="From2021-10-01to2021-12-31_cvm_ErgomedMember" name="cvm:ClinicalServiceTrial" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">12</ix:nonFraction> million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research and Development.&#8221; Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $<ix:nonFraction id="fid_84" contextRef="From2021-10-01to2021-12-31" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">35.3</ix:nonFraction> million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_87" contextRef="From2021-10-01to2021-12-31" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.7</ix:nonFraction> million. During the three months ended December 31, 2021 and 2020, the Company recorded, net of Ergomed&#8217;s discount, approximately $<ix:nonFraction id="fid_85" contextRef="From2021-10-01to2021-12-31_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction id="fid_83" contextRef="From2020-10-01to2020-12-31_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million, respectively, as research and development expense related to Ergomed&#8217;s services.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Lease Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not probable.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 31, 2021 and September 30, 2021, the net book value of the finance lease right of use asset is approximately $<ix:nonFraction id="fid_118" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.3</ix:nonFraction> million and $<ix:nonFraction id="fid_132" contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.7</ix:nonFraction> million, respectively and the balance of the finance lease liability is approximately $<ix:nonFraction id="fid_120" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:BalanceOfTheFinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.5</ix:nonFraction> million and $<ix:nonFraction id="fid_133" contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:BalanceOfTheFinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.8</ix:nonFraction> million, respectively, of which approximately $<ix:nonFraction id="fid_134" contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:CurrentBalance" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million is current in each quarter. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the three months ended December 31, 2021 and 2020 was approximately $<ix:nonFraction id="fid_122" contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:CashPaidRelatedToFinanceLeases" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction id="fid_123" contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:CashPaidRelatedToFinanceLeases" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> million, respectively, of which approximately $<ix:nonFraction id="fid_124" contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="cvm:CashPaidRelatedToFinanceLeasesInterest" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million was for interest in each quarter. As of December 31, 2021, the weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_75" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">8.45</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_81" contextRef="From2021-10-01to2021-12-31" name="cvm:MaturityYears" format="ixt-sec:duryear">6.8</ix:nonNumeric> years.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The project was finished and the improvements were placed in service in October 2021. Total cost was $<ix:nonFraction id="fid_100" contextRef="From2021-10-01to2021-12-31_cvm_LandlordMember" name="cvm:FinancingLeaseContractualArrangement" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.1</ix:nonFraction> million, of which the landlord agreed to finance $<ix:nonFraction id="fid_135" contextRef="From2020-08-01to2020-08-31_cvm_LandlordMember" name="cvm:PaymentsMadeByLandlord" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.4</ix:nonFraction> million. Approximately $<ix:nonFraction id="fid_136" contextRef="From2021-10-01to2021-12-31_cvm_LandlordMember" name="cvm:PaymentsMadeByLandlord" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million of the landlord financing was received as of December 31 2021, and the remaining balance is expected to be received in the second quarter of fiscal year 2022. The landlord financing is being repaid through increased lease payments which started in March 2021 and extend over the remaining lease term. <ix:nonNumeric id="fid_89" contextRef="From2021-10-01to2021-12-31_cvm_LandlordMember" name="us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.</ix:nonNumeric> The Company remeasured the lease liability to account for the modified payments using a <ix:nonFraction id="fid_76" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">8.45</ix:nonFraction>% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. The leasehold improvements are recorded in property and equipment, were deemed to be placed in service in October 2021 and are being amortized over the remaining lease term.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. Under the landlord&#8217;s $2.4 million financing arrangement, the Company was required to deposit an additional $<ix:nonFraction id="fid_91" contextRef="AsOf2021-03-31" name="cvm:FinanceLeaseObligationsNetOfCurrentPortion" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million in March 2021. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. During the quarter ended December 31, 2021, it was determined that the Company met the minimum cash requirement and the deposits were returned in January 2022. The approximate $<ix:nonFraction id="fid_92" contextRef="AsOf2020-12-31" name="cvm:FinanceLeaseObligationsNetOfCurrentPortion" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.9</ix:nonFraction> million deposit is included in current assets at December 31, 2021 and non-current assets at September 30, 2021.</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_0cd2b9" continuedAt="cont_a6841b"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Approximate future minimum lease payments under finance leases as of December 31, 2021 are as follows:</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_a6841b" continuedAt="cont_da8b1c"><ix:nonNumeric id="fid_1161" contextRef="From2021-10-01to2021-12-31" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2022&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_55" contextRef="AsOf2021-12-31" name="cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,083,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_56" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,569,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_57" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,648,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_58" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,733,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_59" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,824,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_60" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_61" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,267,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation* </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_62" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,043,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_63" contextRef="AsOf2021-12-31" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,539,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_64" contextRef="AsOf2021-12-31" name="cvm:NetPresentValueOfLeaseFinanceLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,504,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_da8b1c" continuedAt="cont_9db281"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">*<em>Amount is net of landlord incentive of approximately $0.8 million expected to be received during the quarter ended March 31, 2022.</em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. As of December 31, 2021 and September 30, 2021, the net book value of the operating lease right of use assets is approximately $<ix:nonFraction id="fid_105" contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="cvm:NetBookValueOperatingLeaseRightOfUseAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.0</ix:nonFraction> million and $<ix:nonFraction id="fid_137" contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="cvm:NetBookValueOperatingLeaseRightOfUseAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million, respectively. As of December 31, 2021 and September 30, 2021, the balance of the operating lease liabilities is approximately $<ix:nonFraction id="fid_140" contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million. of which approximately $<ix:nonFraction id="fid_139" contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="cvm:CurrentBalance" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million, is current in each quarter. The Company incurred lease expense for operating leases of approximately $<ix:nonFraction id="fid_114" contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="us-gaap:LeaseAndRentalExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,000</ix:nonFraction> and $<ix:nonFraction id="fid_113" contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="us-gaap:LeaseAndRentalExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction>, respectively, for the three months ended December 31, 2021 and 2020. Total cash paid related to operating leases during the three months ended December 31, 2021 and 2020 was approximately $<ix:nonFraction id="fid_104" contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="us-gaap:OperatingLeasePayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="5">66,000</ix:nonFraction> and $<ix:nonFraction id="fid_103" contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember" name="us-gaap:OperatingLeasePayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="5">48,000</ix:nonFraction>, respectively. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_77" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">9.11</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_82" contextRef="From2021-10-01to2021-12-31" name="cvm:OperatingLeaseMaturityYears" format="ixt-sec:duryear">9.5</ix:nonNumeric> years.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">As of December 31, 2021, future minimum lease payments on operating leases are as follows:</td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_9db281"><ix:nonNumeric id="fid_1162" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_65" contextRef="AsOf2021-12-31" name="cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_66" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_67" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_68" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_69" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_70" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_71" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,325,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_72" contextRef="AsOf2021-12-31" name="cvm:LesseeOperatingLeaseLiabilityPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,203,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_73" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,081,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_74" contextRef="AsOf2021-12-31" name="cvm:cfgh" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,122,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1151" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="cont_56bbfa"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">G.</p></td><td style="vertical-align:top;"><span style="text-decoration:underline">PATENTS</span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021, the Company recorded approximately $<ix:nonFraction id="fid_54" contextRef="From2021-10-01to2021-12-31" name="cvm:PatentImpairmentCharges" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction> in patent impairment charges. No patent impairment charges were recorded during the three months ended December 2020. During the three months ended December 31, 2021 and 2020, amortization of patent costs totaled approximately $14,000 and $<ix:nonFraction id="fid_52" contextRef="From2020-10-01to2020-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction>, respectively. Approximate estimated future amortization expense is as follows:</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160;</p><ix:continuation id="cont_56bbfa"><ix:nonNumeric id="fid_1163" contextRef="From2021-10-01to2021-12-31" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_43" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_44" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_45" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_46" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_47" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_48" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_49" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_50" contextRef="AsOf2021-12-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1152" contextRef="From2021-10-01to2021-12-31" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="cont_ab5b4e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">H. </p></td><td style="vertical-align:top;"><span style="text-decoration:underline">LOSS PER COMMON SHARE </span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. For the years presented, the gain on warrant liabilities priced lower than the average market price during the period is excluded from the numerator and the incremental shares, determined using the treasury stock method, are added to the denominator in calculating diluted loss per share.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The following tables provide the details of the basic and diluted loss per-share computations:</td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_ab5b4e" continuedAt="cont_2af725"><ix:nonNumeric id="fid_1164" contextRef="From2021-10-01to2021-12-31" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" escape="true" continuedAt="cont_f056d7"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ended December 31,</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; basic</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_21" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,022,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_22" contextRef="From2021-10-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,077,961</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3" contextRef="From2020-10-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,670,247</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Basic loss per common share</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_23" contextRef="From2021-10-01to2021-12-31" name="us-gaap:EarningsPerShareBasic" decimals="INF" unitRef="USDPShares" sign="-">0.20</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_5" contextRef="From2020-10-01to2020-12-31" name="us-gaap:EarningsPerShareBasic" decimals="INF" unitRef="USDPShares" sign="-">0.21</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; diluted</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss available to common shareholders - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_24" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,782,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_8" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,022,643</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Gain on derivatives (1)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_25" contextRef="From2021-10-01to2021-12-31" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">25,114</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_10" contextRef="From2020-10-01to2020-12-31" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">164,073</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Net loss available to common shareholders - diluted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_26" contextRef="From2021-10-01to2021-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,807,720</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_12" contextRef="From2020-10-01to2020-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,186,716</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_27" contextRef="From2021-10-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,077,961</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_14" contextRef="From2020-10-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,670,247</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Incremental shares underlying dilutive - warrants and options (1)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_28" contextRef="From2021-10-01to2021-12-31" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,459</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" contextRef="From2020-10-01to2020-12-31" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">97,039</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding &#8211; diluted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_29" contextRef="From2021-10-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,083,420</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_18" contextRef="From2020-10-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,767,286</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Diluted loss earnings per common share</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_511" contextRef="From2021-10-01to2021-12-31" name="us-gaap:EarningsPerShareDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.20</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_20" contextRef="From2020-10-01to2020-12-31" name="us-gaap:EarningsPerShareDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.21</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_2af725" continuedAt="cont_727de9"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(1) </em></p></td><td style="vertical-align:top;"><em>Includes Series CC and HH warrants for the three months ended December 31, 2021 and 2020.</em></td></tr></tbody></table></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><ix:continuation id="cont_727de9" continuedAt="cont_49d15a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:</p></ix:continuation></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:continuation id="cont_49d15a"><ix:continuation id="cont_f056d7"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_37" contextRef="From2021-10-01to2021-12-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,477,966</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_38" contextRef="From2020-10-01to2020-12-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,517,160</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_40" contextRef="From2021-10-01to2021-12-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">151,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_42" contextRef="From2020-10-01to2020-12-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">302,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_39" contextRef="From2021-10-01to2021-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,629,216</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_41" contextRef="From2020-10-01to2020-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,819,660</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:nonNumeric id="fid_1153" contextRef="From2021-10-01to2021-12-31" name="us-gaap:SubsequentEventsTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">J. </p></td><td style="vertical-align:top;"><span style="text-decoration:underline">SUBSEQUENT EVENTS</span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.</td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span class="atag" style="display: inline" id="i2">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Liquidity and Capital Resources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN).&#160; The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation.&#160; This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5 years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison.&#160; The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician. This means that there were 2 treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated.&#160; Therefore, when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to the Company becoming unblinded.&#160; The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time.&#160; The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies.&#160; Based on this the Company aims to file for FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency, nor has its safety or efficacy been established for any use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).&#160; The Company has product candidates under development for the potential treatment of rheumatoid arthritis. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">All of the Company&#8217;s projects are under development. Consequently, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company&#8217;s expenses will continue to exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist in funding the Company&#8217;s capital requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, and the construction and upgrade of the Company&#8217;s manufacturing and laboratory facilities. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all its liquidity and capital requirements and anticipates having to do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &#160;However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $62.6 million as of December 31, 2021 on direct costs for the Phase 3 clinical trial and the filing of the clinical study report to the FDA. The Company estimates it will incur additional expenses of approximately $1.2 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company uses two CROs to manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount.&#160; Approximately $11.7 million of the committed $12 million contribution has been&#160;&#160;realized as of December 31, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021, the Company used approximately $5.1 million in cash, before considering the maturity and transfer to cash of the remaining $6.2 million in U.S. Treasury bills.&#160; Significant components of this increase include cash used to fund the Company&#8217;s regular operations, including its Phase 3 clinical trial, of approximately $4.8 million and approximately $0.3 million in lease payments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2020, the Company&#8217;s cash increased by approximately $6.4 million.&#160; Significant components of this increase include net proceeds from the sale of common stock and the exercise of warrants and options of approximately $13.6 million, offset by net cash used to fund the Company&#8217;s regular operations, including its Phase 3 clinical trial, of approximately $3.8 million, expenditures for leasehold improvements and equipment of approximately $3.2 million, and approximately $0.2 million in lease payments.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid expenses decreased by approximately $0.3 million, or 28%, at December 31, 2021 as compared to September 30, 2021 primarily due to the utilization of amounts paid in advance to Ergomed. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021, the Company completed a major upgrade of its leased manufacturing facility to prepare for the potential commercial production of its products. Total costs of this upgrade were approximately $11.1 million, of which the landlord of the property agreed to finance $2.4 million.&#160; As of December 31, 2021, approximately $1.6 million of the landlord financing was received and the remaining $0.8 million is expected to be received in the second quarter of fiscal year 2022.&#160; The landlord financing is being repaid through increased lease payments over the remaining term of the lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021, 19,705 warrants were exercised at a weighted average exercise price of $4.43 for total proceeds of approximately $87,000.&#160; During the three months ended December 31, 2020, 15,000 warrants were exercised at a weighted average exercise price of $3.16 for total proceeds of approximately $47,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Results of Operations and Financial Condition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021, research and development expenses increased by approximately $0.7 million, or 12%, compared to the three months ended December 31, 2020.&#160; Major components of this increase include approximately $0.6 million in employee stock compensation expense and $0.3 million in depreciation of leasehold improvements to the manufacturing facility that were placed in service in October 2022.&#160; This increase is offset by overall reductions in expenses related to the Phase 3 clinical study and other research and development costs of approximately $0.2 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021, general and administrative expenses decreased by approximately $0.6 million, or 17%, compared to the three months ended December 31, 2020.&#160; A major component of the decrease is an approximate $0.6 million decrease in employee stock compensation costs resulting from a change in the requisite service period for the performance-based stock options. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021 and 2020, the Company recorded derivative gains of approximately $0.4 million and $0.9 million, respectively. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;Net interest expense, which consists primarily of interest paid on lease liabilities, remained relatively constant at approximately $0.3 million for both the three months ended December 31, 2021 and December 31, 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">MULTIKINE</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,791,419</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,011,950</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">291,748</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">402,810</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">TOTAL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6,083,167</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">5,414,760</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><span style="text-decoration:underline">Critical Accounting Estimates and Policies</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Management&#8217;s discussion and analysis of the Company&#8217;s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of leases and stock-based compensation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. &#160;Share-based compensation cost to employees is measured at fair value as of the grant date in accordance with the provisions of ASC 718. The fair value of the stock options is calculated using the Black-Scholes option pricing model which requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period.&#160; Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For more information regarding the Company&#8217;s critical accounting estimates and policies, see Part II, Item&#160;7 of the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2021. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company&#8217;s Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span class="atag" style="display: inline" id="i3">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company does not believe that it has any significant exposures to market risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span class="atag" style="display: inline" id="i4">Item 4. CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Under the direction and with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2021. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective as of December 31, 2021.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Management&#8217;s Report on Internal Control over Financial Reporting</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a process designed by, or under the supervision of CEL-SCI&#8217;s Chief Executive and Principal Financial and Accounting Officer and implemented by CEL-SCI&#8217;s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of CEL-SCI&#8217;s financial statements in accordance with U.S. generally accepted accounting principles.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160; Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the supervision and with the participation of management, including CEL-SCI&#8217;s Principal Executive and Principal Financial Officer, CEL-SCI evaluated the effectiveness of its internal control over financial reporting as of December 31, 2021 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or the COSO Framework. Management&#8217;s assessment included an evaluation of the design of CEL-SCI&#8217;s internal control over financial reporting and testing of the operational effectiveness of those controls. CEL-SCI's Chief Executive and Principal Financial and Accounting Officer concluded that as of such date, CEL-SCI's internal control over financial reporting was effective.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There were no changes in the Company&#8217;s internal control over financial reporting that occurred during the three months ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span class="atag" style="display: inline" id="i2n">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2021, the Company issued 18,020 restricted shares of common stock to consultants for investor relations services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company&#8217;s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="i6"><strong>Item 6.</strong> <strong>Exhibits</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Number </strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:22%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">3(a)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Articles of Incorporation</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">3(b)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Amended Articles</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">3(c)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Amended Articles (Name change only)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incorporated by reference to Exhibit 3(c) of CEL-SCI's Registration Statement on Form S-1 Registration Statement (No. 33-34878).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">3(d)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By laws (as amended)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">Shareholders Rights Agreement, as Amended</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">Incorporated by reference to Exhibit 4 filed with CEL-SCI&#8217;s 8-K report dated October 30, 2020.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4bsept-12.txt">4(b)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4bsept-12.txt">Incentive Stock Option Plan</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4bsept-12.txt">Incorporated by reference to Exhibit 4 (b) filed on September 25, 2012 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-184092.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487814000303/s8exh4baug-14.txt">4(c)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487814000303/s8exh4baug-14.txt">Non-Qualified Stock Option Plan</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487814000303/s8exh4baug-14.txt">Incorporated by reference to Exhibit 4 (b) filed on August 19, 2014 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-198244).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4dsept-12.txt">4(d)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4dsept-12.txt">Stock Bonus Plan</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4dsept-12.txt">Incorporated by reference to Exhibit 4 (d) filed on September 25, 2012 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-184092).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4esept-12.txt">4(e)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4esept-12.txt">Stock Compensation Plan</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487812000317/forms8exh4esept-12.txt">Incorporated by reference to Exhibit 4 (e) filed on September 25, 2012 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-184092).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">4(f)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2014 Incentive Stock Bonus Plan</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Filed with this Amendment No. 2 to CEL-SCI&#8217;s annual report on Form 10-K for the year ended September 30, 2014.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cvm_ex31.htm">31</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cvm_ex32.htm">32</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Date: February 11, 2022</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By: </p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">/s/&#160; Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Geert Kersten&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Principal Executive Officer*&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">* Also signing in the capacity of the Principal Accounting and Financial Officer.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u><strong>CERTIFICATIONS</strong><strong></strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that:</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">c) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">d) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">February 11, 2022 </td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten </td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert Kersten </td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive Officer </p></td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u><strong>CERTIFICATIONS</strong><strong></strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">c) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">d) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. </p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">February 11, 2022 </td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten </td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert Kersten </td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Financial Officer</p></td> <td>&nbsp;</td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Quarterly Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending December 31, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Principal Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:Times New Roman">(1) </font></p></td> <td style="vertical-align:top;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:Times New Roman">(2) </font></p></td> <td style="vertical-align:top;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.</td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive and</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Financial Officer</td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">February 11, 2022</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvm-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2022-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:cvm="http://cvm.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20211231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" id="StatementsOfStockholdersEquityUnaudited">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/OperationsAndFinancing" id="OperationsAndFinancing">
        <link:definition>000008 - Disclosure - OPERATIONS AND FINANCING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000009 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>000010 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000011 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000012 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000013 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShare" id="LossPerCommonShare">
        <link:definition>000014 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000020 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareTables" id="LossPerCommonShareTables">
        <link:definition>000021 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000023 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>000025 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>000026 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>000027 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000028 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>000029 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
        <link:definition>000030 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000035 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000036 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails" id="LossPerCommonShareDetails">
        <link:definition>000037 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails1" id="LossPerCommonShareDetails1">
        <link:definition>000038 - Disclosure - LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <import namespace="http://fasb.org/srt-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" />
  <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <element id="cvm_SuppliesUsedForRdAndManufacturing" name="SuppliesUsedForRdAndManufacturing" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShortTermDeposits" name="ShortTermDeposits" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeaseLiabilitiesCurrentPortion" name="LeaseLiabilitiesCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromTheSaleOfCommonStockShares" name="ProceedsFromTheSaleOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromTheSaleOfCommonStockAmount" name="ProceedsFromTheSaleOfCommonStockAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityBasedCompensationEmployeesShares" name="EquityBasedCompensationEmployeesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityBasedCompensationEmployeesAmount" name="EquityBasedCompensationEmployeesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrantsAmount" name="ModificationOfWarrantsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrant" name="ModificationOfWarrant" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities" name="PropertyPlantEquipmentIncludedInCurrentLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities" name="CapitalizablePatentCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" name="PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExerciseOfDerivativeLiabilities" name="ExerciseOfDerivativeLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInCurrentLiabilities" name="FinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_USTreasuryBills" name="USTreasuryBills" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" name="ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" name="ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock" name="ScheduleOfFairValueOfWarrantLiabilitestabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" name="ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfWarrantOptions" name="SharesIssuableUponExerciseOfWarrantOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueOfSeriesZwarrants" name="FairValueOfSeriesZwarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueOfSeriesAaWarrants" name="FairValueOfSeriesAaWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueOfSeriesCcWarrants" name="FairValueOfSeriesCcWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueOfSeriesHhWarrants" name="FairValueOfSeriesHhWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_TotalFairValueOfDerivativeLiabilities" name="TotalFairValueOfDerivativeLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesWWarrants" name="GainLossSeriesWWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesZWarrants" name="GainLossSeriesZWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesZzWarrants" name="GainLossSeriesZzWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesAaWarrants" name="GainLossSeriesAaWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesBbWarrants" name="GainLossSeriesBbWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesCcWarrants" name="GainLossSeriesCcWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossSeriesHhWarrants" name="GainLossSeriesHhWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueOfStockOption" name="FairValueOfStockOption" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExpired" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromWarrantsExercised" name="ProceedsFromWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePricePer" name="ExercisePricePer" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePricePerShare" name="ExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExpiredDuringPeriod" name="WarrantsExpiredDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonQualifiedStockOptionSharesVest" name="NonQualifiedStockOptionSharesVest" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GrantPerformanceBasedStockOptions" name="GrantPerformanceBasedStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockPrice" name="CommonStockPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockOptionsVest" name="StockOptionsVest" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDateDescription" name="ExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpenseIncluedPrepaidExpenses" name="ExpenseIncluedPrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" name="FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRiskFreeInterestRate" name="WeightedAverageRiskFreeInterestRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageFairValueDerivativeInstruments" name="WeightedAverageFairValueDerivativeInstruments" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceDerivativeInstruments" name="WeightedAverageExercisePriceDerivativeInstruments" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VolatilityRate" name="VolatilityRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageTimeToMaturityYear" name="WeightedAverageTimeToMaturityYear" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" name="DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsIssued" name="WarrantsIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OptionsIssued" name="OptionsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear" name="FinanceLeaseLiabilityPaymentsDueRemainderOfYear" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetPresentValueOfLeaseFinanceLeaseObligations" name="NetPresentValueOfLeaseFinanceLeaseObligations" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" name="LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LesseeOperatingLeaseLiabilityPayments" name="LesseeOperatingLeaseLiabilityPayments" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_cfgh" name="cfgh" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_MaturityYears" name="MaturityYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseMaturityYears" name="OperatingLeaseMaturityYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetOfDiscount" name="NetOfDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationsNetOfCurrentPortion" name="FinanceLeaseObligationsNetOfCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingLeaseContractualArrangement" name="FinancingLeaseContractualArrangement" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PaymentsMadeByLandlord" name="PaymentsMadeByLandlord" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetBookValueOperatingLeaseRightOfUseAssets" name="NetBookValueOperatingLeaseRightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CurrentBalance" name="CurrentBalance" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" name="NetBookValueOfTheFinanceLeaseRightOfUseAsset" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_BalanceOfTheFinanceLeaseLiability" name="BalanceOfTheFinanceLeaseLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CashPaidRelatedToFinanceLeases" name="CashPaidRelatedToFinanceLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CashPaidRelatedToFinanceLeasesInterest" name="CashPaidRelatedToFinanceLeasesInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ClinicalServiceTrial" name="ClinicalServiceTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PatentImpairmentCharges" name="PatentImpairmentCharges" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberOneTwothousandNineTeenMember" id="cvm_OctoberOneTwothousandNineTeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TransactionOneMember" id="cvm_TransactionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TransactionTwoMember" id="cvm_TransactionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUWarrantsMember" id="cvm_SeriesUUWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNWarrantsMember" id="cvm_SeriesNWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXWarrantsMember" id="cvm_SeriesXWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockOptionPlansMember" id="cvm_IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlansMember" id="cvm_IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesBBMember" id="cvm_SeriesBBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesZMember" id="cvm_SeriesZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesCcMember" id="cvm_SeriesCcMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesHhMember" id="cvm_SeriesHhMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAaMember" id="cvm_SeriesAaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesTTMember" id="cvm_SeriesTTMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DecemberTwoThousandTwentyMember" id="cvm_DecemberTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesWWarrantsMember" id="cvm_SeriesWWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOneMember" id="cvm_ConsultantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvm-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2022-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_61e49f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_61e49f" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_62036d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_62036d" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_56c59d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_56c59d" xml:lang="en-US">Current Assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_c8d5df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_c8d5df" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl_d047dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl_d047dc" xml:lang="en-US">U.S. Treasury Bills</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_a7448f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_a7448f" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_b02318" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_b02318" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SuppliesUsedForRdAndManufacturing" xlink:label="cvm_SuppliesUsedForRdAndManufacturing" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRdAndManufacturing" xlink:to="cvm_SuppliesUsedForRdAndManufacturing_lbl_a7274c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRdAndManufacturing_lbl_a7274c" xml:lang="en-US">Supplies used for RD and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ShortTermDeposits" xlink:label="cvm_ShortTermDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShortTermDeposits" xlink:to="cvm_ShortTermDeposits_lbl_b79b5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShortTermDeposits_lbl_b79b5b" xml:lang="en-US">Short-term deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_28aad6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_28aad6" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_10" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_c9dd59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_c9dd59" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_fcf714" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_fcf714" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_b60699" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_b60699" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_38f076" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_38f076" xml:lang="en-US">Patent costs, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_c616c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_c616c7" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_2d618d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_2d618d" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_16" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_73a929" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_73a929" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_95d78e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_95d78e" xml:lang="en-US">Current Liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_ec8e46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_ec8e46" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_b2e11f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_b2e11f" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl_87e3fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl_87e3fa" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl_95b2d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl_95b2d0" xml:lang="en-US">Derivative instruments, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LeaseLiabilitiesCurrentPortion" xlink:label="cvm_LeaseLiabilitiesCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseLiabilitiesCurrentPortion" xlink:to="cvm_LeaseLiabilitiesCurrentPortion_lbl_5772fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseLiabilitiesCurrentPortion_lbl_5772fb" xml:lang="en-US">Lease liabilities, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_700771" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_700771" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_b48036" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_b48036" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_6c5556" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_6c5556" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_566cac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_566cac" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_0129fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_0129fa" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_28" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl_007c8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl_007c8e" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_275b93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_275b93" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_e97bf2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_e97bf2" xml:lang="en-US">Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_dd4f43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_dd4f43" xml:lang="en-US">Common stock, $.01 par value - 600,000,000 shares authorized; 43,259,013 and 43,207,183 shares issued and outstanding at December 31, 2021 and September 30, 2021, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_c02157" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_c02157" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_0bf98e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_0bf98e" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_3cb8ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_3cb8ed" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_35" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_e2daee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_e2daee" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_3bdd1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_3bdd1c" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_0861c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_0861c4" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_7f8530" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_7f8530" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_487542" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_487542" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_562db5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_562db5" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_9bba4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_9bba4c" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_62def6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_62def6" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_5fdc91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_5fdc91" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_b8e429" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_b8e429" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_c9deb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_c9deb4" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_8e9a25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_8e9a25" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_0ecd43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_0ecd43" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_237652" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_237652" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_92e443" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_92e443" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_982f86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_982f86" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="us-gaap_OtherNonoperatingGainsLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingGainsLosses" xlink:to="us-gaap_OtherNonoperatingGainsLosses_lbl_f46bc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingGainsLosses_lbl_f46bc4" xml:lang="en-US">Other non-operating gains</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_ef8008" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_ef8008" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_89a7f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_89a7f3" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_10" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_186417" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_186417" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_190426" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_190426" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_12" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_114790" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_114790" xml:lang="en-US">Net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl_b5849d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl_b5849d" xml:lang="en-US">BASIC and DILUTED</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl_fcc9bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl_fcc9bd" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_a96b2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_a96b2e" xml:lang="en-US">BASIC</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_6957c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_6957c5" xml:lang="en-US">DILUTED</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_cb4090" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_cb4090" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_89daed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_89daed" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_99cb82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_99cb82" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_8bb60c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_8bb60c" xml:lang="en-US">Statement Equity Components Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_9cb6fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_9cb6fb" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_e6cbd3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_e6cbd3" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_362418" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_362418" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_466082" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_466082" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_6c4b2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_6c4b2b" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:to="cvm_ProceedsFromTheSaleOfCommonStockShares_lbl_9a666e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockShares_lbl_9a666e" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromTheSaleOfCommonStockAmount" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromTheSaleOfCommonStockAmount" xlink:to="cvm_ProceedsFromTheSaleOfCommonStockAmount_lbl_a45e6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockAmount_lbl_a45e6c" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantExercisesShares" xlink:label="cvm_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesShares" xlink:to="cvm_WarrantExercisesShares_lbl_ac09b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesShares_lbl_ac09b0" xml:lang="en-US">Warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantExercisesAmount" xlink:label="cvm_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesAmount" xlink:to="cvm_WarrantExercisesAmount_lbl_3bc2f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesAmount_lbl_3bc2f1" xml:lang="en-US">Warrant exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_EquityBasedCompensationEmployeesShares" xlink:label="cvm_EquityBasedCompensationEmployeesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityBasedCompensationEmployeesShares" xlink:to="cvm_EquityBasedCompensationEmployeesShares_lbl_f89990" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityBasedCompensationEmployeesShares_lbl_f89990" xml:lang="en-US">Equity based compensation - employees, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_EquityBasedCompensationEmployeesAmount" xlink:label="cvm_EquityBasedCompensationEmployeesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityBasedCompensationEmployeesAmount" xlink:to="cvm_EquityBasedCompensationEmployeesAmount_lbl_2314d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityBasedCompensationEmployeesAmount_lbl_2314d3" xml:lang="en-US">Equity based compensation - employees, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_f5a1bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_f5a1bc" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_dfe4ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_dfe4ff" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_934d9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_934d9a" xml:lang="en-US">Stock and options issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_824b28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_824b28" xml:lang="en-US">Stock and options issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_d5ae00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_d5ae00" xml:lang="en-US">Option exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_9c132f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_9c132f" xml:lang="en-US">Option exercises, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrantsAmount" xlink:to="cvm_ModificationOfWarrantsAmount_lbl_96b65a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ModificationOfWarrantsAmount_lbl_96b65a" xml:lang="en-US">Modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrantsAmount" xlink:label="cvm_ModificationOfWarrantsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrantsAmount" xlink:to="cvm_ModificationOfWarrantsAmount_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrantsAmount_lbl_16" xml:lang="en-US">[Modification of warrants]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ShareIssuanceCosts" xlink:label="cvm_ShareIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_lbl_0cd04c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareIssuanceCosts_lbl_0cd04c" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_b4994b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_b4994b" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2aee4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_2aee4f" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_b0dcb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_b0dcb3" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_a5bcab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_a5bcab" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_7f41c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_7f41c2" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_2" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_bbf5a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_bbf5a7" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_4e3722" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_4e3722" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_225448" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_225448" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_2df0a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_2df0a6" xml:lang="en-US">Equity based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_985314" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_985314" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl_bb0693" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl_bb0693" xml:lang="en-US">Gain on short-term investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="us-gaap_ImpairmentOfOngoingProject" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfOngoingProject" xlink:to="us-gaap_ImpairmentOfOngoingProject_lbl_a3122d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfOngoingProject_lbl_a3122d" xml:lang="en-US">Loss on patent impairment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl_acbbfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl_acbbfe" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl_10" xml:lang="en-US">[Gain (Loss) on Sale of Derivatives]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrant" xlink:to="cvm_ModificationOfWarrant_lbl_a2d91a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ModificationOfWarrant_lbl_a2d91a" xml:lang="en-US">Modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrant" xlink:label="cvm_ModificationOfWarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrant" xlink:to="cvm_ModificationOfWarrant_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrant_lbl_11" xml:lang="en-US">[Modification of warrants 1]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_8a71a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_8a71a2" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl_772b7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl_772b7b" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl_13" xml:lang="en-US">[Increase (Decrease) in Receivables]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_e8406c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_e8406c" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_14" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInMaterialsAndSupplies" xlink:label="us-gaap_IncreaseDecreaseInMaterialsAndSupplies" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInMaterialsAndSupplies" xlink:to="us-gaap_IncreaseDecreaseInMaterialsAndSupplies_lbl_decdee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInMaterialsAndSupplies_lbl_decdee" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_642c13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_642c13" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_de5279" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_de5279" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_b516b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_b516b3" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_18" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_12e1e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_12e1e3" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl_19" xml:lang="en-US">[Increase (Decrease) in Due to Officers and Stockholders]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_4cef4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_4cef4f" xml:lang="en-US">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl_20" xml:lang="en-US">[Increase (Decrease) in Other Operating Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_976868" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_976868" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_21" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_075645" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_075645" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl_c0d7e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_lbl_c0d7e6" xml:lang="en-US">Proceeds from maturity of US treasury bills</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_b05ff6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_b05ff6" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_24" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_879cb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_879cb0" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_25" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_267976" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_267976" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_26" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_8bc2c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_8bc2c8" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_879a97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_879a97" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_882a3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_882a3a" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_29" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_46572a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_46572a" xml:lang="en-US">Proceeds from exercises of warrants and options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_46d4c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_46d4c1" xml:lang="en-US">Payments on obligations under finance lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_31" xml:lang="en-US">[Finance Lease, Principal Payments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_f2f6a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_f2f6a9" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_32" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_3c0c79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_3c0c79" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl_33" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_caa3f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_caa3f0" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_bb6b94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_bb6b94" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_b6f9a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_b6f9a5" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities" xlink:label="cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities" xlink:to="cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities_lbl_18038a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities_lbl_18038a" xml:lang="en-US">Property and equipment included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities" xlink:label="cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities" xlink:to="cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities_lbl_66a70a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities_lbl_66a70a" xml:lang="en-US">Capitalizable patent costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_ecea19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_ecea19" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock_lbl_2bc7ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock_lbl_2bc7ef" xml:lang="en-US">Prepaid consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExerciseOfDerivativeLiabilities" xlink:label="cvm_ExerciseOfDerivativeLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExerciseOfDerivativeLiabilities" xlink:to="cvm_ExerciseOfDerivativeLiabilities_lbl_ad4047" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExerciseOfDerivativeLiabilities_lbl_ad4047" xml:lang="en-US">Exercise of derivative liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_270fea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_270fea" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_4b50bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_4b50bf" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_78fdfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_78fdfb" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_28c094" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_28c094" xml:lang="en-US">A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_d7b3cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_d7b3cd" xml:lang="en-US">OPERATIONS AND FINANCING</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl_0e249f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl_0e249f" xml:lang="en-US">B. OPERATIONS AND FINANCING</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_ff5685" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_ff5685" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_628980" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_628980" xml:lang="en-US">C. STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_71b7a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_71b7a6" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_23e8bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_23e8bc" xml:lang="en-US">D. FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_60edba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_60edba" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_44ef23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_44ef23" xml:lang="en-US">E. RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_844f1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_844f1f" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_4d6052" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_4d6052" xml:lang="en-US">F. COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_de450f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_de450f" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_3fb09a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_3fb09a" xml:lang="en-US">G. PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_a137a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_a137a1" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_36b187" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_36b187" xml:lang="en-US">H. LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_26e01f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_26e01f" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_6423c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_6423c1" xml:lang="en-US">I. SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c84000" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_c84000" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_USTreasuryBills" xlink:to="cvm_USTreasuryBills_lbl_c52d4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_USTreasuryBills_lbl_c52d4b" xml:lang="en-US">U.S. Treasury Bills</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_USTreasuryBills" xlink:label="cvm_USTreasuryBills" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_USTreasuryBills" xlink:to="cvm_USTreasuryBills_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_USTreasuryBills_lbl_3" xml:lang="en-US">[U.S. Treasury Bills]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_f4b8ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_f4b8ec" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_bc32e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_bc32e5" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_dea575" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_dea575" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl_0cf3e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl_0cf3e2" xml:lang="en-US">Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl_34703b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl_34703b" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_c95ebe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_c95ebe" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_5ef4f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_5ef4f5" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_5eb96a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_5eb96a" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_f5e05a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_f5e05a" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_0421e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_0421e1" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:label="cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:to="cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_lbl_1050da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_lbl_1050da" xml:lang="en-US">Stock options, stock bonuses and compensation granted by the Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_c6d917" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_c6d917" xml:lang="en-US">Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_lbl_1ed312" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_lbl_1ed312" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:to="cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_lbl_4c3953" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_lbl_4c3953" xml:lang="en-US">Derivative liabilities, warrants and other options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock" xlink:label="cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock" xlink:to="cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock_lbl_c9e32e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock_lbl_c9e32e" xml:lang="en-US">Schedule of fair value of warrant liabilites</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" xlink:label="cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" xlink:to="cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock_lbl_f50542" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock_lbl_f50542" xml:lang="en-US">Schedule of gain and (losses) on derivative liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_0984c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_0984c4" xml:lang="en-US">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_2a4ba7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_2a4ba7" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_1571e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_1571e3" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl_b80004" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl_b80004" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_lbl_121649" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_lbl_121649" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_d115e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_d115e9" xml:lang="en-US">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl_d86f85" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl_d86f85" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_ed4269" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_ed4269" xml:lang="en-US">Patent useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_105627" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_105627" xml:lang="en-US">Award Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="cvm_IncentiveStockOptionPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockOptionPlansMember" xlink:to="cvm_IncentiveStockOptionPlansMember_lbl_16383f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockOptionPlansMember_lbl_16383f" xml:lang="en-US">Incentive Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_74fd50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_74fd50" xml:lang="en-US">Non-Qualified Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_6c7be9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_6c7be9" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl_99ba8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl_99ba8d" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="cvm_IncentiveStockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlansMember" xlink:to="cvm_IncentiveStockBonusPlansMember_lbl_5e0f4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlansMember_lbl_5e0f4c" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl_c82f76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl_c82f76" xml:lang="en-US">Total shares reserved under plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_40b1e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_40b1e4" xml:lang="en-US">Shares reserved for outstanding options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_1c2ffb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_1c2ffb" xml:lang="en-US">Remaining options/shares under plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_74584f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl_74584f" xml:lang="en-US">Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_d32fa1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_d32fa1" xml:lang="en-US">Options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_a69495" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_a69495" xml:lang="en-US">Options exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_bac158" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_bac158" xml:lang="en-US">Options forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_e5a494" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_e5a494" xml:lang="en-US">Options expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl_b966a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl_b966a5" xml:lang="en-US">Employees stock based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_fb6eec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_fb6eec" xml:lang="en-US">Non- Employees stock based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_78e780" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_78e780" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_37d731" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_37d731" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_4c09f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_4c09f7" xml:lang="en-US">Range Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_9f4fee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_9f4fee" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_c9156d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_c9156d" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_61f811" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_61f811" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_455dcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_455dcf" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesHhMember" xlink:label="cvm_SeriesHhMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesHhMember" xlink:to="cvm_SeriesHhMember_lbl_748ef7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesHhMember_lbl_748ef7" xml:lang="en-US">Series HH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesAaMember" xlink:label="cvm_SeriesAaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesAaMember" xlink:to="cvm_SeriesAaMember_lbl_99fa00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesAaMember_lbl_99fa00" xml:lang="en-US">Series AA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_c52e66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_c52e66" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_8e3e29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_8e3e29" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_b8e8a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_b8e8a0" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_ddc50a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_ddc50a" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesTTMember" xlink:label="cvm_SeriesTTMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesTTMember" xlink:to="cvm_SeriesTTMember_lbl_ee0a74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesTTMember_lbl_ee0a74" xml:lang="en-US">Series TT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_d4521b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_d4521b" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_adfd8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_adfd8f" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_6658c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_6658c8" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:to="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_d4de39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_d4de39" xml:lang="en-US">Shares issuable upon exercise of warrant/options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_5a8887" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_5a8887" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IssueDate1" xlink:label="cvm_IssueDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssueDate1" xlink:to="cvm_IssueDate1_lbl_ab7a7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssueDate1_lbl_ab7a7f" xml:lang="en-US">Issue date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDate" xlink:label="cvm_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_c223df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate_lbl_c223df" xml:lang="en-US">Expiration date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesZwarrants" xlink:label="cvm_FairValueOfSeriesZwarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueOfSeriesZwarrants" xlink:to="cvm_FairValueOfSeriesZwarrants_lbl_d96495" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueOfSeriesZwarrants_lbl_d96495" xml:lang="en-US">Series Z warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesAaWarrants" xlink:label="cvm_FairValueOfSeriesAaWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueOfSeriesAaWarrants" xlink:to="cvm_FairValueOfSeriesAaWarrants_lbl_1ecd68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueOfSeriesAaWarrants_lbl_1ecd68" xml:lang="en-US">Series AA warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesCcWarrants" xlink:label="cvm_FairValueOfSeriesCcWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueOfSeriesCcWarrants" xlink:to="cvm_FairValueOfSeriesCcWarrants_lbl_7785c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueOfSeriesCcWarrants_lbl_7785c9" xml:lang="en-US">Series CC warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesHhWarrants" xlink:label="cvm_FairValueOfSeriesHhWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueOfSeriesHhWarrants" xlink:to="cvm_FairValueOfSeriesHhWarrants_lbl_23c0b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueOfSeriesHhWarrants_lbl_23c0b2" xml:lang="en-US">Series HH warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TotalFairValueOfDerivativeLiabilities" xlink:label="cvm_TotalFairValueOfDerivativeLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TotalFairValueOfDerivativeLiabilities" xlink:to="cvm_TotalFairValueOfDerivativeLiabilities_lbl_d2270a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TotalFairValueOfDerivativeLiabilities_lbl_d2270a" xml:lang="en-US">Total warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesWWarrants" xlink:label="cvm_GainLossSeriesWWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesWWarrants" xlink:to="cvm_GainLossSeriesWWarrants_lbl_0b13ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesWWarrants_lbl_0b13ff" xml:lang="en-US">Gains on Series W warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesZWarrants" xlink:label="cvm_GainLossSeriesZWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesZWarrants" xlink:to="cvm_GainLossSeriesZWarrants_lbl_452fd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesZWarrants_lbl_452fd0" xml:lang="en-US">Gains on Series Z warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesZzWarrants" xlink:label="cvm_GainLossSeriesZzWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesZzWarrants" xlink:to="cvm_GainLossSeriesZzWarrants_lbl_b60ebf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesZzWarrants_lbl_b60ebf" xml:lang="en-US">Gains on Series ZZ warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesAaWarrants" xlink:label="cvm_GainLossSeriesAaWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesAaWarrants" xlink:to="cvm_GainLossSeriesAaWarrants_lbl_c699c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesAaWarrants_lbl_c699c8" xml:lang="en-US">Gains on Series AA warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesBbWarrants" xlink:label="cvm_GainLossSeriesBbWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesBbWarrants" xlink:to="cvm_GainLossSeriesBbWarrants_lbl_5a0cc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesBbWarrants_lbl_5a0cc6" xml:lang="en-US">Gains on Series BB warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesCcWarrants" xlink:label="cvm_GainLossSeriesCcWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesCcWarrants" xlink:to="cvm_GainLossSeriesCcWarrants_lbl_fa1bd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesCcWarrants_lbl_fa1bd7" xml:lang="en-US">Gains on Series CC warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesHhWarrants" xlink:label="cvm_GainLossSeriesHhWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossSeriesHhWarrants" xlink:to="cvm_GainLossSeriesHhWarrants_lbl_7e5ced" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossSeriesHhWarrants_lbl_7e5ced" xml:lang="en-US">Gains on Series HH warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl_2a50ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl_2a50ed" xml:lang="en-US">Net gain on warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_f754e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_f754e0" xml:lang="en-US">Award Date Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_cfa083" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_cfa083" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_5ac59c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_5ac59c" xml:lang="en-US">Plan Name Axis</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_3415d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_3415d0" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesCcMember" xlink:label="cvm_SeriesCcMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesCcMember" xlink:to="cvm_SeriesCcMember_lbl_22c518" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesCcMember_lbl_22c518" xml:lang="en-US">Series CC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesZMember" xlink:label="cvm_SeriesZMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesZMember" xlink:to="cvm_SeriesZMember_lbl_f32428" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesZMember_lbl_f32428" xml:lang="en-US">Series Z [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesBBMember" xlink:label="cvm_SeriesBBMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesBBMember" xlink:to="cvm_SeriesBBMember_lbl_4d5837" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesBBMember_lbl_4d5837" xml:lang="en-US">Series BB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DecemberTwoThousandTwentyMember" xlink:label="cvm_DecemberTwoThousandTwentyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DecemberTwoThousandTwentyMember" xlink:to="cvm_DecemberTwoThousandTwentyMember_lbl_ca7342" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DecemberTwoThousandTwentyMember_lbl_ca7342" xml:lang="en-US">December 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_49b82f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_49b82f" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesWWarrantsMember" xlink:label="cvm_SeriesWWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesWWarrantsMember" xlink:to="cvm_SeriesWWarrantsMember_lbl_f9eb2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesWWarrantsMember_lbl_f9eb2e" xml:lang="en-US">Series W Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsOneMember" xlink:label="cvm_ConsultantsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOneMember" xlink:to="cvm_ConsultantsOneMember_lbl_74fae4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOneMember_lbl_74fae4" xml:lang="en-US">Consultants One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNWarrantsMember" xlink:label="cvm_SeriesNWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNWarrantsMember" xlink:to="cvm_SeriesNWarrantsMember_lbl_a95c5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNWarrantsMember_lbl_a95c5b" xml:lang="en-US">Series N Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUWarrantsMember" xlink:label="cvm_SeriesUUWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUWarrantsMember" xlink:to="cvm_SeriesUUWarrantsMember_lbl_fd53e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUWarrantsMember_lbl_fd53e4" xml:lang="en-US">Series UU warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_83efac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_83efac" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl_a97c05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl_a97c05" xml:lang="en-US">Realized through sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_b05cb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_b05cb9" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfStockOption" xlink:label="cvm_FairValueOfStockOption" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueOfStockOption" xlink:to="cvm_FairValueOfStockOption_lbl_810abe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueOfStockOption_lbl_810abe" xml:lang="en-US">Fair value of stock option</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsExpired" xlink:label="cvm_WarrantsExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExpired" xlink:to="cvm_WarrantsExpired_lbl_4c7e43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExpired_lbl_4c7e43" xml:lang="en-US">Warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromWarrantsExercised" xlink:label="cvm_ProceedsFromWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromWarrantsExercised" xlink:to="cvm_ProceedsFromWarrantsExercised_lbl_e5b527" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromWarrantsExercised_lbl_e5b527" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePricePer" xlink:label="cvm_ExercisePricePer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePricePer" xlink:to="cvm_ExercisePricePer_lbl_9eb43d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePricePer_lbl_9eb43d" xml:lang="en-US">Exercise price of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePricePerShare" xlink:label="cvm_ExercisePricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePricePerShare" xlink:to="cvm_ExercisePricePerShare_lbl_9b7604" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePricePerShare_lbl_9b7604" xml:lang="en-US">Exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsExpiredDuringPeriod" xlink:label="cvm_WarrantsExpiredDuringPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExpiredDuringPeriod" xlink:to="cvm_WarrantsExpiredDuringPeriod_lbl_60ff20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExpiredDuringPeriod_lbl_60ff20" xml:lang="en-US">Warrants expired during period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_41f22d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_41f22d" xml:lang="en-US">Common stock price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_b43814" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_b43814" xml:lang="en-US">Common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_ad9dba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_ad9dba" xml:lang="en-US">Offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_dfd372" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_dfd372" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_f0574f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_f0574f" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" xlink:label="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" xlink:to="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued_lbl_417a35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued_lbl_417a35" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionSharesVest" xlink:label="cvm_NonQualifiedStockOptionSharesVest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionSharesVest" xlink:to="cvm_NonQualifiedStockOptionSharesVest_lbl_567e61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionSharesVest_lbl_567e61" xml:lang="en-US">Non-Qualified Stock Option shares vest</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GrantPerformanceBasedStockOptions" xlink:label="cvm_GrantPerformanceBasedStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GrantPerformanceBasedStockOptions" xlink:to="cvm_GrantPerformanceBasedStockOptions_lbl_0ef9ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GrantPerformanceBasedStockOptions_lbl_0ef9ee" xml:lang="en-US">Grant performance-based stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CommonStockPrice" xlink:label="cvm_CommonStockPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockPrice" xlink:to="cvm_CommonStockPrice_lbl_e6299a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockPrice_lbl_e6299a" xml:lang="en-US">Common stock price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_StockOptionsVest" xlink:label="cvm_StockOptionsVest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockOptionsVest" xlink:to="cvm_StockOptionsVest_lbl_999943" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockOptionsVest_lbl_999943" xml:lang="en-US">Stock options vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl_e91a10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl_e91a10" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDateDescription" xlink:label="cvm_ExpirationDateDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDateDescription" xlink:to="cvm_ExpirationDateDescription_lbl_069fb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDateDescription_lbl_069fb9" xml:lang="en-US">Expiration date description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_f6da4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ExpirationDate_lbl_f6da4f" xml:lang="en-US">Expiration date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_d38611" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_d38611" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_23" xml:lang="en-US">[Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Options Issued]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpenseIncluedPrepaidExpenses" xlink:label="cvm_ExpenseIncluedPrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpenseIncluedPrepaidExpenses" xlink:to="cvm_ExpenseIncluedPrepaidExpenses_lbl_da505d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpenseIncluedPrepaidExpenses_lbl_da505d" xml:lang="en-US">Total expense inclued prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_5a07d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_5a07d0" xml:lang="en-US">Total expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_70d0a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_70d0a4" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_2" xml:lang="en-US">[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl_de7fcc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl_de7fcc" xml:lang="en-US">Issuances</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_61f15e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_61f15e" xml:lang="en-US">Exercises</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_4" xml:lang="en-US">[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:label="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:to="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_lbl_345a27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_lbl_345a27" xml:lang="en-US">Realized and unrealized (gains) and losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_69a22d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_69a22d" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_4b8b00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_4b8b00" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl_f8d831" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl_f8d831" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl_987091" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl_987091" xml:lang="en-US">Fair Value Inputs Level 1 (Level 1)</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="cvm_WeightedAverageRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRiskFreeInterestRate" xlink:to="cvm_WeightedAverageRiskFreeInterestRate_lbl_9f19ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRiskFreeInterestRate_lbl_9f19ba" xml:lang="en-US">Weighted average risk free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageFairValueDerivativeInstruments" xlink:label="cvm_WeightedAverageFairValueDerivativeInstruments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageFairValueDerivativeInstruments" xlink:to="cvm_WeightedAverageFairValueDerivativeInstruments_lbl_61545e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageFairValueDerivativeInstruments_lbl_61545e" xml:lang="en-US">Weighted average fair value, Derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:label="cvm_WeightedAverageExercisePriceDerivativeInstruments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:to="cvm_WeightedAverageExercisePriceDerivativeInstruments_lbl_3aebc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceDerivativeInstruments_lbl_3aebc7" xml:lang="en-US">Weighted average exercise price, Derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_VolatilityRate" xlink:label="cvm_VolatilityRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VolatilityRate" xlink:to="cvm_VolatilityRate_lbl_42534e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VolatilityRate_lbl_42534e" xml:lang="en-US">Volatility rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageTimeToMaturityYear" xlink:label="cvm_WeightedAverageTimeToMaturityYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageTimeToMaturityYear" xlink:to="cvm_WeightedAverageTimeToMaturityYear_lbl_66f3f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageTimeToMaturityYear_lbl_66f3f2" xml:lang="en-US">Weighted average time to maturity year</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXWarrantsMember" xlink:label="cvm_SeriesXWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXWarrantsMember" xlink:to="cvm_SeriesXWarrantsMember_lbl_3ccbee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXWarrantsMember_lbl_3ccbee" xml:lang="en-US">Series X Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl_df8865" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl_df8865" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" xlink:label="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" xlink:to="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders_lbl_272d35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders_lbl_272d35" xml:lang="en-US">Deemed dividend after net loss to arrive at net loss available common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsIssued" xlink:label="cvm_WarrantsIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsIssued" xlink:to="cvm_WarrantsIssued_lbl_3a0df5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsIssued_lbl_3a0df5" xml:lang="en-US">Warrants issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl_1eb525" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl_1eb525" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsIssued" xlink:to="cvm_OptionsIssued_lbl_ea125c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_OptionsIssued_lbl_ea125c" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OptionsIssued" xlink:label="cvm_OptionsIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsIssued" xlink:to="cvm_OptionsIssued_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsIssued_lbl_5" xml:lang="en-US">[Options issued]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear" xlink:label="cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear" xlink:to="cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear_lbl_f95b40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear_lbl_f95b40" xml:lang="en-US">Nine months ending September 30, 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_233a69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_233a69" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_f5ea93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_f5ea93" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_2acd72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_2acd72" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_cf914a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_cf914a" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6a4699" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6a4699" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_ae2c4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_ae2c4a" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_8eb339" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_8eb339" xml:lang="en-US">Total future minimum finance lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_403f0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_403f0a" xml:lang="en-US">Less: imputed interest on financing lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetPresentValueOfLeaseFinanceLeaseObligations" xlink:label="cvm_NetPresentValueOfLeaseFinanceLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetPresentValueOfLeaseFinanceLeaseObligations" xlink:to="cvm_NetPresentValueOfLeaseFinanceLeaseObligations_lbl_b7e8f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetPresentValueOfLeaseFinanceLeaseObligations_lbl_b7e8f2" xml:lang="en-US">Net present value of lease finance lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" xlink:to="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear_lbl_e8dad2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear_lbl_e8dad2" xml:lang="en-US">Nine months ending September 30, 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" xlink:label="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" xlink:to="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear_lbl_2" xml:lang="en-US">[Nine months ending September 30, 2022]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_6f34fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_6f34fd" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_29d187" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_29d187" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_27c6a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_27c6a6" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_3d5f79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_3d5f79" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_ec97a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_ec97a6" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_ec8e32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_ec8e32" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_8" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LesseeOperatingLeaseLiabilityPayments" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPayments" xlink:to="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_fd49d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_fd49d3" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_c8f1c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_c8f1c9" xml:lang="en-US">Less imputed interest on operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_cfgh" xlink:label="cvm_cfgh" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_cfgh" xlink:to="cvm_cfgh_lbl_2b4d9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_cfgh_lbl_2b4d9b" xml:lang="en-US">Net present value of operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl_abea5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl_abea5d" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_f6191f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_f6191f" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OctoberOneTwothousandNineTeenMember" xlink:label="cvm_OctoberOneTwothousandNineTeenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OctoberOneTwothousandNineTeenMember" xlink:to="cvm_OctoberOneTwothousandNineTeenMember_lbl_b23dd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OctoberOneTwothousandNineTeenMember_lbl_b23dd0" xml:lang="en-US">October 1, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TransactionOneMember" xlink:label="cvm_TransactionOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TransactionOneMember" xlink:to="cvm_TransactionOneMember_lbl_02be22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TransactionOneMember_lbl_02be22" xml:lang="en-US">Transaction One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_5ab50a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_5ab50a" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_c61fe2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_c61fe2" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TransactionTwoMember" xlink:label="cvm_TransactionTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TransactionTwoMember" xlink:to="cvm_TransactionTwoMember_lbl_3cdd11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TransactionTwoMember_lbl_3cdd11" xml:lang="en-US">Transaction Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_1f404d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_1f404d" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_09b8a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_09b8a8" xml:lang="en-US">Weighted average discount rate operating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_MaturityYears" xlink:label="cvm_MaturityYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_MaturityYears" xlink:to="cvm_MaturityYears_lbl_eb21cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_MaturityYears_lbl_eb21cb" xml:lang="en-US">Maturity years</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OperatingLeaseMaturityYears" xlink:label="cvm_OperatingLeaseMaturityYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseMaturityYears" xlink:to="cvm_OperatingLeaseMaturityYears_lbl_18dca4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseMaturityYears_lbl_18dca4" xml:lang="en-US">Operating lease maturity years</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_1ec611" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_1ec611" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetOfDiscount" xlink:label="cvm_NetOfDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetOfDiscount" xlink:to="cvm_NetOfDiscount_lbl_6aa7af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetOfDiscount_lbl_6aa7af" xml:lang="en-US">Net of discount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:label="cvm_FinanceLeaseObligationsNetOfCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:to="cvm_FinanceLeaseObligationsNetOfCurrentPortion_lbl_d3bad6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationsNetOfCurrentPortion_lbl_d3bad6" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CurrentBalance" xlink:label="cvm_CurrentBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CurrentBalance" xlink:to="cvm_CurrentBalance_lbl_f9e1a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CurrentBalance_lbl_f9e1a0" xml:lang="en-US">Current balance</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:label="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:to="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset_lbl_b2f3a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset_lbl_b2f3a9" xml:lang="en-US">Net book value of the finance lease right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_BalanceOfTheFinanceLeaseLiability" xlink:label="cvm_BalanceOfTheFinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BalanceOfTheFinanceLeaseLiability" xlink:to="cvm_BalanceOfTheFinanceLeaseLiability_lbl_7d1a6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_BalanceOfTheFinanceLeaseLiability_lbl_7d1a6e" xml:lang="en-US">Balance of the finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CashPaidRelatedToFinanceLeases" xlink:label="cvm_CashPaidRelatedToFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CashPaidRelatedToFinanceLeases" xlink:to="cvm_CashPaidRelatedToFinanceLeases_lbl_d375bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CashPaidRelatedToFinanceLeases_lbl_d375bc" xml:lang="en-US">Cash paid related to finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:label="cvm_CashPaidRelatedToFinanceLeasesInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:to="cvm_CashPaidRelatedToFinanceLeasesInterest_lbl_9947b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CashPaidRelatedToFinanceLeasesInterest_lbl_9947b4" xml:lang="en-US">Cash paid related to finance leases interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="us-gaap_DerivativeVariableInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeVariableInterestRate" xlink:to="us-gaap_DerivativeVariableInterestRate_lbl_0782ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeVariableInterestRate_lbl_0782ff" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl_95d821" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl_95d821" xml:lang="en-US">Lease description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="cvm_FinancingLeaseContractualArrangement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingLeaseContractualArrangement" xlink:to="cvm_FinancingLeaseContractualArrangement_lbl_d880a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingLeaseContractualArrangement_lbl_d880a1" xml:lang="en-US">Financing arrangement</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PaymentsMadeByLandlord" xlink:label="cvm_PaymentsMadeByLandlord" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PaymentsMadeByLandlord" xlink:to="cvm_PaymentsMadeByLandlord_lbl_4a13d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PaymentsMadeByLandlord_lbl_4a13d4" xml:lang="en-US">Payments made by landlord</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ClinicalServiceTrial" xlink:label="cvm_ClinicalServiceTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ClinicalServiceTrial" xlink:to="cvm_ClinicalServiceTrial_lbl_d41cb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ClinicalServiceTrial_lbl_d41cb8" xml:lang="en-US">Clinical service trial</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_0f8fe8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_0f8fe8" xml:lang="en-US">Weighted average time to maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl_baf347" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl_baf347" xml:lang="en-US">Cash paid related to operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:label="cvm_NetBookValueOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:to="cvm_NetBookValueOperatingLeaseRightOfUseAssets_lbl_cf0612" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetBookValueOperatingLeaseRightOfUseAssets_lbl_cf0612" xml:lang="en-US">Net book value operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_789838" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_789838" xml:lang="en-US">Operating lease - liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_acfc19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_acfc19" xml:lang="en-US">Operating lease expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_c990e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_c990e9" xml:lang="en-US">Nine months ending September 30, 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_4b7556" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_4b7556" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_5f6b2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_5f6b2d" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_ecb08d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_ecb08d" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_dab456" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_dab456" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_82c692" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_82c692" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_614cb7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_614cb7" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xml:lang="en-US">[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_1c6895" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_1c6895" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_9" xml:lang="en-US">[Finite-Lived Intangible Assets, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PatentImpairmentCharges" xlink:label="cvm_PatentImpairmentCharges" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PatentImpairmentCharges" xlink:to="cvm_PatentImpairmentCharges_lbl_79c064" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PatentImpairmentCharges_lbl_79c064" xml:lang="en-US">Patent impairment charges</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_b1a086" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_b1a086" xml:lang="en-US">Amortization of patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl_0bddbe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl_0bddbe" xml:lang="en-US">Net loss available to common shareholders - basic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_61c62b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_61c62b" xml:lang="en-US">Weighted average shares outstanding - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_9224ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl_9224ea" xml:lang="en-US">Basic loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl_15072d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl_15072d" xml:lang="en-US">Loss per share- diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_bd7b39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_bd7b39" xml:lang="en-US">Net loss available to common shareholders -basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl_7b2f16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl_7b2f16" xml:lang="en-US">Gain on derivatives</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl_15f387" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl_15f387" xml:lang="en-US">Net loss available to common shareholders - diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_4274a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_4274a9" xml:lang="en-US">Weighted average shares outstanding - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_9" xml:lang="en-US">[Weighted Average Number of Shares Outstanding, Basic and Diluted]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl_dc630a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl_dc630a" xml:lang="en-US">Incremental shares underlying dilutive - warrants and options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_6a0c80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_6a0c80" xml:lang="en-US">Weighted average shares outstanding - diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_e03c6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_e03c6e" xml:lang="en-US">Diluted loss earnings per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_e412a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_e412a1" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_db6310" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_db6310" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_145ab5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_145ab5" xml:lang="en-US">Antidilutive securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_MaturityYears" xlink:to="cvm_MaturityYears_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_MaturityYears_d">Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ExpirationDate_d">Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" xlink:to="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued_d">Gross number of share options (or share units) granted during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ExpirationDateDescription" xlink:to="cvm_ExpirationDateDescription_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ExpirationDateDescription_d">Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obli</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ShareIssuanceCosts_d">Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_WarrantsExpired" xlink:to="cvm_WarrantsExpired_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_WarrantsExpired_d">Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" xlink:to="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders_d">The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvm-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2022-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20211231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20211231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20211231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20211231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20211231.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20211231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/OperationsAndFinancing" xlink:href="cvm-20211231.xsd#OperationsAndFinancing" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20211231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20211231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20211231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20211231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20211231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20211231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20211231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20211231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20211231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20211231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20211231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20211231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20211231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20211231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20211231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ShortTermDeposits" xlink:label="loc_cvmShortTermDeposits" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cvmShortTermDeposits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SuppliesUsedForRdAndManufacturing" xlink:label="loc_cvmSuppliesUsedForRdAndManufacturing" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cvmSuppliesUsedForRdAndManufacturing" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LeaseLiabilitiesCurrentPortion" xlink:label="loc_cvmLeaseLiabilitiesCurrentPortion" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmLeaseLiabilitiesCurrentPortion" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaapOtherNonoperatingGainsLosses" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingGainsLosses" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInMaterialsAndSupplies" xlink:label="loc_us-gaapIncreaseDecreaseInMaterialsAndSupplies" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInMaterialsAndSupplies" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrant" xlink:label="loc_cvmModificationOfWarrant" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmModificationOfWarrant" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="loc_us-gaapImpairmentOfOngoingProject" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfOngoingProject" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaapProceedsFromSaleOfHeldToMaturitySecurities" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/OperationsAndFinancing" xlink:title="000008 - Disclosure - OPERATIONS AND FINANCING" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000010 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000011 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000012 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000013 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000014 - Disclosure - LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000015 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000020 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000021 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000026 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000027 - Disclosure - STOCKHOLDERS EQUITY (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000028 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000030 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000035 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000036 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000037 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000038 - Disclosure - LOSS PER COMMON SHARE (Details 1)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cvm-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2022-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20211231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20211231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20211231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20211231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20211231.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20211231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/OperationsAndFinancing" xlink:href="cvm-20211231.xsd#OperationsAndFinancing" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20211231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20211231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20211231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20211231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20211231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20211231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20211231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20211231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20211231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20211231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20211231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20211231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20211231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20211231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20211231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_e3733c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_0acd82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e3733c" xlink:to="loc_us-gaapAssetsAbstract_0acd82" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_ad44f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_0acd82" xlink:to="loc_us-gaapAssetsCurrentAbstract_ad44f3" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_e646c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_e646c5" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_86ffd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapShortTermInvestments_86ffd6" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_4271fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_4271fc" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_e4b07b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapPrepaidExpenseCurrent_e4b07b" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SuppliesUsedForRdAndManufacturing" xlink:label="loc_cvmSuppliesUsedForRdAndManufacturing_3137ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_cvmSuppliesUsedForRdAndManufacturing_3137ca" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ShortTermDeposits" xlink:label="loc_cvmShortTermDeposits_832bc8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_cvmShortTermDeposits_832bc8" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_ae962c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapAssetsCurrent_ae962c" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_8bcb23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_8bcb23" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_d6375b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_d6375b" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_e3955b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_e3955b" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_eb4cce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapFiniteLivedPatentsGross_eb4cce" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_4884e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_4884e6" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_06ec76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapAssets_06ec76" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_d90794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_ad44f3" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_d90794" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_d90794" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_8bdc3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapAccountsPayableCurrent_8bdc3c" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_27d863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_27d863" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent_0071b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent_0071b4" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_01041f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_01041f" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LeaseLiabilitiesCurrentPortion" xlink:label="loc_cvmLeaseLiabilitiesCurrentPortion_dea38d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_cvmLeaseLiabilitiesCurrentPortion_dea38d" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_75ba04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapLiabilitiesCurrent_75ba04" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_b2a780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_b2a780" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_ce353e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_ce353e" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_2ea886" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_2ea886" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_c9874b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapLiabilities_c9874b" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_3083be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapCommitmentsAndContingencies_3083be" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_d35321" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_fd6313" xlink:to="loc_us-gaapStockholdersEquityAbstract_d35321" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_80acc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_d35321" xlink:to="loc_us-gaapPreferredStockValue_80acc0" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_c0a985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_d35321" xlink:to="loc_us-gaapCommonStockValue_c0a985" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_87a09c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_d35321" xlink:to="loc_us-gaapAdditionalPaidInCapital_87a09c" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_5756c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_d35321" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_5756c8" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_b43c27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_d35321" xlink:to="loc_us-gaapStockholdersEquity_b43c27" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_9f21bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_d35321" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_9f21bb" order="35" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_54cfe7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_54cfe7" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_fe0b3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_fe0b3c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_8c27f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapPreferredStockSharesIssued_8c27f9" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_7bcf99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_7bcf99" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_c94c25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_c94c25" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_86ad97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapCommonStockSharesAuthorized_86ad97" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_42096f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapCommonStockSharesIssued_42096f" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_62ce1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_76dd14" xlink:to="loc_us-gaapCommonStockSharesOutstanding_62ce1d" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_f01579" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_15a8d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_f01579" xlink:to="loc_us-gaapOperatingExpensesAbstract_15a8d7" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_5847bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_5847bd" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_4abdb1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_4abdb1" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_c8db8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapOperatingExpenses_c8db8d" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_58646b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapOperatingIncomeLoss_58646b" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_32f8f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_32f8f7" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaapOtherNonoperatingGainsLosses_fd43fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapOtherNonoperatingGainsLosses_fd43fa" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_d5c185" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapInterestIncomeExpenseNet_d5c185" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2e0e99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapNetIncomeLoss_2e0e99" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_df826b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_cvmModificationOfWarrants_df826b" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_bd3625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_bd3625" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_9078a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_15a8d7" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_9078a7" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_a9d321" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_9078a7" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_a9d321" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_45ef00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_9078a7" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_45ef00" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_aee4c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_45ef00" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_aee4c3" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_643409" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_45ef00" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_643409" order="16" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_5a1b18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_18e4d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_5a1b18" xlink:to="loc_us-gaapStatementTable_18e4d7" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8c8daf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_18e4d7" xlink:to="loc_us-gaapStatementLineItems_8c8daf" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_8df18b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_18e4d7" xlink:to="loc_us-gaapStatementEquityComponentsAxis_8df18b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_2acc78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_8df18b" xlink:to="loc_us-gaapEquityComponentDomain_2acc78" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_8ddd90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_2acc78" xlink:to="loc_us-gaapCommonStockMember_8ddd90" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_ee83be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_2acc78" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_ee83be" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_577734" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_2acc78" xlink:to="loc_us-gaapRetainedEarningsMember_577734" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_10dddb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapSharesIssued_10dddb" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_01aaff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockholdersEquity_01aaff" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockShares_5716e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockShares_5716e5" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromTheSaleOfCommonStockAmount" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockAmount_3a0c0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockAmount_3a0c0e" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares_6112ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmWarrantExercisesShares_6112ab" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount_6371b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmWarrantExercisesAmount_6371b6" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_EquityBasedCompensationEmployeesShares" xlink:label="loc_cvmEquityBasedCompensationEmployeesShares_5da426" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmEquityBasedCompensationEmployeesShares_5da426" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_EquityBasedCompensationEmployeesAmount" xlink:label="loc_cvmEquityBasedCompensationEmployeesAmount_445507" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmEquityBasedCompensationEmployeesAmount_445507" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_01b641" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_01b641" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_578a94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_578a94" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_007ef9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_007ef9" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_2b09e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_2b09e8" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2174a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_2174a0" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_27a0a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_27a0a8" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrantsAmount" xlink:label="loc_cvmModificationOfWarrantsAmount_19b074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmModificationOfWarrantsAmount_19b074" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts_3d3d5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_cvmShareIssuanceCosts_3d3d5c" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_a85d49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapNetIncomeLoss_a85d49" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_7c0b87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapSharesIssued_7c0b87" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_1e6532" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8c8daf" xlink:to="loc_us-gaapStockholdersEquity_1e6532" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_e5dea8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_51419b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e5dea8" xlink:to="loc_us-gaapProfitLoss_51419b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e5dea8" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_0814cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapDepreciationAndAmortization_0814cf" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_609bfa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_609bfa" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_2fc8d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapShareBasedCompensation_2fc8d1" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_ac007a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_ac007a" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_9cb2f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapGainLossOnInvestments_9cb2f3" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfOngoingProject" xlink:label="loc_us-gaapImpairmentOfOngoingProject_e2b477" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapImpairmentOfOngoingProject_e2b477" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives_9a2946" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives_9a2946" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrant" xlink:label="loc_cvmModificationOfWarrant_f01fe9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_cvmModificationOfWarrant_f01fe9" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d67fd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_591fdf" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d67fd2" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables_c19505" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d67fd2" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables_c19505" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_349e45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d67fd2" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_349e45" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInMaterialsAndSupplies" xlink:label="loc_us-gaapIncreaseDecreaseInMaterialsAndSupplies_d508ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d67fd2" xlink:to="loc_us-gaapIncreaseDecreaseInMaterialsAndSupplies_d508ab" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_d67fd2" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_41867c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_41867c" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_9fb0d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_9fb0d9" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders_b815ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders_b815ee" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities_5a129e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities_5a129e" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_33d32b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_33d32b" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_f67a18" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:label="loc_us-gaapProceedsFromSaleOfHeldToMaturitySecurities_8fdf56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" xlink:to="loc_us-gaapProceedsFromSaleOfHeldToMaturitySecurities_8fdf56" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_478614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_478614" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_82f048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_82f048" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_ba97a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_ba97a0" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_e39851" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_0f3d9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_0f3d9d" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_6fd20f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_6fd20f" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_009d65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapProceedsFromWarrantExercises_009d65" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_89a0c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_89a0c0" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_c2eacb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_c2eacb" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b490e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b490e" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_245673" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_245673" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2d3a60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2d3a60" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_cdb620" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" order="35" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyPlantEquipmentIncludedInCurrentLiabilities_966e65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_cvmPropertyPlantEquipmentIncludedInCurrentLiabilities_966e65" order="36" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmCapitalizablePatentCostsIncludedInCurrentLiabilities_715349" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_cvmCapitalizablePatentCostsIncludedInCurrentLiabilities_715349" order="37" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_a0be5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_a0be5b" order="38" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmPrepaidConsultingServicesPaidWithIssuanceOfCommonStock_f83cb1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_cvmPrepaidConsultingServicesPaidWithIssuanceOfCommonStock_f83cb1" order="39" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExerciseOfDerivativeLiabilities" xlink:label="loc_cvmExerciseOfDerivativeLiabilities_4d848d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_cvmExerciseOfDerivativeLiabilities_4d848d" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmFinancingCostsIncludedInCurrentLiabilities_5fe322" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_cvmFinancingCostsIncludedInCurrentLiabilities_5fe322" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_82d9a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4b5f27" xlink:to="loc_us-gaapInterestPaidNet_82d9a5" order="42" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_29ce79" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_44f1c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_29ce79" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_44f1c1" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/OperationsAndFinancing" xlink:title="000008 - Disclosure - OPERATIONS AND FINANCING">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_ed738b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations_20aff0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_ed738b" xlink:to="loc_us-gaapNatureOfOperations_20aff0" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_5528de" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_238ae6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5528de" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_238ae6" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000010 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_fe5c25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_36706b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_fe5c25" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_36706b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000011 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_7564a5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_41946b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_7564a5" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_41946b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000012 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_dd2aec" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_6fb62b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_dd2aec" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_6fb62b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000013 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_279810" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_148671" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_279810" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_148671" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000014 - Disclosure - LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_56d6d6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_5698d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_56d6d6" xlink:to="loc_us-gaapEarningsPerShareTextBlock_5698d6" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000015 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_deeaa6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_87faf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_deeaa6" xlink:to="loc_us-gaapSubsequentEventsTextBlock_87faf0" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_85c58b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_5a5702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_5a5702" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_USTreasuryBills" xlink:label="loc_cvmUSTreasuryBills_771721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_cvmUSTreasuryBills_771721" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_61b74a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_61b74a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_e391c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_e391c8" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_59eb2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_cvmLeasesPolicyTextBlock_59eb2c" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock_a27b7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapDerivativesPolicyTextBlock_a27b7a" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock_3d59eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock_3d59eb" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_e6ac31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_e6ac31" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_c4abe6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_c4abe6" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_5b7ba4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_5b7ba4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_814213" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapUseOfEstimates_814213" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_567232" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_85c58b" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_567232" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_6e4848" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:label="loc_cvmScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_070c9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6e4848" xlink:to="loc_cvmScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_070c9f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c68d86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6e4848" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c68d86" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_f786a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6e4848" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_f786a5" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:label="loc_cvmScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_31b4e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6e4848" xlink:to="loc_cvmScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_31b4e2" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock" xlink:label="loc_cvmScheduleOfFairValueOfWarrantLiabilitestabletextblock_4fdaa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6e4848" xlink:to="loc_cvmScheduleOfFairValueOfWarrantLiabilitestabletextblock_4fdaa0" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock" xlink:label="loc_cvmScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock_8eb673" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6e4848" xlink:to="loc_cvmScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock_8eb673" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_a9bc13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_896cf4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_a9bc13" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_896cf4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a70770" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_2b4906" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a70770" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_2b4906" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_82211b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a70770" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_82211b" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000020 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_9b6bf5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2471a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_9b6bf5" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2471a5" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000021 - Disclosure - LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_e30dab" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_12c02f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_e30dab" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock_12c02f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_82c640" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b61885" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_82c640" xlink:to="loc_us-gaapStatementTable_b61885" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_52df19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b61885" xlink:to="loc_us-gaapStatementLineItems_52df19" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_e723ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b61885" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_e723ec" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_2bf696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_e723ec" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_2bf696" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_6f1456" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_2bf696" xlink:to="loc_us-gaapPatentsMember_6f1456" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_875f6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_52df19" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_875f6b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_e2797b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5dd2c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_e2797b" xlink:to="loc_us-gaapStatementTable_5dd2c4" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_af6f4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5dd2c4" xlink:to="loc_us-gaapStatementLineItems_af6f4a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_eb62e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5dd2c4" xlink:to="loc_us-gaapAwardTypeAxis_eb62e2" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_eb62e2" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember_ba4d34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" xlink:to="loc_cvmIncentiveStockOptionPlansMember_ba4d34" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_48928b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_48928b" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_3fc889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" xlink:to="loc_cvmStockBonusPlansMember_3fc889" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_7064c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" xlink:to="loc_us-gaapStockCompensationPlanMember_7064c3" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember_77c8e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_160833" xlink:to="loc_cvmIncentiveStockBonusPlansMember_77c8e7" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5b4261" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_af6f4a" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5b4261" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_db985c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_af6f4a" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_db985c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3f393a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_af6f4a" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3f393a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_cee66c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_af6f4a" xlink:to="loc_us-gaapSharesIssued_cee66c" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_d86baf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2dda1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d86baf" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2dda1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_cae4e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d86baf" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_cae4e2" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8be459" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d86baf" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8be459" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6ced77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d86baf" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6ced77" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_2db8a1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_0369d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2db8a1" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_0369d6" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_e724c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2db8a1" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_e724c3" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000026 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_175b05" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7a947c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_175b05" xlink:to="loc_us-gaapStatementTable_7a947c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3da120" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a947c" xlink:to="loc_us-gaapStatementLineItems_3da120" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_0cb81d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a947c" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_0cb81d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_0cb81d" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_b70f74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a947c" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_b70f74" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_b4e210" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_b70f74" xlink:to="loc_us-gaapRelatedPartyDomain_b4e210" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_79bd3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7a947c" xlink:to="loc_srtRangeAxis_79bd3f" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_c3e853" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_79bd3f" xlink:to="loc_srtRangeMember_c3e853" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_a26b4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesNMember_a26b4b" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_f22138" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesUUMember_f22138" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_c5c031" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesXMember_c5c031" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_220545" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesYMember_220545" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesHhMember" xlink:label="loc_cvmSeriesHhMember_a699c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesHhMember_a699c9" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesAaMember" xlink:label="loc_cvmSeriesAaMember_df149f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesAaMember_df149f" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_cd7f91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesMMMember_cd7f91" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_a73628" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesNNMember_a73628" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_805b67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesRRMember_805b67" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_a2a60d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesSSMember_a2a60d" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember_b2045c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6717a2" xlink:to="loc_cvmSeriesTTMember_b2045c" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_1b65b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_b4e210" xlink:to="loc_cvmConsultantsMember_1b65b5" order="72" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_7a6232" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_c3e853" xlink:to="loc_srtMinimumMember_7a6232" order="73" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_75684e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_c3e853" xlink:to="loc_srtMaximumMember_75684e" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_4eb72c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3da120" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_4eb72c" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_b3ddef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3da120" xlink:to="loc_cvmExercisePrice_b3ddef" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1_27e43d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3da120" xlink:to="loc_cvmIssueDate1_27e43d" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_adf0ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3da120" xlink:to="loc_cvmExpirationDate_adf0ae" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000027 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_704088" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesZwarrants" xlink:label="loc_cvmFairValueOfSeriesZwarrants_411344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmFairValueOfSeriesZwarrants_411344" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesAaWarrants" xlink:label="loc_cvmFairValueOfSeriesAaWarrants_261b63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmFairValueOfSeriesAaWarrants_261b63" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesCcWarrants" xlink:label="loc_cvmFairValueOfSeriesCcWarrants_fc7962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmFairValueOfSeriesCcWarrants_fc7962" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfSeriesHhWarrants" xlink:label="loc_cvmFairValueOfSeriesHhWarrants_624c5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmFairValueOfSeriesHhWarrants_624c5e" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TotalFairValueOfDerivativeLiabilities" xlink:label="loc_cvmTotalFairValueOfDerivativeLiabilities_ac32cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmTotalFairValueOfDerivativeLiabilities_ac32cd" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesWWarrants" xlink:label="loc_cvmGainLossSeriesWWarrants_f07629" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesWWarrants_f07629" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesZWarrants" xlink:label="loc_cvmGainLossSeriesZWarrants_d30372" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesZWarrants_d30372" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesZzWarrants" xlink:label="loc_cvmGainLossSeriesZzWarrants_a57a73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesZzWarrants_a57a73" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesAaWarrants" xlink:label="loc_cvmGainLossSeriesAaWarrants_efd873" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesAaWarrants_efd873" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesBbWarrants" xlink:label="loc_cvmGainLossSeriesBbWarrants_cadceb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesBbWarrants_cadceb" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesCcWarrants" xlink:label="loc_cvmGainLossSeriesCcWarrants_320104" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesCcWarrants_320104" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GainLossSeriesHhWarrants" xlink:label="loc_cvmGainLossSeriesHhWarrants_46f953" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_cvmGainLossSeriesHhWarrants_46f953" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax_7c9ee9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_704088" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax_7c9ee9" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000028 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_0f9fe5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_dd2c46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_0f9fe5" xlink:to="loc_us-gaapStatementTable_dd2c46" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8ef373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapStatementLineItems_8ef373" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_f3a4bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_f3a4bc" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_f3a4bc" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_2f89a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapAwardDateAxis_2f89a2" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_2794cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_2f89a2" xlink:to="loc_us-gaapAwardDateDomain_2794cc" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e5348" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e5348" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_09f2f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e5348" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_09f2f5" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_9c1e05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_9c1e05" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_fa7bf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_9c1e05" xlink:to="loc_us-gaapRelatedPartyDomain_fa7bf3" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_2d38b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapAwardTypeAxis_2d38b0" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5406f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_2d38b0" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5406f0" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_d84fa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd2c46" xlink:to="loc_us-gaapPlanNameAxis_d84fa0" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_fafb08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_d84fa0" xlink:to="loc_us-gaapPlanNameDomain_fafb08" order="90" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_bc574e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5406f0" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_bc574e" order="91" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_17f3df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesXMember_17f3df" order="92" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_f93c24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesYMember_f93c24" order="93" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_f59813" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesNNMember_f59813" order="94" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember_1cf403" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesTTMember_1cf403" order="95" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_23e1fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_fa7bf3" xlink:to="loc_cvmConsultantsMember_23e1fd" order="96" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesCcMember" xlink:label="loc_cvmSeriesCcMember_a11b84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesCcMember_a11b84" order="97" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember_1ceca4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesZMember_1ceca4" order="98" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember_18d43b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesBBMember_18d43b" order="99" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DecemberTwoThousandTwentyMember" xlink:label="loc_cvmDecemberTwoThousandTwentyMember_86251e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_2794cc" xlink:to="loc_cvmDecemberTwoThousandTwentyMember_86251e" order="100" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_8cac3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_09f2f5" xlink:to="loc_cvmRestrictedStocksMember_8cac3a" order="101" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesWWarrantsMember" xlink:label="loc_cvmSeriesWWarrantsMember_0df8de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5406f0" xlink:to="loc_cvmSeriesWWarrantsMember_0df8de" order="102" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsOneMember" xlink:label="loc_cvmConsultantsOneMember_1effca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_fa7bf3" xlink:to="loc_cvmConsultantsOneMember_1effca" order="103" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNWarrantsMember" xlink:label="loc_cvmSeriesNWarrantsMember_cb3cdb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesNWarrantsMember_cb3cdb" order="104" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember_3d96d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7865bd" xlink:to="loc_cvmSeriesUUWarrantsMember_3d96d5" order="105" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_d94b8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_fafb08" xlink:to="loc_cvmConsultingAgreementsMember_d94b8a" order="106" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_ba4365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_ba4365" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59f002" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59f002" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfStockOption" xlink:label="loc_cvmFairValueOfStockOption_5091db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmFairValueOfStockOption_5091db" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsExpired" xlink:label="loc_cvmWarrantsExpired_2f82d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmWarrantsExpired_2f82d5" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromWarrantsExercised" xlink:label="loc_cvmProceedsFromWarrantsExercised_abef66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmProceedsFromWarrantsExercised_abef66" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePricePer" xlink:label="loc_cvmExercisePricePer_ec01e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmExercisePricePer_ec01e4" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePricePerShare" xlink:label="loc_cvmExercisePricePerShare_f024ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmExercisePricePerShare_f024ce" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsExpiredDuringPeriod" xlink:label="loc_cvmWarrantsExpiredDuringPeriod_29b5e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmWarrantsExpiredDuringPeriod_29b5e2" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fae6a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fae6a2" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_271912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_271912" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_f43965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapSaleOfStockPricePerShare_f43965" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_41fb7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_41fb7f" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_cd5035" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_cd5035" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" xlink:label="loc_cvmNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued_758022" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued_758022" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionSharesVest" xlink:label="loc_cvmNonQualifiedStockOptionSharesVest_1106e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmNonQualifiedStockOptionSharesVest_1106e6" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GrantPerformanceBasedStockOptions" xlink:label="loc_cvmGrantPerformanceBasedStockOptions_fd0e9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmGrantPerformanceBasedStockOptions_fd0e9b" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CommonStockPrice" xlink:label="loc_cvmCommonStockPrice_6588e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmCommonStockPrice_6588e1" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_StockOptionsVest" xlink:label="loc_cvmStockOptionsVest_4e5399" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmStockOptionsVest_4e5399" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaapDefinedBenefitPlanInterestCost_53861a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapDefinedBenefitPlanInterestCost_53861a" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDateDescription" xlink:label="loc_cvmExpirationDateDescription_0bef68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmExpirationDateDescription_0bef68" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_813ec0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmExpirationDate_813ec0" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_9c771f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_9c771f" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpenseIncluedPrepaidExpenses" xlink:label="loc_cvmExpenseIncluedPrepaidExpenses_d526dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_cvmExpenseIncluedPrepaidExpenses_d526dd" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_e87057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8ef373" xlink:to="loc_us-gaapCostsAndExpenses_e87057" order="24" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_228ddf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b86ecb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_228ddf" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b86ecb" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_17a12b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_228ddf" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_17a12b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_e54769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_228ddf" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_e54769" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:label="loc_cvmFairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_f1fd80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_228ddf" xlink:to="loc_cvmFairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_f1fd80" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_179c79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_228ddf" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_179c79" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000030 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_22f8bf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7e62c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_22f8bf" xlink:to="loc_us-gaapStatementTable_7e62c4" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d97041" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7e62c4" xlink:to="loc_us-gaapStatementLineItems_d97041" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_f07749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7e62c4" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_f07749" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_28efbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_f07749" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_28efbe" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_1fc012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_28efbe" xlink:to="loc_us-gaapFairValueInputsLevel3Member_1fc012" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_7d2e10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_28efbe" xlink:to="loc_us-gaapFairValueInputsLevel1Member_7d2e10" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="loc_cvmWeightedAverageRiskFreeInterestRate_074055" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d97041" xlink:to="loc_cvmWeightedAverageRiskFreeInterestRate_074055" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageFairValueDerivativeInstruments" xlink:label="loc_cvmWeightedAverageFairValueDerivativeInstruments_685dd3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d97041" xlink:to="loc_cvmWeightedAverageFairValueDerivativeInstruments_685dd3" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:label="loc_cvmWeightedAverageExercisePriceDerivativeInstruments_dfd8f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d97041" xlink:to="loc_cvmWeightedAverageExercisePriceDerivativeInstruments_dfd8f1" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_VolatilityRate" xlink:label="loc_cvmVolatilityRate_d77956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d97041" xlink:to="loc_cvmVolatilityRate_d77956" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageTimeToMaturityYear" xlink:label="loc_cvmWeightedAverageTimeToMaturityYear_319f72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d97041" xlink:to="loc_cvmWeightedAverageTimeToMaturityYear_319f72" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_33e2bb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_058f73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_33e2bb" xlink:to="loc_us-gaapStatementTable_058f73" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5dffa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_058f73" xlink:to="loc_us-gaapStatementLineItems_5dffa3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_870b22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_058f73" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_870b22" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_63af89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_870b22" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_63af89" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_c1dbf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_058f73" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_c1dbf3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_fd4561" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_c1dbf3" xlink:to="loc_us-gaapRelatedPartyDomain_fd4561" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember_860893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_63af89" xlink:to="loc_cvmSeriesUUWarrantsMember_860893" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXWarrantsMember" xlink:label="loc_cvmSeriesXWarrantsMember_30e0b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_63af89" xlink:to="loc_cvmSeriesXWarrantsMember_30e0b5" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_2c2182" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_fd4561" xlink:to="loc_srtOfficerMember_2c2182" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" xlink:label="loc_cvmDeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders_20f667" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dffa3" xlink:to="loc_cvmDeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders_20f667" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsIssued" xlink:label="loc_cvmWarrantsIssued_e066a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dffa3" xlink:to="loc_cvmWarrantsIssued_e066a8" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty_c0e490" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dffa3" xlink:to="loc_us-gaapInterestExpenseRelatedParty_c0e490" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OptionsIssued" xlink:label="loc_cvmOptionsIssued_11aefb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5dffa3" xlink:to="loc_cvmOptionsIssued_11aefb" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear" xlink:label="loc_cvmFinanceLeaseLiabilityPaymentsDueRemainderOfYear_c13c33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_cvmFinanceLeaseLiabilityPaymentsDueRemainderOfYear_c13c33" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2727de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2727de" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_dc6c37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_dc6c37" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_6ae5ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_6ae5ff" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_8bf1b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_8bf1b5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_aeb4ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_aeb4ae" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_9d78e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_9d78e8" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_490979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_490979" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_3dc447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_3dc447" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetPresentValueOfLeaseFinanceLeaseObligations" xlink:label="loc_cvmNetPresentValueOfLeaseFinanceLeaseObligations_8a8713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_f36816" xlink:to="loc_cvmNetPresentValueOfLeaseFinanceLeaseObligations_8a8713" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear" xlink:label="loc_cvmLesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear_c88678" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_cvmLesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear_c88678" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_df5aa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_df5aa0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0dae55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0dae55" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8ee0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8ee0b" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_56a4de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_56a4de" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_5b6486" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_5b6486" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6999c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6999c6" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LesseeOperatingLeaseLiabilityPayments" xlink:label="loc_cvmLesseeOperatingLeaseLiabilityPayments_4a3df4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_cvmLesseeOperatingLeaseLiabilityPayments_4a3df4" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6a92ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6a92ae" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_cfgh" xlink:label="loc_cvmcfgh_e666ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9120d7" xlink:to="loc_cvmcfgh_e666ac" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_22ca5f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_2e8495" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_22ca5f" xlink:to="loc_us-gaapStatementTable_2e8495" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_55d975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e8495" xlink:to="loc_us-gaapStatementLineItems_55d975" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_5efe2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e8495" xlink:to="loc_us-gaapAwardDateAxis_5efe2d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_64718f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_5efe2d" xlink:to="loc_us-gaapAwardDateDomain_64718f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis_d2dfa4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e8495" xlink:to="loc_us-gaapTransactionTypeAxis_d2dfa4" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_2f92aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis_d2dfa4" xlink:to="loc_us-gaapTransactionDomain_2f92aa" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_e38c3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e8495" xlink:to="loc_srtTitleOfIndividualAxis_e38c3e" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_53bcb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_e38c3e" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_53bcb4" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_b707da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2e8495" xlink:to="loc_us-gaapPlanNameAxis_b707da" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_97f8b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_b707da" xlink:to="loc_us-gaapPlanNameDomain_97f8b6" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OctoberOneTwothousandNineTeenMember" xlink:label="loc_cvmOctoberOneTwothousandNineTeenMember_9ee19c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_64718f" xlink:to="loc_cvmOctoberOneTwothousandNineTeenMember_9ee19c" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TransactionOneMember" xlink:label="loc_cvmTransactionOneMember_0eb23d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain_2f92aa" xlink:to="loc_cvmTransactionOneMember_0eb23d" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_5e58d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_53bcb4" xlink:to="loc_cvmLandlordMember_5e58d7" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_84079c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_97f8b6" xlink:to="loc_cvmErgomedMember_84079c" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TransactionTwoMember" xlink:label="loc_cvmTransactionTwoMember_b1432f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain_2f92aa" xlink:to="loc_cvmTransactionTwoMember_b1432f" order="65" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_277dbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_277dbc" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_f99b9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_f99b9e" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_MaturityYears" xlink:label="loc_cvmMaturityYears_1737d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmMaturityYears_1737d5" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OperatingLeaseMaturityYears" xlink:label="loc_cvmOperatingLeaseMaturityYears_130034" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmOperatingLeaseMaturityYears_130034" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_3824bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_3824bb" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount_786e7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmNetOfDiscount_786e7c" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:label="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion_eccd6e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion_eccd6e" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CurrentBalance" xlink:label="loc_cvmCurrentBalance_56b80f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmCurrentBalance_56b80f" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:label="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset_ce9a72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset_ce9a72" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_BalanceOfTheFinanceLeaseLiability" xlink:label="loc_cvmBalanceOfTheFinanceLeaseLiability_c6021c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmBalanceOfTheFinanceLeaseLiability_c6021c" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CashPaidRelatedToFinanceLeases" xlink:label="loc_cvmCashPaidRelatedToFinanceLeases_414511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmCashPaidRelatedToFinanceLeases_414511" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:label="loc_cvmCashPaidRelatedToFinanceLeasesInterest_2807b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmCashPaidRelatedToFinanceLeasesInterest_2807b5" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="loc_us-gaapDerivativeVariableInterestRate_04820e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapDerivativeVariableInterestRate_04820e" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_edafba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_edafba" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="loc_cvmFinancingLeaseContractualArrangement_0cdf48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmFinancingLeaseContractualArrangement_0cdf48" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PaymentsMadeByLandlord" xlink:label="loc_cvmPaymentsMadeByLandlord_dbe8be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmPaymentsMadeByLandlord_dbe8be" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial_388068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmClinicalServiceTrial_388068" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_ea788d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_ea788d" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_f3c7d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapOperatingLeasePayments_f3c7d3" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:label="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets_cd644f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets_cd644f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_911380" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapOperatingLeaseLiability_911380" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_0963cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_55d975" xlink:to="loc_us-gaapLeaseAndRentalExpense_0963cd" order="22" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000035 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_59eee2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_59eee2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3b2915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3b2915" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_16df80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_16df80" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ba0080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ba0080" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_51b0b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_51b0b0" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a75730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a75730" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1b5c71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_1b5c71" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_bd434e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_343b5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_bd434e" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000036 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_2a9843" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PatentImpairmentCharges" xlink:label="loc_cvmPatentImpairmentCharges_44b31e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_2a9843" xlink:to="loc_cvmPatentImpairmentCharges_44b31e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_4dd673" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_2a9843" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_4dd673" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000037 - Disclosure - LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_7a863a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_bf5a1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_7a863a" xlink:to="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_bf5a1a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_a3dbb5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_7a863a" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_a3dbb5" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_7532a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_7a863a" xlink:to="loc_us-gaapEarningsPerShareBasic_7532a4" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_7a863a" xlink:to="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_e80dce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_e80dce" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives_7d0666" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives_7d0666" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_0c1d1b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_0c1d1b" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_f54316" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_f54316" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_6747c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_6747c3" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_82dda9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_82dda9" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_ef3da3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareDilutedAbstract_2ed2fa" xlink:to="loc_us-gaapEarningsPerShareDiluted_ef3da3" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000038 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_ca4608" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fcb6ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_ca4608" xlink:to="loc_us-gaapStatementTable_fcb6ec" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d5d12a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fcb6ec" xlink:to="loc_us-gaapStatementLineItems_d5d12a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_61c2c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fcb6ec" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_61c2c4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_a61cf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_61c2c4" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_a61cf6" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_a02508" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_a61cf6" xlink:to="loc_cvmOptionsMember_a02508" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_a536f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_a61cf6" xlink:to="loc_cvmUnvestedRestrictedStockMember_a536f4" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3a1860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d5d12a" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3a1860" order="1" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2022-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20211231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20211231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20211231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20211231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20211231.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20211231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/OperationsAndFinancing" xlink:href="cvm-20211231.xsd#OperationsAndFinancing" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20211231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20211231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20211231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20211231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20211231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20211231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20211231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20211231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20211231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20211231.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20211231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20211231.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20211231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20211231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20211231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20211231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromTheSaleOfCommonStockShares" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromTheSaleOfCommonStockAmount" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_EquityBasedCompensationEmployeesShares" xlink:label="loc_cvmEquityBasedCompensationEmployeesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityBasedCompensationEmployeesShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_EquityBasedCompensationEmployeesAmount" xlink:label="loc_cvmEquityBasedCompensationEmployeesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityBasedCompensationEmployeesAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ModificationOfWarrantsAmount" xlink:label="loc_cvmModificationOfWarrantsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmModificationOfWarrantsAmount" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareIssuanceCosts" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="17" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/OperationsAndFinancing" xlink:title="000008 - Disclosure - OPERATIONS AND FINANCING" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000010 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000011 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000012 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000013 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000014 - Disclosure - LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000015 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000020 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000021 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockOptionPlansMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmStockBonusPlansMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlansMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000026 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesHhMember" xlink:label="loc_cvmSeriesHhMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesHhMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesAaMember" xlink:label="loc_cvmSeriesAaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesAaMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesSSMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesTTMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="73" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssueDate1" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000027 - Disclosure - STOCKHOLDERS EQUITY (Details 4)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000028 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="110" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="91" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="92" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="93" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="94" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesTTMember" order="95" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="96" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesCcMember" xlink:label="loc_cvmSeriesCcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCcMember" order="97" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZMember" order="98" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesBBMember" order="99" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DecemberTwoThousandTwentyMember" xlink:label="loc_cvmDecemberTwoThousandTwentyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmDecemberTwoThousandTwentyMember" order="100" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="101" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesWWarrantsMember" xlink:label="loc_cvmSeriesWWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmSeriesWWarrantsMember" order="102" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultantsOneMember" xlink:label="loc_cvmConsultantsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOneMember" order="103" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesNWarrantsMember" xlink:label="loc_cvmSeriesNWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNWarrantsMember" order="104" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUWarrantsMember" order="105" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="106" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FairValueOfStockOption" xlink:label="loc_cvmFairValueOfStockOption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFairValueOfStockOption" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsExpired" xlink:label="loc_cvmWarrantsExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExpired" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ProceedsFromWarrantsExercised" xlink:label="loc_cvmProceedsFromWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromWarrantsExercised" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePricePer" xlink:label="loc_cvmExercisePricePer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePricePer" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExercisePricePerShare" xlink:label="loc_cvmExercisePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePricePerShare" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsExpiredDuringPeriod" xlink:label="loc_cvmWarrantsExpiredDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExpiredDuringPeriod" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" xlink:label="loc_cvmNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NonQualifiedStockOptionSharesVest" xlink:label="loc_cvmNonQualifiedStockOptionSharesVest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNonQualifiedStockOptionSharesVest" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_GrantPerformanceBasedStockOptions" xlink:label="loc_cvmGrantPerformanceBasedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmGrantPerformanceBasedStockOptions" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CommonStockPrice" xlink:label="loc_cvmCommonStockPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCommonStockPrice" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_StockOptionsVest" xlink:label="loc_cvmStockOptionsVest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockOptionsVest" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaapDefinedBenefitPlanInterestCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDefinedBenefitPlanInterestCost" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDateDescription" xlink:label="loc_cvmExpirationDateDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDateDescription" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ExpenseIncluedPrepaidExpenses" xlink:label="loc_cvmExpenseIncluedPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpenseIncluedPrepaidExpenses" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="24" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000030 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="loc_cvmWeightedAverageRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRiskFreeInterestRate" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageFairValueDerivativeInstruments" xlink:label="loc_cvmWeightedAverageFairValueDerivativeInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageFairValueDerivativeInstruments" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageExercisePriceDerivativeInstruments" xlink:label="loc_cvmWeightedAverageExercisePriceDerivativeInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceDerivativeInstruments" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_VolatilityRate" xlink:label="loc_cvmVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVolatilityRate" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WeightedAverageTimeToMaturityYear" xlink:label="loc_cvmWeightedAverageTimeToMaturityYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageTimeToMaturityYear" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesUUWarrantsMember" xlink:label="loc_cvmSeriesUUWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUWarrantsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_SeriesXWarrantsMember" xlink:label="loc_cvmSeriesXWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXWarrantsMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtOfficerMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" xlink:label="loc_cvmDeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_WarrantsIssued" xlink:label="loc_cvmWarrantsIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsIssued" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseRelatedParty" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OptionsIssued" xlink:label="loc_cvmOptionsIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOptionsIssued" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OctoberOneTwothousandNineTeenMember" xlink:label="loc_cvmOctoberOneTwothousandNineTeenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmOctoberOneTwothousandNineTeenMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TransactionOneMember" xlink:label="loc_cvmTransactionOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_cvmTransactionOneMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_TransactionTwoMember" xlink:label="loc_cvmTransactionTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_cvmTransactionTwoMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_MaturityYears" xlink:label="loc_cvmMaturityYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmMaturityYears" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OperatingLeaseMaturityYears" xlink:label="loc_cvmOperatingLeaseMaturityYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOperatingLeaseMaturityYears" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetOfDiscount" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinanceLeaseObligationsNetOfCurrentPortion" xlink:label="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeaseObligationsNetOfCurrentPortion" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CurrentBalance" xlink:label="loc_cvmCurrentBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCurrentBalance" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset" xlink:label="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetBookValueOfTheFinanceLeaseRightOfUseAsset" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_BalanceOfTheFinanceLeaseLiability" xlink:label="loc_cvmBalanceOfTheFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmBalanceOfTheFinanceLeaseLiability" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CashPaidRelatedToFinanceLeases" xlink:label="loc_cvmCashPaidRelatedToFinanceLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCashPaidRelatedToFinanceLeases" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_CashPaidRelatedToFinanceLeasesInterest" xlink:label="loc_cvmCashPaidRelatedToFinanceLeasesInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCashPaidRelatedToFinanceLeasesInterest" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeVariableInterestRate" xlink:label="loc_us-gaapDerivativeVariableInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeVariableInterestRate" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="loc_cvmFinancingLeaseContractualArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingLeaseContractualArrangement" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_PaymentsMadeByLandlord" xlink:label="loc_cvmPaymentsMadeByLandlord" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPaymentsMadeByLandlord" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmClinicalServiceTrial" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_NetBookValueOperatingLeaseRightOfUseAssets" xlink:label="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetBookValueOperatingLeaseRightOfUseAssets" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" order="22" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000035 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000036 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000037 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000038 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604535656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,275,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604386072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,109,917<span></span>
</td>
<td class="nump">$ 36,060,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">U.S. Treasury Bills</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,151,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">54,922<span></span>
</td>
<td class="nump">54,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">723,782<span></span>
</td>
<td class="nump">998,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SuppliesUsedForRdAndManufacturing', window );">Supplies used for RD and manufacturing</a></td>
<td class="nump">2,067,723<span></span>
</td>
<td class="nump">2,006,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShortTermDeposits', window );">Short-term deposits</a></td>
<td class="nump">1,910,917<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">41,867,261<span></span>
</td>
<td class="nump">45,271,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">12,252,663<span></span>
</td>
<td class="nump">12,691,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">2,014,185<span></span>
</td>
<td class="nump">2,056,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,290,109<span></span>
</td>
<td class="nump">13,663,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patent costs, net</a></td>
<td class="nump">247,521<span></span>
</td>
<td class="nump">275,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,910,917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">69,671,739<span></span>
</td>
<td class="nump">75,869,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,192,825<span></span>
</td>
<td class="nump">1,675,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">899,901<span></span>
</td>
<td class="nump">859,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to employees</a></td>
<td class="nump">475,039<span></span>
</td>
<td class="nump">265,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative instruments, current portion</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">437,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LeaseLiabilitiesCurrentPortion', window );">Lease liabilities, current portion</a></td>
<td class="nump">763,535<span></span>
</td>
<td class="nump">698,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,333,495<span></span>
</td>
<td class="nump">3,937,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">12,880,449<span></span>
</td>
<td class="nump">13,252,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,981,340<span></span>
</td>
<td class="nump">2,021,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,320,284<span></span>
</td>
<td class="nump">19,335,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value - 600,000,000 shares authorized; 43,259,013 and 43,207,183 shares issued and outstanding at December 31, 2021 and September 30, 2021, respectively</a></td>
<td class="nump">432,590<span></span>
</td>
<td class="nump">432,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">477,897,883<span></span>
</td>
<td class="nump">474,298,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(426,979,018)<span></span>
</td>
<td class="num">(418,196,412)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">51,351,455<span></span>
</td>
<td class="nump">56,534,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 69,671,739<span></span>
</td>
<td class="nump">$ 75,869,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseLiabilitiesCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseLiabilitiesCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRdAndManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRdAndManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604457816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,259,013<span></span>
</td>
<td class="nump">43,207,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,259,013<span></span>
</td>
<td class="nump">43,207,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604476952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,083,167<span></span>
</td>
<td class="nump">$ 5,414,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,760,208<span></span>
</td>
<td class="nump">3,316,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,843,375<span></span>
</td>
<td class="nump">8,730,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(8,843,375)<span></span>
</td>
<td class="num">(8,730,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative instruments</a></td>
<td class="nump">364,596<span></span>
</td>
<td class="nump">932,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Other non-operating gains</a></td>
<td class="num">(30,793)<span></span>
</td>
<td class="nump">121,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(273,034)<span></span>
</td>
<td class="num">(260,390)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,782,606)<span></span>
</td>
<td class="num">(7,936,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,779)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (8,782,606)<span></span>
</td>
<td class="num">$ (8,022,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC and DILUTED</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">BASIC</a></td>
<td class="nump">43,077,961<span></span>
</td>
<td class="nump">38,670,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">DILUTED</a></td>
<td class="nump">43,083,420<span></span>
</td>
<td class="nump">38,767,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936603179656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,730,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2020</a></td>
<td class="nump">$ 19,726,674<span></span>
</td>
<td class="nump">$ 387,302<span></span>
</td>
<td class="nump">$ 401,174,675<span></span>
</td>
<td class="num">$ (381,835,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromTheSaleOfCommonStockShares', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromTheSaleOfCommonStockAmount', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">13,559,500<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">13,549,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">89,250<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">89,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityBasedCompensationEmployeesShares', window );">Equity based compensation - employees, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityBasedCompensationEmployeesAmount', window );">Equity based compensation - employees, amount</a></td>
<td class="nump">3,296,309<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">3,296,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">41,671<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">41,635<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock and options issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock and options issued to nonemployees for service, amount</a></td>
<td class="nump">$ 152,450<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">152,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises, amount</a></td>
<td class="nump">$ 23,511<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">23,458<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrantsAmount', window );">Modification of warrants</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(117,021)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(117,021)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,936,864)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,936,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,767,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td>
<td class="nump">28,835,672<span></span>
</td>
<td class="nump">$ 397,671<span></span>
</td>
<td class="nump">418,210,168<span></span>
</td>
<td class="num">(389,772,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,207,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2021</a></td>
<td class="nump">56,534,226<span></span>
</td>
<td class="nump">$ 432,072<span></span>
</td>
<td class="nump">474,298,566<span></span>
</td>
<td class="num">(418,196,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">157,954<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">157,757<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_EquityBasedCompensationEmployeesAmount', window );">Equity based compensation - employees, amount</a></td>
<td class="nump">3,262,296<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,262,296<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">52,555<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">52,479<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock and options issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock and options issued to nonemployees for service, amount</a></td>
<td class="nump">$ 143,160<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">142,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises, amount</a></td>
<td class="nump">$ 29,835<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">29,770<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(45,965)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(45,965)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,782,606)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,782,606)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,259,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2021</a></td>
<td class="nump">$ 51,351,455<span></span>
</td>
<td class="nump">$ 432,590<span></span>
</td>
<td class="nump">$ 477,897,883<span></span>
</td>
<td class="num">$ (426,979,018)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityBasedCompensationEmployeesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityBasedCompensationEmployeesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityBasedCompensationEmployeesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityBasedCompensationEmployeesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromTheSaleOfCommonStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromTheSaleOfCommonStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromTheSaleOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromTheSaleOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604209608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,782,606)<span></span>
</td>
<td class="num">$ (7,936,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">887,930<span></span>
</td>
<td class="nump">550,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">218,318<span></span>
</td>
<td class="nump">248,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">3,262,296<span></span>
</td>
<td class="nump">3,296,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">52,555<span></span>
</td>
<td class="nump">41,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on short-term investments</a></td>
<td class="num">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfOngoingProject', window );">Loss on patent impairment</a></td>
<td class="nump">30,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Gain on derivative instruments</a></td>
<td class="num">(364,596)<span></span>
</td>
<td class="num">(932,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ModificationOfWarrant', window );">Modification of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">144,542<span></span>
</td>
<td class="num">(332,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInMaterialsAndSupplies', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="num">(61,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(523,152)<span></span>
</td>
<td class="nump">532,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">95,685<span></span>
</td>
<td class="nump">143,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">Due to employees</a></td>
<td class="nump">209,046<span></span>
</td>
<td class="nump">10,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">24,997<span></span>
</td>
<td class="nump">18,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,805,946)<span></span>
</td>
<td class="num">(3,827,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from maturity of US treasury bills</a></td>
<td class="nump">6,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(17,036)<span></span>
</td>
<td class="num">(3,149,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(22,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">6,112,223<span></span>
</td>
<td class="num">(3,149,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,559,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(32,800)<span></span>
</td>
<td class="num">(79,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of warrants and options</a></td>
<td class="nump">117,200<span></span>
</td>
<td class="nump">70,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on obligations under finance lease</a></td>
<td class="num">(340,908)<span></span>
</td>
<td class="num">(221,620)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(256,508)<span></span>
</td>
<td class="nump">13,329,292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">1,049,769<span></span>
</td>
<td class="nump">6,351,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">36,060,148<span></span>
</td>
<td class="nump">15,508,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">37,109,917<span></span>
</td>
<td class="nump">21,860,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities', window );">Property and equipment included in current liabilities</a></td>
<td class="nump">469,005<span></span>
</td>
<td class="nump">1,700,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities', window );">Capitalizable patent costs included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock', window );">Prepaid consulting services paid with issuance of common stock</a></td>
<td class="nump">233,753<span></span>
</td>
<td class="nump">243,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExerciseOfDerivativeLiabilities', window );">Exercise of derivative liabilities</a></td>
<td class="nump">70,589<span></span>
</td>
<td class="nump">41,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">13,165<span></span>
</td>
<td class="nump">88,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 290,212<span></span>
</td>
<td class="nump">$ 277,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExerciseOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExerciseOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfOngoingProject">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfOngoingProject</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount of capitalized costs of materials, supplies, or both, which are not included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606193400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2021 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2021 is derived from the September 30, 2021 audited financial statements.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Patents</em> - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company adopted Accounting Standards Update (ASU) 2020-06, <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </em>effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 <em>Compensation &#8211; Stock Compensation</em>. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2021 and September 30, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company adopted ASU No. 2019-12, <em>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </em>effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#8217;s financial statements.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>New Accounting Pronouncements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606332664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATIONS AND FINANCING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>OPERATIONS AND FINANCING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">B. OPERATIONS AND FINANCING</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">OPERATIONS AND FINANCING</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#174; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5 year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5 years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Primarily as a result of the Company&#8217;s losses incurred to date, the Company&#8217;s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that here is sufficient cash on hand to meet the Company&#8217;s budgeted cash requirements, substantial doubt about the Company&#8217;s ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impact of the COVID-19 Pandemic</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In response to the global outbreak of COVID-19 and the World Health Organization&#8217;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention&#8217;s (&#8220;CDC&#8221;) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#8217;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606314216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">C. STOCKHOLDERS' EQUITY</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2020, the Company sold 1,000,000shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Equity Compensation</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Underlying share information for equity compensation plans as of December 31, 2021 is as follows:</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"><strong>Total Shares Reserved <br/>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"><strong>Shares <br/>Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,204,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">172,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,691</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">413,036</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">153,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,395</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Underlying share information for equity compensation plans as of September 30, 2021 is as follows:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"><strong>Total Shares Reserved <br/>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"><strong>Shares <br/>Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,972,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">363,086</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,641</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">153,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,395</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Stock option activity:</span></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended December31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,166</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the quarter ended December 31, 2021, the Company granted 250,000performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $10.48per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#8217;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. All options which have not vested as of November 18, 2031 will be canceled. On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost is recognized relating to these options as of December 31, 2021. Management will re-assess the probability of achieving the performance condition at each reporting date.</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Stock-Based Compensation Expense</span></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Three months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,262,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,296,309</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,318</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">248,660</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><em>Warrants and Non-Employee Options</em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The following chart represents the warrants and non-employee options outstanding at December 31, 2021:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Warrant/Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>Shares Issuable upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"><strong>Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Reference</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">8/18/2022&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">6/30/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">7/13/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">8/15/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/23/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.13</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 8.1pt; text-align:right;">2/16/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">8/26/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">100,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">13.75</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/22/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">6/22/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">205,587</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/24/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">251,761</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">10/30/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">12/19/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">12/18/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/5/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">600</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.24</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 - 11/18/2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">$2.18 $11.61</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/17/2022 - 7/27/2027</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* No current period changes to these warrants</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1. </p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Derivative Liabilities</span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The table below presents the fair value of the warrant liabilities at the balance sheet dates:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>September 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">795</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The table below presents the gains on the warrant liabilities for the three months ended December 31:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series W warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">278,363</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series ZZ warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,867</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">274,635</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,808</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series BB warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,632</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,372</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,345</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">802</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">251</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net gain on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">364,596</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">932,836</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Changes in Warrant Liabilities</span></em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021, 15,205 Series CC warrants were exercised at an exercise price of $5.00for gross proceeds of $76,000. During the three months ended December 31, 2020, 5,000 Series CC warrants were exercised at an exercise price of $5.00for gross proceeds of $25,000.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 8, 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. On November 23, 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75, expired. On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75, expired.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Equity Warrants</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Changes in Equity Warrants</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021, 4,500 Series NN warrants were exercised at an exercise price of $2.52 for gross proceeds of $11,340.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2020, 10,000 Series TT warrants were exercised at an exercise price of $2.24 for gross proceeds of $22,400.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021. The incremental cost of this extension was approximately $1,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series N warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021. The incremental cost of this extension was approximately $85,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series X warrants are also held by the de Clara Trust.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of the Series Y warrants, which were issued in connection with a financing, was extended six months from February 15, 2021 to August 15, 2021. The incremental cost of this extension was approximately $41,000 and was recorded as additional paid-in capital.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of Series UU warrants was extended six months from December 31, 2020 to June 30, 2021. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021 and 2020, the Company issued 18,020 and 15,044 shares of restricted common stock, respectively, to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $9.93 and $12.45 per share, respectively, during the three months ended December 31, 2021 and 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2020, the Company issued to a consultant 5,000 options to purchase common stock with an exercise price of $11.61. The options are exercisable beginning May 18, 2021 and expire on November 17, 2022. The options were expensed on a straight-line basis over the six month vesting period at a fair value of approximately $28,000 or $5.65 per option.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2021 and September 30, 2021, 15,000 options issued to consultants remained outstanding, all of which were issued from the Non-Qualified Stock Option plans. All 15,000 options are vested as of December 31, 2021.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021 and 2020, the Company recorded total expense of approximately $218,000 and $249,000, respectively, relating to the share based compensation under&#160;these consulting agreements. At December 31, 2021 and September 30, 2021, approximately $234,000and $364,000, respectively, are included in prepaid expenses.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Securities Purchase Agreement</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into a Securities Purchase Agreement with Ergomed plc (Ergomed), one of the Company&#8217;s CROs responsible for managing the Company&#8217;s Phase 3 clinical trial, to facilitate payment of amounts due to Ergomed. Under the Agreement, the Company issued Ergomed shares of common stock and the net proceeds from&#160;Ergomed's sales of those shares would reduce outstanding amounts due to&#160;Ergomed. Upon issuance, the Company expensed the full value of the shares as other non-operating gain/loss and subsequently offset the gain/loss as amounts were realized through the sale by Ergomed and reduced accounts payable to Ergomed.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No sales were made by Ergomed during the three months ended December 31, 2021. As of December 31, 2021, Ergomed had no shares for resale. During the three months ended December 31, 2020, the Company realized approximately $0.1 million through the sale by Ergomed of 9,000 shares of the Company&#8217;s common stock and the Company reduced the payables to Ergomed and credited Other Operating Gain by that amount. No shares were issued to Ergomed during the three months ended December 31, 2021 and 2020.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936686037576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">D. FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">FAIR VALUE MEASUREMENTS</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC 820-10, <em>&#8220;Fair Value Measurements,&#8221;</em> the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions. Assumptions from market participants are used when pricing the asset or liabilities, given there is no readily available market information.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company&#8217;s assessment of the significance of an input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company purchased short-term U.S. Treasury bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments; therefore, they were categorized as Level 1 in the fair value hierarchy. The Treasury bills matured in December 2021 and yielded a weighted average interest rate of 0.10%.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2021 and September 30, 2021, all of the Company&#8217;s derivative instruments are classified as Level 3 on the fair value hierarchy.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following sets forth a reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2021 and the year ended September 30, 2021:</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>3 months ended December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>12 months ended September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,023,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Realized and unrealized (gains) and losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(364,596</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">694,858</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair values of the Company&#8217;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#8217;s stock, as well as U.S. Treasury Bill rates, are observable in active markets. At December 31, 2021, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $0.02 per share and a weighted average exercise price of $13.73 per share. Fair values were determined using a weighted average risk-free interest rate of 0.06% and weighted average volatility of 79%. The instruments have a weighted average time to maturity of 0.14 years. At September 30, 2021, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk-free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936608739128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">E. RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the quarter ended December 31, 2021, the Company issued officers 250,000 options that vest upon FDA approval of the marketing application. See Note C for more information about the options.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust were extended by six months (Note C). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606246024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">F. COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">F. </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Clinical Research Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research and Development.&#8221; Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.3 million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $11.7 million. During the three months ended December 31, 2021 and 2020, the Company recorded, net of Ergomed&#8217;s discount, approximately $0.2 million and $0.6 million, respectively, as research and development expense related to Ergomed&#8217;s services.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Lease Agreements</em></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not probable.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 31, 2021 and September 30, 2021, the net book value of the finance lease right of use asset is approximately $12.3 million and $12.7 million, respectively and the balance of the finance lease liability is approximately $13.5 million and $13.8 million, respectively, of which approximately $0.6 million is current in each quarter. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the three months ended December 31, 2021 and 2020 was approximately $0.6 million and $0.5 million, respectively, of which approximately $0.3 million was for interest in each quarter. As of December 31, 2021, the weighted average discount rate of the Company&#8217;s finance leases is 8.45% and the weighted average time to maturity is 6.8 years.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The project was finished and the improvements were placed in service in October 2021. Total cost was $11.1 million, of which the landlord agreed to finance $2.4 million. Approximately $1.6 million of the landlord financing was received as of December 31 2021, and the remaining balance is expected to be received in the second quarter of fiscal year 2022. The landlord financing is being repaid through increased lease payments which started in March 2021 and extend over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. The leasehold improvements are recorded in property and equipment, were deemed to be placed in service in October 2021 and are being amortized over the remaining lease term.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. Under the landlord&#8217;s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. During the quarter ended December 31, 2021, it was determined that the Company met the minimum cash requirement and the deposits were returned in January 2022. The approximate $1.9 million deposit is included in current assets at December 31, 2021 and non-current assets at September 30, 2021.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">Approximate future minimum lease payments under finance leases as of December 31, 2021 are as follows:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2022&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,083,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,569,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,648,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,733,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,824,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,919,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,267,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation* </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,043,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,539,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">13,504,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">*<em>Amount is net of landlord incentive of approximately $0.8 million expected to be received during the quarter ended March 31, 2022.</em></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. As of December 31, 2021 and September 30, 2021, the net book value of the operating lease right of use assets is approximately $2.0 million and $2.1 million, respectively. As of December 31, 2021 and September 30, 2021, the balance of the operating lease liabilities is approximately $2.1 million. of which approximately $0.1 million, is current in each quarter. The Company incurred lease expense for operating leases of approximately $91,000 and $66,000, respectively, for the three months ended December 31, 2021 and 2020. Total cash paid related to operating leases during the three months ended December 31, 2021 and 2020 was approximately $66,000 and $48,000, respectively. The weighted average discount rate of the Company&#8217;s operating leases is 9.11% and the weighted average time to maturity is 9.5 years.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">As of December 31, 2021, future minimum lease payments on operating leases are as follows:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">243,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,325,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,203,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,081,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,122,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936609552424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">G. PATENTS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">G.</p></td><td style="vertical-align:top;"><span style="text-decoration:underline">PATENTS</span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended December 31, 2021, the Company recorded approximately $31,000 in patent impairment charges. No patent impairment charges were recorded during the three months ended December 2020. During the three months ended December 31, 2021 and 2020, amortization of patent costs totaled approximately $14,000 and $13,000, respectively. Approximate estimated future amortization expense is as follows:</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">248,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936609544024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">H. LOSS PER COMMON SHARE</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">H. </p></td><td style="vertical-align:top;"><span style="text-decoration:underline">LOSS PER COMMON SHARE </span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. For the years presented, the gain on warrant liabilities priced lower than the average market price during the period is excluded from the numerator and the incremental shares, determined using the treasury stock method, are added to the denominator in calculating diluted loss per share.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The following tables provide the details of the basic and diluted loss per-share computations:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ended December 31,</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; basic</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,782,606</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,022,643</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,077,961</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,670,247</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Basic loss per common share</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.21</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; diluted</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss available to common shareholders - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(8,782,606</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(8,022,643</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Gain on derivatives (1)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,114</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(164,073</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Net loss available to common shareholders - diluted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,807,720</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,186,716</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">43,077,961</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">38,670,247</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Incremental shares underlying dilutive - warrants and options (1)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,459</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">97,039</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding &#8211; diluted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,083,420</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,767,286</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Diluted loss earnings per common share</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.21</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(1) </em></p></td><td style="vertical-align:top;"><em>Includes Series CC and HH warrants for the three months ended December 31, 2021 and 2020.</em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,477,966</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,517,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">302,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">10,629,216</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6,819,660</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606230968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">I. SUBSEQUENT EVENTS</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:1%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">J. </p></td><td style="vertical-align:top;"><span style="text-decoration:underline">SUBSEQUENT EVENTS</span></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;">The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604189800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_USTreasuryBills', window );">U.S. Treasury Bills</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Patents</em> - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company adopted Accounting Standards Update (ASU) 2020-06, <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </em>effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 <em>Compensation &#8211; Stock Compensation</em>. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2021 and September 30, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company adopted ASU No. 2019-12, <em>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </em>effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_USTreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_USTreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936603095384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany', window );">Stock options, stock bonuses and compensation granted by the Company</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"><strong>Total Shares Reserved <br/>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"><strong>Shares <br/>Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,204,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">172,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,691</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">413,036</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">153,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,395</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"><strong>Total Shares Reserved <br/>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"><strong>Shares <br/>Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,972,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">363,086</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,641</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">153,195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">462,395</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Stock option activity:</span></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended December31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,166</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock', window );">Stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Stock-Based Compensation Expense</span></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Three months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,262,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,296,309</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,318</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">248,660</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions', window );">Derivative liabilities, warrants and other options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Warrant/Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>Shares Issuable upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"><strong>Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Reference</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">8/18/2022&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">6/30/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">7/13/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;">8/15/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/23/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.13</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 8.1pt; text-align:right;">2/16/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">8/26/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">100,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">13.75</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/22/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">6/22/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">205,587</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/24/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">251,761</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">10/30/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">12/19/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">12/18/2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2/5/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">600</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.24</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 - 11/18/2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">$2.18 $11.61</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/17/2022 - 7/27/2027</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock', window );">Schedule of fair value of warrant liabilites</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>September 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,961</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">795</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock', window );">Schedule of gain and (losses) on derivative liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series W warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">278,363</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series ZZ warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,867</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">274,635</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,808</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series BB warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,632</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,372</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,345</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">802</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">251</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net gain on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">364,596</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">932,836</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20517-108367<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606208232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>3 months ended December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>12 months ended September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,023,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Realized and unrealized (gains) and losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(364,596</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">694,858</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606241880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2022&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,083,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,569,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,648,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,733,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,824,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,919,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,267,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation* </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,043,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,539,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">13,504,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Nine months ending September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">243,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,325,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,203,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,081,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,122,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606296936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">248,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606269816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ended December 31,</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; basic</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Net loss available to common shareholders - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,782,606</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,022,643</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,077,961</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,670,247</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Basic loss per common share</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.21</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; diluted</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss available to common shareholders - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(8,782,606</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(8,022,643</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Gain on derivatives (1)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(25,114</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(164,073</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Net loss available to common shareholders - diluted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,807,720</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,186,716</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding - basic</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">43,077,961</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">38,670,247</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Incremental shares underlying dilutive - warrants and options (1)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,459</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">97,039</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Weighted average shares outstanding &#8211; diluted</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,083,420</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,767,286</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Diluted loss earnings per common share</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.21</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,477,966</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,517,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">302,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">10,629,216</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6,819,660</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606180408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Patent useful life</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606395176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockOptionPlansMember', window );">Incentive Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved under plans</a></td>
<td class="nump">138,400<span></span>
</td>
<td class="nump">138,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares reserved for outstanding options</a></td>
<td class="nump">76,829<span></span>
</td>
<td class="nump">76,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining options/shares under plans</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved under plans</a></td>
<td class="nump">11,787,200<span></span>
</td>
<td class="nump">11,787,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares reserved for outstanding options</a></td>
<td class="nump">11,204,380<span></span>
</td>
<td class="nump">10,972,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining options/shares under plans</a></td>
<td class="nump">172,592<span></span>
</td>
<td class="nump">410,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved under plans</a></td>
<td class="nump">783,760<span></span>
</td>
<td class="nump">783,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining options/shares under plans</a></td>
<td class="nump">413,036<span></span>
</td>
<td class="nump">420,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="nump">370,691<span></span>
</td>
<td class="nump">363,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved under plans</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="nump">634,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining options/shares under plans</a></td>
<td class="nump">462,395<span></span>
</td>
<td class="nump">462,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="nump">153,195<span></span>
</td>
<td class="nump">153,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved under plans</a></td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining options/shares under plans</a></td>
<td class="nump">25,500<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="nump">614,500<span></span>
</td>
<td class="nump">614,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936603245960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">251,000<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">42,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936605874744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employees stock based compensation expense</a></td>
<td class="nump">$ 3,262,296<span></span>
</td>
<td class="nump">$ 3,296,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non- Employees stock based compensation expense</a></td>
<td class="nump">$ 218,318<span></span>
</td>
<td class="nump">$ 248,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936600723176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">November 17, 2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">11/17/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 11.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">11/18/2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">8/18/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">6/30/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">7/13/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">8/15/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHhMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">2/23/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">2/16/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAaMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">8/26/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">2/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">6/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">205,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">7/24/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">251,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">10/30/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">12/19/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">12/18/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesTTMember', window );">Series TT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares issuable upon exercise of warrant/options | shares</a></td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue date</a></td>
<td class="text">2/5/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">2/5/2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfWarrantOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfWarrantOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesTTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesTTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936603117576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueOfSeriesZwarrants', window );">Series Z warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 64,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueOfSeriesAaWarrants', window );">Series AA warrants</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">276,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueOfSeriesCcWarrants', window );">Series CC warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">94,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueOfSeriesHhWarrants', window );">Series HH warrants</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_TotalFairValueOfDerivativeLiabilities', window );">Total warrant liabilities</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">437,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesWWarrants', window );">Gains on Series W warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesZWarrants', window );">Gains on Series Z warrants</a></td>
<td class="nump">64,787<span></span>
</td>
<td class="nump">278,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesZzWarrants', window );">Gains on Series ZZ warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesAaWarrants', window );">Gains on Series AA warrants</a></td>
<td class="nump">274,635<span></span>
</td>
<td class="nump">333,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesBbWarrants', window );">Gains on Series BB warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesCcWarrants', window );">Gains on Series CC warrants</a></td>
<td class="nump">24,372<span></span>
</td>
<td class="nump">164,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GainLossSeriesHhWarrants', window );">Gains on Series HH warrants</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Net gain on warrant liabilities</a></td>
<td class="nump">$ 364,596<span></span>
</td>
<td class="nump">$ 932,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueOfSeriesAaWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueOfSeriesAaWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueOfSeriesCcWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueOfSeriesCcWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueOfSeriesHhWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueOfSeriesHhWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueOfSeriesZwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueOfSeriesZwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesAaWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesAaWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesBbWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesBbWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesCcWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesCcWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesHhWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesHhWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesWWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesWWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesZWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesZWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossSeriesZzWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossSeriesZzWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_TotalFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_TotalFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936598856248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 08, 2021</div></th>
<th class="th"><div>Nov. 23, 2021</div></th>
<th class="th"><div>Aug. 22, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Oct. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Realized through sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueOfStockOption', window );">Fair value of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,559,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpenseIncluedPrepaidExpenses', window );">Total expense inclued prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,000<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_GrantPerformanceBasedStockOptions', window );">Grant performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CommonStockPrice', window );">Common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_StockOptionsVest', window );">Stock options vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_SeriesWWarrantsMember', window );">Series W Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">November 17, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember', window );">Consultants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NonQualifiedStockOptionSharesVest', window );">Non-Qualified Stock Option shares vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember', window );">Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="nump">$ 12.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,020<span></span>
</td>
<td class="nump">15,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cvm_DecemberTwoThousandTwentyMember', window );">December 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7/13/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8/15/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromWarrantsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePricePer', window );">Exercise price of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7/24/2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesTTMember', window );">Series TT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromWarrantsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePricePer', window );">Exercise price of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2/5/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCcMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ProceedsFromWarrantsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExercisePricePerShare', window );">Exercise price per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpiredDuringPeriod', window );">Warrants expired during period</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,205<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsExpiredDuringPeriod', window );">Warrants expired during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember', window );">Series N Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember', window );">Series UU warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ExpirationDateDescription', window );">Expiration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the expiration date of Series UU warrants was extended six months from December 31, 2020 to June 30, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePricePer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePricePer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpenseIncluedPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpenseIncluedPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obli</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GrantPerformanceBasedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GrantPerformanceBasedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonQualifiedStockOptionSharesVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonQualifiedStockOptionSharesVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockOptionsVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockOptionsVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_SeriesWWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_SeriesWWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_DecemberTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_DecemberTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesTTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesTTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936603196888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 437,380<span></span>
</td>
<td class="nump">$ 3,765,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Exercises</a></td>
<td class="num">(70,589)<span></span>
</td>
<td class="num">(4,023,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings', window );">Realized and unrealized (gains) and losses</a></td>
<td class="num">(364,596)<span></span>
</td>
<td class="nump">694,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="nump">$ 437,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604309944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRiskFreeInterestRate', window );">Weighted average risk free interest rate</a></td>
<td class="nump">0.06%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageFairValueDerivativeInstruments', window );">Weighted average fair value, Derivative instruments</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceDerivativeInstruments', window );">Weighted average exercise price, Derivative instruments</a></td>
<td class="nump">$ 13.73<span></span>
</td>
<td class="nump">$ 13.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_VolatilityRate', window );">Volatility rate</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageTimeToMaturityYear', window );">Weighted average time to maturity year</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">1 month 20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value Inputs Level 1 (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WeightedAverageRiskFreeInterestRate', window );">Weighted average risk free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageFairValueDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageFairValueDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageTimeToMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageTimeToMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936605854936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative ) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_OptionsIssued', window );">Options issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember', window );">Series UU warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember', window );">Series X Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders', window );">Deemed dividend after net loss to arrive at net loss available common shareholders</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OptionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OptionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604212056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear', window );">Nine months ending September 30, 2022</a></td>
<td class="nump">$ 1,083,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,569,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,733,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,824,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,919,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,267,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum finance lease obligation</a></td>
<td class="nump">18,043,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest on financing lease obligation</a></td>
<td class="num">(4,539,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetPresentValueOfLeaseFinanceLeaseObligations', window );">Net present value of lease finance lease obligations</a></td>
<td class="nump">$ 13,504,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetPresentValueOfLeaseFinanceLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetPresentValueOfLeaseFinanceLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936600625272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear', window );">Nine months ending September 30, 2022</a></td>
<td class="nump">$ 243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">348,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">357,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_LesseeOperatingLeaseLiabilityPayments', window );">Total future minimum lease obligation</a></td>
<td class="nump">3,203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on operating lease obligation</a></td>
<td class="num">(1,081,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_cfgh', window );">Net present value of operating lease obligation</a></td>
<td class="nump">$ 2,122,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LesseeOperatingLeaseLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LesseeOperatingLeaseLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_cfgh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_cfgh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936602957976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_MaturityYears', window );">Maturity years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_OperatingLeaseMaturityYears', window );">Operating lease maturity years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinanceLeaseObligationsNetOfCurrentPortion', window );">Finance lease obligations, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_ClinicalServiceTrial', window );">Clinical service trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average time to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0845%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_FinancingLeaseContractualArrangement', window );">Financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PaymentsMadeByLandlord', window );">Payments made by landlord</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember', window );">October 1, 2019 [Member] | Transaction One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CurrentBalance', window );">Current balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset', window );">Net book value of the finance lease right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_BalanceOfTheFinanceLeaseLiability', window );">Balance of the finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CashPaidRelatedToFinanceLeases', window );">Cash paid related to finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CashPaidRelatedToFinanceLeasesInterest', window );">Cash paid related to finance leases interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000.0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember', window );">October 1, 2019 [Member] | Transaction Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_CurrentBalance', window );">Current balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid related to operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000,000<span></span>
</td>
<td class="nump">4,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_NetBookValueOperatingLeaseRightOfUseAssets', window );">Net book value operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease - liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_BalanceOfTheFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_BalanceOfTheFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CashPaidRelatedToFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CashPaidRelatedToFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CashPaidRelatedToFinanceLeasesInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CashPaidRelatedToFinanceLeasesInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ClinicalServiceTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ClinicalServiceTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CurrentBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CurrentBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationsNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationsNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingLeaseContractualArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingLeaseContractualArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_MaturityYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_MaturityYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetBookValueOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetBookValueOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseMaturityYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseMaturityYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PaymentsMadeByLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PaymentsMadeByLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123397816&amp;loc=SL2265659-115463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_OctoberOneTwothousandNineTeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cvm_TransactionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cvm_TransactionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cvm_TransactionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cvm_TransactionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936603837992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Nine months ending September 30, 2022</a></td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 248,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936606340808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_PatentImpairmentCharges', window );">Patent impairment charges</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent costs</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PatentImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PatentImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936604252280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net loss available to common shareholders - basic</a></td>
<td class="num">$ (8,782,606)<span></span>
</td>
<td class="num">$ (8,022,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">43,077,961<span></span>
</td>
<td class="nump">38,670,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Loss per share- diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders -basic</a></td>
<td class="num">$ (8,782,606)<span></span>
</td>
<td class="num">$ (8,022,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain on derivatives</a></td>
<td class="num">(25,114)<span></span>
</td>
<td class="num">(164,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss available to common shareholders - diluted</a></td>
<td class="num">$ (8,807,720)<span></span>
</td>
<td class="num">$ (8,186,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">43,077,961<span></span>
</td>
<td class="nump">38,670,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Incremental shares underlying dilutive - warrants and options</a></td>
<td class="nump">5,459<span></span>
</td>
<td class="nump">97,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted</a></td>
<td class="nump">43,083,420<span></span>
</td>
<td class="nump">38,767,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss earnings per common share</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139936609647864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,629,216<span></span>
</td>
<td class="nump">6,819,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,477,966<span></span>
</td>
<td class="nump">6,517,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">151,250<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>cvm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-10-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-08-01to2020-08-31_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:OctoberOneTwothousandNineTeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cvm:TransactionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-07_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesXWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-07_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesUUWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesNWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_ConsultantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-28_cvm_SeriesWWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:SeriesWWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-28</instant>
        </period>
    </context>
    <context id="From2020-10-01to2020-10-28_cvm_SeriesWWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:SeriesWWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-28</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_DecemberTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:DecemberTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_DecemberTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:DecemberTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-08-21to2021-08-22_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-21</startDate>
            <endDate>2021-08-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-22_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-22</instant>
        </period>
    </context>
    <context id="AsOf2021-11-23_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-23</instant>
        </period>
    </context>
    <context id="From2021-11-22to2021-11-23_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-23</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_cvm_SeriesCcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesCcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-01to2021-12-08_cvm_SeriesCcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-08</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_srt_MaximumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_srt_MinimumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesAaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesHhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesAaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesHhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-02-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-10-01to2021-12-31">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-10-01to2021-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-10-01to2021-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-10-01to2021-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2021-10-01to2021-12-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">43207183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="0" unitRef="Shares">43259013</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <cvm:FairValueOfSeriesZwarrants contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</cvm:FairValueOfSeriesZwarrants>
    <cvm:FairValueOfSeriesCcWarrants contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</cvm:FairValueOfSeriesCcWarrants>
    <cvm:GainLossSeriesWWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</cvm:GainLossSeriesWWarrants>
    <cvm:GainLossSeriesZzWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</cvm:GainLossSeriesZzWarrants>
    <cvm:GainLossSeriesBbWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">0</cvm:GainLossSeriesBbWarrants>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="AsOf2021-12-31_cvm_LandlordMember"
      decimals="INF"
      unitRef="Pure">0.000845</us-gaap:DerivativeVariableInterestRate>
    <cvm:CurrentBalance
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="0"
      unitRef="USD">600000.0</cvm:CurrentBalance>
    <cvm:CurrentBalance
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="0"
      unitRef="USD">100000.0</cvm:CurrentBalance>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="0"
      unitRef="USD">2100000.0</us-gaap:OperatingLeaseLiability>
    <cvm:CashPaidRelatedToFinanceLeasesInterest
      contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="0"
      unitRef="USD">300000.0</cvm:CashPaidRelatedToFinanceLeasesInterest>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2021-10-01to2021-12-31_cvm_ErgomedMember">P7Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">14000</us-gaap:AmortizationOfIntangibleAssets>
    <dei:DocumentType contextRef="From2021-10-01to2021-12-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-10-01to2021-12-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-10-01to2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-10-01to2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-10-01to2021-12-31">001-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-10-01to2021-12-31">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-10-01to2021-12-31">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-10-01to2021-12-31">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-10-01to2021-12-31">8229 Boone Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-10-01to2021-12-31">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-10-01to2021-12-31">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-10-01to2021-12-31">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-10-01to2021-12-31">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-10-01to2021-12-31">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-10-01to2021-12-31">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-10-01to2021-12-31">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-10-01to2021-12-31">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-10-01to2021-12-31">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-10-01to2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-10-01to2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-10-01to2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-10-01to2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-10-01to2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-10-01to2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-02-02" decimals="INF" unitRef="Shares">43275738</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_847"
      unitRef="USD">37109917</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_848"
      unitRef="USD">36060148</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_849"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_850"
      unitRef="USD">6151385</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_851"
      unitRef="USD">54922</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_852"
      unitRef="USD">54922</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_853"
      unitRef="USD">723782</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_854"
      unitRef="USD">998482</us-gaap:PrepaidExpenseCurrent>
    <cvm:SuppliesUsedForRdAndManufacturing
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_855"
      unitRef="USD">2067723</cvm:SuppliesUsedForRdAndManufacturing>
    <cvm:SuppliesUsedForRdAndManufacturing
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_856"
      unitRef="USD">2006584</cvm:SuppliesUsedForRdAndManufacturing>
    <cvm:ShortTermDeposits
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_1165"
      unitRef="USD">1910917</cvm:ShortTermDeposits>
    <cvm:ShortTermDeposits
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1166"
      unitRef="USD">0</cvm:ShortTermDeposits>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_859"
      unitRef="USD">41867261</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_860"
      unitRef="USD">45271521</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_861"
      unitRef="USD">12252663</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_862"
      unitRef="USD">12691921</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_863"
      unitRef="USD">2014185</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_864"
      unitRef="USD">2056178</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_865"
      unitRef="USD">13290109</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_866"
      unitRef="USD">13663562</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_867"
      unitRef="USD">247521</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_868"
      unitRef="USD">275866</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_869"
      unitRef="USD">0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_870"
      unitRef="USD">1910917</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_871"
      unitRef="USD">69671739</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_872"
      unitRef="USD">75869965</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_875"
      unitRef="USD">1192825</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_876"
      unitRef="USD">1675813</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_877"
      unitRef="USD">899901</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_878"
      unitRef="USD">859216</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_879"
      unitRef="USD">475039</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_880"
      unitRef="USD">265993</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_881"
      unitRef="USD">2195</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_882"
      unitRef="USD">437380</us-gaap:DerivativeLiabilitiesCurrent>
    <cvm:LeaseLiabilitiesCurrentPortion
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_883"
      unitRef="USD">763535</cvm:LeaseLiabilitiesCurrentPortion>
    <cvm:LeaseLiabilitiesCurrentPortion
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_884"
      unitRef="USD">698665</cvm:LeaseLiabilitiesCurrentPortion>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_885"
      unitRef="USD">3333495</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_886"
      unitRef="USD">3937067</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_913"
      unitRef="USD">12880449</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_914"
      unitRef="USD">13252364</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_921"
      unitRef="USD">1981340</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_922"
      unitRef="USD">2021308</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_889"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_890"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_891"
      unitRef="USD">18320284</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_892"
      unitRef="USD">19335739</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_1184"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1185"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_578"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_580"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_582"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_917"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_918"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="fid_909"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_910"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_911"
      unitRef="Shares">43259013</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_595"
      unitRef="Shares">43207183</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_919"
      unitRef="USD">432590</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_920"
      unitRef="USD">432072</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_896"
      unitRef="USD">477897883</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_897"
      unitRef="USD">474298566</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_898"
      unitRef="USD">-426979018</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_899"
      unitRef="USD">-418196412</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_900"
      unitRef="USD">51351455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_901"
      unitRef="USD">56534226</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_902"
      unitRef="USD">69671739</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_903"
      unitRef="USD">75869965</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_924"
      unitRef="USD">6083167</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_925"
      unitRef="USD">5414760</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_926"
      unitRef="USD">2760208</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_927"
      unitRef="USD">3316156</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_928"
      unitRef="USD">8843375</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_929"
      unitRef="USD">8730916</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_930"
      unitRef="USD">-8843375</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_931"
      unitRef="USD">-8730916</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_932"
      unitRef="USD">364596</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_933"
      unitRef="USD">932836</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_934"
      unitRef="USD">-30793</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_935"
      unitRef="USD">121606</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_936"
      unitRef="USD">-273034</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_937"
      unitRef="USD">-260390</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_938"
      unitRef="USD">-8782606</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_939"
      unitRef="USD">-7936864</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_941"
      unitRef="USD">-85779</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_942"
      unitRef="USD">-8782606</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_943"
      unitRef="USD">-8022643</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      id="fid_945"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      id="fid_946"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_948"
      unitRef="Shares">43077961</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_949"
      unitRef="Shares">38670247</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_950"
      unitRef="Shares">43083420</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_951"
      unitRef="Shares">38767286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1176"
      unitRef="Shares">43207183</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_990"
      unitRef="USD">432072</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1177"
      unitRef="USD">474298566</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1178"
      unitRef="USD">-418196412</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1179"
      unitRef="USD">56534226</us-gaap:StockholdersEquity>
    <cvm:WarrantExercisesShares
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_957"
      unitRef="Shares">19705</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_958"
      unitRef="USD">197</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_959"
      unitRef="USD">157757</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1015"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_961"
      unitRef="USD">157954</cvm:WarrantExercisesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_962"
      unitRef="USD">0</cvm:EquityBasedCompensationEmployeesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_963"
      unitRef="USD">3262296</cvm:EquityBasedCompensationEmployeesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1020"
      unitRef="USD">0</cvm:EquityBasedCompensationEmployeesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_965"
      unitRef="USD">3262296</cvm:EquityBasedCompensationEmployeesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_966"
      unitRef="Shares">7605</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_967"
      unitRef="USD">76</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_968"
      unitRef="USD">52479</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1025"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_970"
      unitRef="USD">52555</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_971"
      unitRef="Shares">18020</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_972"
      unitRef="USD">180</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_973"
      unitRef="USD">142980</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1030"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_975"
      unitRef="USD">143160</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_976"
      unitRef="Shares">6500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_977"
      unitRef="USD">65</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_978"
      unitRef="USD">29770</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1035"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_980"
      unitRef="USD">29835</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1041"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_982"
      unitRef="USD">-45965</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1043"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_984"
      unitRef="USD">-45965</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1045"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1046"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_987"
      unitRef="USD">-8782606</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_988"
      unitRef="USD">-8782606</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_989"
      unitRef="Shares">43259013</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1170"
      unitRef="USD">432590</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_991"
      unitRef="USD">477897883</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_992"
      unitRef="USD">-426979018</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_993"
      unitRef="USD">51351455</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1171"
      unitRef="Shares">38730150</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1050"
      unitRef="USD">387302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1172"
      unitRef="USD">401174675</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1173"
      unitRef="USD">-381835303</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1174"
      unitRef="USD">19726674</us-gaap:StockholdersEquity>
    <cvm:ProceedsFromTheSaleOfCommonStockShares
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1007"
      unitRef="Shares">1000000</cvm:ProceedsFromTheSaleOfCommonStockShares>
    <cvm:ProceedsFromTheSaleOfCommonStockAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1008"
      unitRef="USD">10000</cvm:ProceedsFromTheSaleOfCommonStockAmount>
    <cvm:ProceedsFromTheSaleOfCommonStockAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1009"
      unitRef="USD">13549500</cvm:ProceedsFromTheSaleOfCommonStockAmount>
    <cvm:ProceedsFromTheSaleOfCommonStockAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1010"
      unitRef="USD">0</cvm:ProceedsFromTheSaleOfCommonStockAmount>
    <cvm:ProceedsFromTheSaleOfCommonStockAmount
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1011"
      unitRef="USD">13559500</cvm:ProceedsFromTheSaleOfCommonStockAmount>
    <cvm:WarrantExercisesShares
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1012"
      unitRef="Shares">15000</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1013"
      unitRef="USD">150</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1014"
      unitRef="USD">89100</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_960"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1016"
      unitRef="USD">89250</cvm:WarrantExercisesAmount>
    <cvm:EquityBasedCompensationEmployeesShares
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1017"
      unitRef="Shares">-2000</cvm:EquityBasedCompensationEmployeesShares>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1018"
      unitRef="USD">-20</cvm:EquityBasedCompensationEmployeesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1019"
      unitRef="USD">3296329</cvm:EquityBasedCompensationEmployeesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_964"
      unitRef="USD">0</cvm:EquityBasedCompensationEmployeesAmount>
    <cvm:EquityBasedCompensationEmployeesAmount
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1021"
      unitRef="USD">3296309</cvm:EquityBasedCompensationEmployeesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1022"
      unitRef="Shares">3564</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1023"
      unitRef="USD">36</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1024"
      unitRef="USD">41635</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_969"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1026"
      unitRef="USD">41671</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1027"
      unitRef="Shares">15044</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1028"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1029"
      unitRef="USD">152300</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_974"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1031"
      unitRef="USD">152450</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1032"
      unitRef="Shares">5300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1033"
      unitRef="USD">53</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1034"
      unitRef="USD">23458</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_979"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1036"
      unitRef="USD">23511</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1037"
      unitRef="USD">0</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1038"
      unitRef="USD">192</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1039"
      unitRef="USD">0</cvm:ModificationOfWarrantsAmount>
    <cvm:ModificationOfWarrantsAmount
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1040"
      unitRef="USD">192</cvm:ModificationOfWarrantsAmount>
    <cvm:ShareIssuanceCosts
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_981"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1042"
      unitRef="USD">-117021</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2021-10-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_983"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1044"
      unitRef="USD">-117021</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_985"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_986"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1047"
      unitRef="USD">-7936864</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1048"
      unitRef="USD">-7936864</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1049"
      unitRef="Shares">39767058</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1168"
      unitRef="USD">397671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1051"
      unitRef="USD">418210168</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1052"
      unitRef="USD">-389772167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1053"
      unitRef="USD">28835672</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1054"
      unitRef="USD">-8782606</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1055"
      unitRef="USD">-7936864</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1058"
      unitRef="USD">887930</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1059"
      unitRef="USD">550682</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1060"
      unitRef="USD">218318</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1061"
      unitRef="USD">248660</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1062"
      unitRef="USD">3262296</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1063"
      unitRef="USD">3296309</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1064"
      unitRef="USD">52555</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1065"
      unitRef="USD">41671</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <us-gaap:GainLossOnInvestments
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1066"
      unitRef="USD">-615</us-gaap:GainLossOnInvestments>
    <us-gaap:ImpairmentOfOngoingProject
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1068"
      unitRef="USD">30793</us-gaap:ImpairmentOfOngoingProject>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1070"
      unitRef="USD">-364596</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1071"
      unitRef="USD">-932836</us-gaap:GainLossOnSaleOfDerivatives>
    <cvm:ModificationOfWarrant
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1073"
      unitRef="USD">192</cvm:ModificationOfWarrant>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1076"
      unitRef="USD">532328</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1077"
      unitRef="USD">144542</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1078"
      unitRef="USD">-332785</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInMaterialsAndSupplies
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1079"
      unitRef="USD">-61139</us-gaap:IncreaseDecreaseInMaterialsAndSupplies>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1082"
      unitRef="USD">-523152</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1083"
      unitRef="USD">532679</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1084"
      unitRef="USD">95685</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1085"
      unitRef="USD">143028</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1086"
      unitRef="USD">209046</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1087"
      unitRef="USD">10718</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1088"
      unitRef="USD">24997</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1089"
      unitRef="USD">18319</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1090"
      unitRef="USD">-4805946</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1091"
      unitRef="USD">-3827899</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1093"
      unitRef="USD">6152000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1095"
      unitRef="USD">17036</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1096"
      unitRef="USD">3149820</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1097"
      unitRef="USD">22741</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1099"
      unitRef="USD">6112223</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1100"
      unitRef="USD">-3149820</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1103"
      unitRef="USD">13559500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1104"
      unitRef="USD">32800</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1105"
      unitRef="USD">79499</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1106"
      unitRef="USD">117200</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1107"
      unitRef="USD">70911</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1108"
      unitRef="USD">340908</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1109"
      unitRef="USD">221620</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1110"
      unitRef="USD">-256508</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1111"
      unitRef="USD">13329292</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1112"
      unitRef="USD">1049769</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1113"
      unitRef="USD">6351573</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1114"
      unitRef="USD">36060148</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1115"
      unitRef="USD">15508909</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_1116"
      unitRef="USD">37109917</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1117"
      unitRef="USD">21860482</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cvm:PropertyPlantEquipmentIncludedInCurrentLiabilities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1119"
      unitRef="USD">469005</cvm:PropertyPlantEquipmentIncludedInCurrentLiabilities>
    <cvm:PropertyPlantEquipmentIncludedInCurrentLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1120"
      unitRef="USD">1700969</cvm:PropertyPlantEquipmentIncludedInCurrentLiabilities>
    <cvm:CapitalizablePatentCostsIncludedInCurrentLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1122"
      unitRef="USD">15000</cvm:CapitalizablePatentCostsIncludedInCurrentLiabilities>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1123"
      unitRef="USD">771</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1124"
      unitRef="USD">1752</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1125"
      unitRef="USD">233753</cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1126"
      unitRef="USD">243687</cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:ExerciseOfDerivativeLiabilities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1127"
      unitRef="USD">70589</cvm:ExerciseOfDerivativeLiabilities>
    <cvm:ExerciseOfDerivativeLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1128"
      unitRef="USD">41850</cvm:ExerciseOfDerivativeLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1129"
      unitRef="USD">13165</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1130"
      unitRef="USD">88021</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_1131"
      unitRef="USD">290212</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1132"
      unitRef="USD">277618</us-gaap:InterestPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1133">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;A. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary for a fair presentation of the Company&#x2019;s financial position as of December 31, 2021 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2021 is derived from the September 30, 2021 audited financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Summary of Significant Accounting Policies:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;U.S. Treasury Bills &#x2013; &lt;/em&gt;U.S. Treasury Bills (&#x201c;T-bills&#x201d;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Derivative Instruments&lt;/em&gt; &#x2013; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company adopted Accounting Standards Update (ASU) 2020-06, &lt;em&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/em&gt;effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt;. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2021 and September 30, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company adopted ASU No. 2019-12, &lt;em&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes &lt;/em&gt;effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1134">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <cvm:USTreasuryBills contextRef="From2021-10-01to2021-12-31" id="fid_1135">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;U.S. Treasury Bills &#x2013; &lt;/em&gt;U.S. Treasury Bills (&#x201c;T-bills&#x201d;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&lt;/p&gt;</cvm:USTreasuryBills>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1136">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2021-10-01to2021-12-31" id="fid_1145">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="From2021-10-01to2021-12-31_us-gaap_PatentsMember"
      id="fid_488">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <cvm:LeasesPolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1137">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;</cvm:LeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1138">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Derivative Instruments&lt;/em&gt; &#x2013; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company adopted Accounting Standards Update (ASU) 2020-06, &lt;em&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/em&gt;effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1139">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt;. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-10-01to2021-12-31" id="fid_1140">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1141">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260 &#x201c;Earnings Per Share&#x201d; (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1142">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2021 and September 30, 2021.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company adopted ASU No. 2019-12, &lt;em&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes &lt;/em&gt;effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-10-01to2021-12-31" id="fid_1143">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities, stock options and the lease assets and liabilities to be significant.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1144">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2021-10-01to2021-12-31" id="fid_1146">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;B. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;OPERATIONS AND FINANCING&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine&#xae; (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5 year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5 years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Liquidity&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similarly to the way it has funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Primarily as a result of the Company&#x2019;s losses incurred to date, the Company&#x2019;s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Management has evaluated the significance of those conditions and has concluded that here is sufficient cash on hand to meet the Company&#x2019;s budgeted cash requirements, substantial doubt about the Company&#x2019;s ability to continue as a going concern for more than twelve months from the date of these financial statements has been alleviated.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Impact of the COVID-19 Pandemic&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In response to the global outbreak of COVID-19 and the World Health Organization&#x2019;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention&#x2019;s (&#x201c;CDC&#x201d;) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#x2019;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1147">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;C. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In December 2020, the Company sold 1,000,000shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Equity Compensation&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Underlying share information for equity compensation plans as of December 31, 2021 is as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;br/&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"&gt;&lt;strong&gt;Shares Reserved for Outstanding Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"&gt;&lt;strong&gt;Shares &lt;br/&gt;Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"&gt;&lt;strong&gt;Remaining Options/Shares &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76,829&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,204,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;172,592&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;783,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;370,691&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;413,036&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;153,195&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;462,395&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;614,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Underlying share information for equity compensation plans as of September 30, 2021 is as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;br/&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"&gt;&lt;strong&gt;Shares Reserved for Outstanding Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"&gt;&lt;strong&gt;Shares &lt;br/&gt;Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"&gt;&lt;strong&gt;Remaining Options/Shares &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76,829&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,972,880&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;410,592&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;783,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;363,086&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;420,641&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;153,195&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;462,395&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;614,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Stock option activity:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;&#160;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;251,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;42,166&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the quarter ended December 31, 2021, the Company granted 250,000performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $10.48per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#x2019;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. All options which have not vested as of November 18, 2031 will be canceled. On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost is recognized relating to these options as of December 31, 2021. Management will re-assess the probability of achieving the performance condition at each reporting date.&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;Three months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,262,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,296,309&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,318&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;248,660&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;em&gt;Warrants and Non-Employee Options&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The following chart represents the warrants and non-employee options outstanding at December 31, 2021:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;Warrant/Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Issue Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;Shares Issuable upon Exercise &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;of Warrants/ Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Expiration Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Reference&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;8/18/2022&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;6/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;7/13/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;8/15/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/23/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 8.1pt; text-align:right;"&gt;2/16/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;6/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;205,587&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;7/24/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;251,761&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 - 11/18/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;$2.18 $11.61&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11/17/2022 - 7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;* No current period changes to these warrants&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;span style="text-decoration:underline"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The table below presents the fair value of the warrant liabilities at the balance sheet dates:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series Z warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series AA warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series CC warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;94,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series HH warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;795&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,597&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total warrant liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,195&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The table below presents the gains on the warrant liabilities for the three months ended December 31:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series W warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,570&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series Z warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;278,363&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series ZZ warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;51,867&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series AA warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;274,635&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;333,808&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series BB warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,632&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series CC warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,372&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;164,345&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series HH warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;802&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;251&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Net gain on warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;364,596&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;932,836&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#x2019;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#x2019;s stock because future equity offerings or sales of the Company&#x2019;s stock are not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d; option on equity shares, and equity classification is therefore precluded.&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Changes in Warrant Liabilities&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2021, 15,205 Series CC warrants were exercised at an exercise price of $5.00for gross proceeds of $76,000. During the three months ended December 31, 2020, 5,000 Series CC warrants were exercised at an exercise price of $5.00for gross proceeds of $25,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 8, 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. On November 23, 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On August 22, 2021, 16,000 Series BB warrants, with an exercise price of $13.75, expired. On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75, expired.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Equity Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2021, 4,500 Series NN warrants were exercised at an exercise price of $2.52 for gross proceeds of $11,340.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2020, 10,000 Series TT warrants were exercised at an exercise price of $2.24 for gross proceeds of $22,400.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021. The incremental cost of this extension was approximately $1,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series N warrants are held by the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021. The incremental cost of this extension was approximately $85,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series X warrants are also held by the de Clara Trust.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration date of the Series Y warrants, which were issued in connection with a financing, was extended six months from February 15, 2021 to August 15, 2021. The incremental cost of this extension was approximately $41,000 and was recorded as additional paid-in capital.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration date of Series UU warrants was extended six months from December 31, 2020 to June 30, 2021. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;3. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Options and Shares Issued to Consultants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2021 and 2020, the Company issued 18,020 and 15,044 shares of restricted common stock, respectively, to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $9.93 and $12.45 per share, respectively, during the three months ended December 31, 2021 and 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2020, the Company issued to a consultant 5,000 options to purchase common stock with an exercise price of $11.61. The options are exercisable beginning May 18, 2021 and expire on November 17, 2022. The options were expensed on a straight-line basis over the six month vesting period at a fair value of approximately $28,000 or $5.65 per option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2021 and September 30, 2021, 15,000 options issued to consultants remained outstanding, all of which were issued from the Non-Qualified Stock Option plans. All 15,000 options are vested as of December 31, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2021 and 2020, the Company recorded total expense of approximately $218,000 and $249,000, respectively, relating to the share based compensation under&#160;these consulting agreements. At December 31, 2021 and September 30, 2021, approximately $234,000and $364,000, respectively, are included in prepaid expenses.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;4. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Securities Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company entered into a Securities Purchase Agreement with Ergomed plc (Ergomed), one of the Company&#x2019;s CROs responsible for managing the Company&#x2019;s Phase 3 clinical trial, to facilitate payment of amounts due to Ergomed. Under the Agreement, the Company issued Ergomed shares of common stock and the net proceeds from&#160;Ergomed's sales of those shares would reduce outstanding amounts due to&#160;Ergomed. Upon issuance, the Company expensed the full value of the shares as other non-operating gain/loss and subsequently offset the gain/loss as amounts were realized through the sale by Ergomed and reduced accounts payable to Ergomed.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;No sales were made by Ergomed during the three months ended December 31, 2021. As of December 31, 2021, Ergomed had no shares for resale. During the three months ended December 31, 2020, the Company realized approximately $0.1 million through the sale by Ergomed of 9,000 shares of the Company&#x2019;s common stock and the Company reduced the payables to Ergomed and credited Other Operating Gain by that amount. No shares were issued to Ergomed during the three months ended December 31, 2021 and 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-10-01to2021-12-31_cvm_DecemberTwoThousandTwentyMember"
      decimals="0"
      id="fid_343"
      unitRef="Shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-12-31_cvm_DecemberTwoThousandTwentyMember"
      decimals="INF"
      id="fid_346"
      unitRef="USDPShares">14.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-01to2021-12-31_cvm_DecemberTwoThousandTwentyMember"
      decimals="-5"
      id="fid_391"
      unitRef="USD">13600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany contextRef="From2021-10-01to2021-12-31" id="fid_1154">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;br/&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"&gt;&lt;strong&gt;Shares Reserved for Outstanding Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"&gt;&lt;strong&gt;Shares &lt;br/&gt;Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"&gt;&lt;strong&gt;Remaining Options/Shares &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76,829&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,204,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;172,592&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;783,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;370,691&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;413,036&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;153,195&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;462,395&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;614,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.05pt; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;br/&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; text-align:center;"&gt;&lt;strong&gt;Shares Reserved for Outstanding Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5pt; text-align:center;"&gt;&lt;strong&gt;Shares &lt;br/&gt;Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.5pt; text-align:center;"&gt;&lt;strong&gt;Remaining Options/Shares &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.85pt; TEXT-INDENT: 1.7pt; text-align:center;"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76,829&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,972,880&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;410,592&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;783,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;363,086&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;420,641&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;153,195&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;462,395&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;614,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_160"
      unitRef="Shares">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_165"
      unitRef="Shares">76829</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_167"
      unitRef="Shares">213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_161"
      unitRef="Shares">11787200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_166"
      unitRef="Shares">11204380</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_168"
      unitRef="Shares">172592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_162"
      unitRef="Shares">783760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_172"
      unitRef="Shares">370691</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_169"
      unitRef="Shares">413036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_163"
      unitRef="Shares">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_173"
      unitRef="Shares">153195</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_170"
      unitRef="Shares">462395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_164"
      unitRef="Shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_174"
      unitRef="Shares">614500</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_171"
      unitRef="Shares">25500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_175"
      unitRef="Shares">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_176"
      unitRef="Shares">76829</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_177"
      unitRef="Shares">213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_178"
      unitRef="Shares">11787200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_182"
      unitRef="Shares">10972880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_183"
      unitRef="Shares">410592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_179"
      unitRef="Shares">783760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_184"
      unitRef="Shares">363086</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_185"
      unitRef="Shares">420641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-09-30_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_180"
      unitRef="Shares">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_186"
      unitRef="Shares">153195</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_187"
      unitRef="Shares">462395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_181"
      unitRef="Shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_188"
      unitRef="Shares">614500</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_189"
      unitRef="Shares">25500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1155">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Stock option activity:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;&#160;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;251,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;42,166&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_193"
      unitRef="Shares">251000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_192"
      unitRef="Shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_197"
      unitRef="Shares">6500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_196"
      unitRef="Shares">5300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_204"
      unitRef="Shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_200"
      unitRef="Shares">42166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_202"
      unitRef="Shares">55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <cvm:GrantPerformanceBasedStockOptions
      contextRef="From2021-10-01to2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_398"
      unitRef="Shares">250000</cvm:GrantPerformanceBasedStockOptions>
    <cvm:CommonStockPrice
      contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_400"
      unitRef="USDPShares">10.48</cvm:CommonStockPrice>
    <cvm:StockOptionsVest
      contextRef="AsOf2021-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_401"
      unitRef="Pure">1</cvm:StockOptionsVest>
    <us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1156">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;Three months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,262,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,296,309&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,318&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;248,660&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_207"
      unitRef="USD">3262296</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_205"
      unitRef="USD">3296309</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_211"
      unitRef="USD">218318</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_209"
      unitRef="USD">248660</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions contextRef="From2021-10-01to2021-12-31" id="fid_1157">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;Warrant/Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;&lt;strong&gt;Issue Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;Shares Issuable upon Exercise &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;&lt;strong&gt;of Warrants/ Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Expiration Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Reference&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;8/18/2022&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;6/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;7/13/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 2.6pt; text-align:right;"&gt;8/15/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/23/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.13&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 8.1pt; text-align:right;"&gt;2/16/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;8/26/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;100,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;6/22/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;205,587&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;7/24/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;251,761&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 - 11/18/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;$2.18 $11.61&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11/17/2022 - 7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNMember"
      id="fid_243">8/18/2008</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesNMember"
      decimals="0"
      id="fid_212"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesNMember"
      decimals="INF"
      id="fid_227"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNMember"
      id="fid_261">8/18/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUMember"
      id="fid_244">6/11/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesUUMember"
      decimals="0"
      id="fid_213"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_228"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUMember"
      id="fid_262">6/30/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesXMember"
      id="fid_245">1/13/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesXMember"
      decimals="0"
      id="fid_214"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesXMember"
      decimals="INF"
      id="fid_229"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesXMember"
      id="fid_260">7/13/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesYMember"
      id="fid_246">2/15/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesYMember"
      decimals="0"
      id="fid_215"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesYMember"
      decimals="INF"
      id="fid_230"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesYMember"
      id="fid_263">8/15/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesHhMember"
      id="fid_250">2/23/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesHhMember"
      decimals="0"
      id="fid_219"
      unitRef="Shares">200</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesHhMember"
      decimals="INF"
      id="fid_234"
      unitRef="USDPShares">3.13</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesHhMember"
      id="fid_267">2/16/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesAaMember"
      id="fid_251">8/26/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesAaMember"
      decimals="0"
      id="fid_220"
      unitRef="Shares">100000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesAaMember"
      decimals="INF"
      id="fid_235"
      unitRef="USDPShares">13.75</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesAaMember"
      id="fid_268">2/22/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesMMMember"
      id="fid_252">6/22/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesMMMember"
      decimals="0"
      id="fid_221"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_236"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesMMMember"
      id="fid_269">6/22/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember"
      id="fid_253">7/24/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesNNMember"
      decimals="0"
      id="fid_222"
      unitRef="Shares">205587</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_237"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember"
      id="fid_270">7/24/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesRRMember"
      id="fid_254">10/30/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_223"
      unitRef="Shares">251761</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_238"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesRRMember"
      id="fid_271">10/30/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesSSMember"
      id="fid_255">12/19/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesSSMember"
      decimals="0"
      id="fid_224"
      unitRef="Shares">200000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_239"
      unitRef="USDPShares">2.09</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesSSMember"
      id="fid_272">12/18/2022</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember"
      id="fid_256">2/5/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_SeriesTTMember"
      decimals="0"
      id="fid_225"
      unitRef="Shares">600</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_240"
      unitRef="USDPShares">2.24</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember"
      id="fid_273">2/5/2023</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_srt_MinimumMember_cvm_ConsultantsMember"
      id="fid_257">7/28/2017</cvm:IssueDate1>
    <cvm:IssueDate1
      contextRef="From2021-10-01to2021-12-31_srt_MaximumMember_cvm_ConsultantsMember"
      id="fid_258">11/18/2020</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2021-12-31_cvm_ConsultantsMember"
      decimals="0"
      id="fid_226"
      unitRef="Shares">15000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_srt_MinimumMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_241"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2021-12-31_srt_MaximumMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_242"
      unitRef="USDPShares">11.61</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_srt_MinimumMember_cvm_ConsultantsMember"
      id="fid_274">11/17/2022</cvm:ExpirationDate>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_srt_MaximumMember_cvm_ConsultantsMember"
      id="fid_275">7/27/2027</cvm:ExpirationDate>
    <cvm:ScheduleOfFairValueOfWarrantLiabilitestabletextblock contextRef="From2021-10-01to2021-12-31" id="fid_1158">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series Z warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series AA warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series CC warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;94,961&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series HH warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;795&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,597&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total warrant liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,195&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfFairValueOfWarrantLiabilitestabletextblock>
    <cvm:FairValueOfSeriesZwarrants
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_279"
      unitRef="USD">64787</cvm:FairValueOfSeriesZwarrants>
    <cvm:FairValueOfSeriesAaWarrants
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_281"
      unitRef="USD">1400</cvm:FairValueOfSeriesAaWarrants>
    <cvm:FairValueOfSeriesAaWarrants
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_282"
      unitRef="USD">276035</cvm:FairValueOfSeriesAaWarrants>
    <cvm:FairValueOfSeriesCcWarrants
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_286"
      unitRef="USD">94961</cvm:FairValueOfSeriesCcWarrants>
    <cvm:FairValueOfSeriesHhWarrants
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_287"
      unitRef="USD">795</cvm:FairValueOfSeriesHhWarrants>
    <cvm:FairValueOfSeriesHhWarrants
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_288"
      unitRef="USD">1597</cvm:FairValueOfSeriesHhWarrants>
    <cvm:TotalFairValueOfDerivativeLiabilities
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_289"
      unitRef="USD">2195</cvm:TotalFairValueOfDerivativeLiabilities>
    <cvm:TotalFairValueOfDerivativeLiabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_290"
      unitRef="USD">437380</cvm:TotalFairValueOfDerivativeLiabilities>
    <cvm:ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1159">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series W warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,570&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series Z warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;278,363&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series ZZ warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;51,867&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series AA warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;274,635&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;333,808&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series BB warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,632&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series CC warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,372&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;164,345&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series HH warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;802&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;251&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Net gain on warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;364,596&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;932,836&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock>
    <cvm:GainLossSeriesWWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_295"
      unitRef="USD">73570</cvm:GainLossSeriesWWarrants>
    <cvm:GainLossSeriesZWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_302"
      unitRef="USD">64787</cvm:GainLossSeriesZWarrants>
    <cvm:GainLossSeriesZWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_301"
      unitRef="USD">278363</cvm:GainLossSeriesZWarrants>
    <cvm:GainLossSeriesZzWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_303"
      unitRef="USD">51867</cvm:GainLossSeriesZzWarrants>
    <cvm:GainLossSeriesAaWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_310"
      unitRef="USD">274635</cvm:GainLossSeriesAaWarrants>
    <cvm:GainLossSeriesAaWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_309"
      unitRef="USD">333808</cvm:GainLossSeriesAaWarrants>
    <cvm:GainLossSeriesBbWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_313"
      unitRef="USD">30632</cvm:GainLossSeriesBbWarrants>
    <cvm:GainLossSeriesCcWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_318"
      unitRef="USD">24372</cvm:GainLossSeriesCcWarrants>
    <cvm:GainLossSeriesCcWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_317"
      unitRef="USD">164345</cvm:GainLossSeriesCcWarrants>
    <cvm:GainLossSeriesHhWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_326"
      unitRef="USD">802</cvm:GainLossSeriesHhWarrants>
    <cvm:GainLossSeriesHhWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_325"
      unitRef="USD">251</cvm:GainLossSeriesHhWarrants>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_338"
      unitRef="USD">364596</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_337"
      unitRef="USD">932836</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <cvm:WarrantsExpiredDuringPeriod
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesCcMember"
      decimals="0"
      id="fid_1187"
      unitRef="Shares">15205</cvm:WarrantsExpiredDuringPeriod>
    <cvm:ExercisePricePerShare
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesCcMember"
      decimals="INF"
      id="fid_1197"
      unitRef="USDPShares">5.00</cvm:ExercisePricePerShare>
    <cvm:ProceedsFromWarrantsExercised
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesCcMember"
      decimals="0"
      id="fid_436"
      unitRef="USD">76000</cvm:ProceedsFromWarrantsExercised>
    <cvm:WarrantsExpiredDuringPeriod
      contextRef="From2020-10-01to2020-12-31_cvm_SeriesCcMember"
      decimals="0"
      id="fid_1188"
      unitRef="Shares">5000</cvm:WarrantsExpiredDuringPeriod>
    <cvm:ExercisePricePerShare
      contextRef="From2020-10-01to2020-12-31_cvm_SeriesCcMember"
      decimals="INF"
      id="fid_1198"
      unitRef="USDPShares">5.00</cvm:ExercisePricePerShare>
    <cvm:ProceedsFromWarrantsExercised
      contextRef="From2020-10-01to2020-12-31_cvm_SeriesCcMember"
      decimals="0"
      id="fid_440"
      unitRef="USD">25000</cvm:ProceedsFromWarrantsExercised>
    <cvm:WarrantsExpiredDuringPeriod
      contextRef="From2021-12-01to2021-12-08_cvm_SeriesCcMember"
      decimals="0"
      id="fid_1186"
      unitRef="Shares">640</cvm:WarrantsExpiredDuringPeriod>
    <cvm:ExercisePricePerShare
      contextRef="From2021-12-01to2021-12-08_cvm_SeriesCcMember"
      decimals="INF"
      id="fid_1196"
      unitRef="USDPShares">5.00</cvm:ExercisePricePerShare>
    <cvm:WarrantsExpired
      contextRef="From2021-11-22to2021-11-23_cvm_SeriesZMember"
      decimals="0"
      id="fid_452"
      unitRef="Shares">184800</cvm:WarrantsExpired>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-23_cvm_SeriesZMember"
      decimals="INF"
      id="fid_453"
      unitRef="USDPShares">13.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:WarrantsExpiredDuringPeriod
      contextRef="From2021-08-21to2021-08-22_cvm_SeriesBBMember"
      decimals="0"
      id="fid_1192"
      unitRef="Shares">16000</cvm:WarrantsExpiredDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-08-22_cvm_SeriesBBMember"
      decimals="INF"
      id="fid_459"
      unitRef="USDPShares">13.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:WarrantsExpired
      contextRef="From2020-10-01to2020-10-28_cvm_SeriesWWarrantsMember"
      decimals="0"
      id="fid_370"
      unitRef="Shares">688930</cvm:WarrantsExpired>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-10-28_cvm_SeriesWWarrantsMember"
      decimals="INF"
      id="fid_427"
      unitRef="USDPShares">16.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:WarrantsExpired
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember"
      decimals="0"
      id="fid_473"
      unitRef="Shares">4500</cvm:WarrantsExpired>
    <cvm:ExercisePricePer
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_470"
      unitRef="USDPShares">2.52</cvm:ExercisePricePer>
    <cvm:ProceedsFromWarrantsExercised
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNNMember"
      decimals="0"
      id="fid_461"
      unitRef="USD">11340</cvm:ProceedsFromWarrantsExercised>
    <cvm:WarrantsExpired
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember"
      decimals="0"
      id="fid_476"
      unitRef="Shares">10000</cvm:WarrantsExpired>
    <cvm:ExercisePricePer
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_467"
      unitRef="USDPShares">2.24</cvm:ExercisePricePer>
    <cvm:ProceedsFromWarrantsExercised
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesTTMember"
      decimals="0"
      id="fid_478"
      unitRef="USD">22400</cvm:ProceedsFromWarrantsExercised>
    <cvm:ExpirationDateDescription
      contextRef="From2020-12-01to2020-12-07_cvm_SeriesNWarrantsMember"
      id="fid_417">the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021</cvm:ExpirationDateDescription>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesNWarrantsMember"
      decimals="0"
      id="fid_410"
      unitRef="USD">1000</us-gaap:DefinedBenefitPlanInterestCost>
    <cvm:ExpirationDateDescription
      contextRef="From2020-12-01to2020-12-07_cvm_SeriesXMember"
      id="fid_418">the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021</cvm:ExpirationDateDescription>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesXMember"
      decimals="0"
      id="fid_412"
      unitRef="USD">85000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesYMember"
      decimals="0"
      id="fid_414"
      unitRef="USD">41000</us-gaap:DefinedBenefitPlanInterestCost>
    <cvm:ExpirationDateDescription
      contextRef="From2020-12-01to2020-12-07_cvm_SeriesUUWarrantsMember"
      id="fid_419">the expiration date of Series UU warrants was extended six months from December 31, 2020 to June 30, 2021</cvm:ExpirationDateDescription>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_411"
      unitRef="USD">192</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-10-01to2021-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_384"
      unitRef="Shares">18020</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-10-01to2020-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_481"
      unitRef="Shares">15044</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-01to2021-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_360"
      unitRef="USDPShares">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-01to2020-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_480"
      unitRef="USDPShares">12.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1
      contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsMember"
      decimals="0"
      id="fid_429"
      unitRef="Shares">5000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1>
    <cvm:ExpirationDate
      contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsMember"
      id="fid_422">November 17, 2022</cvm:ExpirationDate>
    <cvm:FairValueOfStockOption
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_365"
      unitRef="USD">28000</cvm:FairValueOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      id="fid_364"
      unitRef="USDPShares">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cvm:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued
      contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsOneMember"
      decimals="0"
      id="fid_395"
      unitRef="Shares">15000</cvm:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued>
    <cvm:NonQualifiedStockOptionSharesVest
      contextRef="From2021-10-01to2021-12-31_cvm_ConsultantsOneMember"
      decimals="0"
      id="fid_397"
      unitRef="Shares">15000</cvm:NonQualifiedStockOptionSharesVest>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-10-01to2021-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_431"
      unitRef="USD">218000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2020-10-01to2020-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_482"
      unitRef="USD">249000</us-gaap:CostsAndExpenses>
    <cvm:ExpenseIncluedPrepaidExpenses
      contextRef="AsOf2021-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1181"
      unitRef="USD">234000</cvm:ExpenseIncluedPrepaidExpenses>
    <cvm:ExpenseIncluedPrepaidExpenses
      contextRef="AsOf2021-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1183"
      unitRef="USD">364000</cvm:ExpenseIncluedPrepaidExpenses>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2021-10-01to2021-12-31"
      decimals="-5"
      id="fid_487"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1148">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;D. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC 820-10, &lt;em&gt;&#x201c;Fair Value Measurements,&#x201d;&lt;/em&gt; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions. Assumptions from market participants are used when pricing the asset or liabilities, given there is no readily available market information.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company&#x2019;s assessment of the significance of an input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company purchased short-term U.S. Treasury bills during the year ended September 30, 2021 that are classified as trading securities. Quoted market prices were applied to determine the fair value of short-term investments; therefore, they were categorized as Level 1 in the fair value hierarchy. The Treasury bills matured in December 2021 and yielded a weighted average interest rate of 0.10%.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2021 and September 30, 2021, all of the Company&#x2019;s derivative instruments are classified as Level 3 on the fair value hierarchy.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following sets forth a reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2021 and the year ended September 30, 2021:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;3 months ended December 31, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;12 months ended September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(70,589&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,023,091&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Realized and unrealized (gains) and losses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(364,596&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;694,858&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,195&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The fair values of the Company&#x2019;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#x2019;s stock, as well as U.S. Treasury Bill rates, are observable in active markets. At December 31, 2021, the Company&#x2019;s Level 3 derivative instruments have a weighted average fair value of $0.02 per share and a weighted average exercise price of $13.73 per share. Fair values were determined using a weighted average risk-free interest rate of 0.06% and weighted average volatility of 79%. The instruments have a weighted average time to maturity of 0.14 years. At September 30, 2021, the Company&#x2019;s Level 3 derivative instruments have a weighted average fair value of $1.45 per share and a weighted average exercise price of $13.28 per share. Fair values were determined using a weighted average risk-free interest rate of 0.05% and volatility of 109%. The instruments have a weighted average time to maturity of 0.3 years.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="INF"
      id="fid_503"
      unitRef="Pure">0.0010</cvm:WeightedAverageRiskFreeInterestRate>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1160">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;3 months ended December 31, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;12 months ended September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,765,613&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(70,589&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,023,091&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Realized and unrealized (gains) and losses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(364,596&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;694,858&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,195&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_498"
      unitRef="USD">437380</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_512"
      unitRef="USD">3765613</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_492"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_493"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_494"
      unitRef="USD">70589</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_495"
      unitRef="USD">4023091</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_496"
      unitRef="USD">-364596</cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings>
    <cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings
      contextRef="From2020-10-01to2021-09-30"
      decimals="0"
      id="fid_497"
      unitRef="USD">694858</cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_491"
      unitRef="USD">2195</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_489"
      unitRef="USD">437380</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <cvm:WeightedAverageFairValueDerivativeInstruments
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_502"
      unitRef="USDPShares">0.02</cvm:WeightedAverageFairValueDerivativeInstruments>
    <cvm:WeightedAverageExercisePriceDerivativeInstruments
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_504"
      unitRef="USDPShares">13.73</cvm:WeightedAverageExercisePriceDerivativeInstruments>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_505"
      unitRef="Pure">0.0006</cvm:WeightedAverageRiskFreeInterestRate>
    <cvm:VolatilityRate
      contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_506"
      unitRef="Pure">0.79</cvm:VolatilityRate>
    <cvm:WeightedAverageTimeToMaturityYear
      contextRef="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member"
      id="fid_507">P0Y1M20D</cvm:WeightedAverageTimeToMaturityYear>
    <cvm:WeightedAverageFairValueDerivativeInstruments
      contextRef="AsOf2021-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_500"
      unitRef="USDPShares">1.45</cvm:WeightedAverageFairValueDerivativeInstruments>
    <cvm:WeightedAverageExercisePriceDerivativeInstruments
      contextRef="AsOf2021-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_501"
      unitRef="USDPShares">13.28</cvm:WeightedAverageExercisePriceDerivativeInstruments>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_508"
      unitRef="Pure">0.0005</cvm:WeightedAverageRiskFreeInterestRate>
    <cvm:VolatilityRate
      contextRef="From2020-10-01to2021-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="fid_509"
      unitRef="Pure">1.09</cvm:VolatilityRate>
    <cvm:WeightedAverageTimeToMaturityYear
      contextRef="From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="fid_510">P0Y3M18D</cvm:WeightedAverageTimeToMaturityYear>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1149">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;E. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the quarter ended December 31, 2021, the Company issued officers 250,000 options that vest upon FDA approval of the marketing application. See Note C for more information about the options.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust were extended by six months (Note C). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:OptionsIssued
      contextRef="From2021-10-01to2021-12-31_srt_OfficerMember"
      decimals="0"
      id="fid_159"
      unitRef="Shares">250000</cvm:OptionsIssued>
    <cvm:DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesXWarrantsMember"
      decimals="0"
      id="fid_147"
      unitRef="USD">86000</cvm:DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders>
    <cvm:WarrantsIssued
      contextRef="AsOf2020-12-07_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_152"
      unitRef="Shares">93603</cvm:WarrantsIssued>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-10-01to2021-12-31_cvm_SeriesUUWarrantsMember"
      decimals="0"
      id="fid_155"
      unitRef="USD">192</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1150">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;F. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Clinical Research Agreements&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#x2019;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#x201c;Research and Development.&#x201d; Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.3 million for Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s discount of approximately $11.7 million. During the three months ended December 31, 2021 and 2020, the Company recorded, net of Ergomed&#x2019;s discount, approximately $0.2 million and $0.6 million, respectively, as research and development expense related to Ergomed&#x2019;s services.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not probable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 31, 2021 and September 30, 2021, the net book value of the finance lease right of use asset is approximately $12.3 million and $12.7 million, respectively and the balance of the finance lease liability is approximately $13.5 million and $13.8 million, respectively, of which approximately $0.6 million is current in each quarter. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the three months ended December 31, 2021 and 2020 was approximately $0.6 million and $0.5 million, respectively, of which approximately $0.3 million was for interest in each quarter. As of December 31, 2021, the weighted average discount rate of the Company&#x2019;s finance leases is 8.45% and the weighted average time to maturity is 6.8 years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In August 2020, the Company entered into an amendment to the San Tomas lease under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The project was finished and the improvements were placed in service in October 2021. Total cost was $11.1 million, of which the landlord agreed to finance $2.4 million. Approximately $1.6 million of the landlord financing was received as of December 31 2021, and the remaining balance is expected to be received in the second quarter of fiscal year 2022. The landlord financing is being repaid through increased lease payments which started in March 2021 and extend over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. The leasehold improvements are recorded in property and equipment, were deemed to be placed in service in October 2021 and are being amortized over the remaining lease term.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. Under the landlord&#x2019;s $2.4 million financing arrangement, the Company was required to deposit an additional $0.2 million in March 2021. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. During the quarter ended December 31, 2021, it was determined that the Company met the minimum cash requirement and the deposits were returned in January 2022. The approximate $1.9 million deposit is included in current assets at December 31, 2021 and non-current assets at September 30, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Approximate future minimum lease payments under finance leases as of December 31, 2021 are as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2022&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,083,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,569,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,648,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,733,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,824,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,919,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,267,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation* &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,043,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,539,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,504,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;*&lt;em&gt;Amount is net of landlord incentive of approximately $0.8 million expected to be received during the quarter ended March 31, 2022.&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. As of December 31, 2021 and September 30, 2021, the net book value of the operating lease right of use assets is approximately $2.0 million and $2.1 million, respectively. As of December 31, 2021 and September 30, 2021, the balance of the operating lease liabilities is approximately $2.1 million. of which approximately $0.1 million, is current in each quarter. The Company incurred lease expense for operating leases of approximately $91,000 and $66,000, respectively, for the three months ended December 31, 2021 and 2020. Total cash paid related to operating leases during the three months ended December 31, 2021 and 2020 was approximately $66,000 and $48,000, respectively. The weighted average discount rate of the Company&#x2019;s operating leases is 9.11% and the weighted average time to maturity is 9.5 years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;As of December 31, 2021, future minimum lease payments on operating leases are as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;243,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;348,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,325,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,203,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,081,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,122,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cvm:ClinicalServiceTrial
      contextRef="From2021-10-01to2021-12-31_cvm_ErgomedMember"
      decimals="-6"
      id="fid_126"
      unitRef="USD">12000000</cvm:ClinicalServiceTrial>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="-5"
      id="fid_84"
      unitRef="USD">35300000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2021-10-01to2021-12-31"
      decimals="-5"
      id="fid_87"
      unitRef="USD">11700000</cvm:NetOfDiscount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2021-12-31_cvm_ErgomedMember"
      decimals="-5"
      id="fid_85"
      unitRef="USD">200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2020-12-31_cvm_ErgomedMember"
      decimals="-5"
      id="fid_83"
      unitRef="USD">600000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_118"
      unitRef="USD">12300000</cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset>
    <cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_132"
      unitRef="USD">12700000</cvm:NetBookValueOfTheFinanceLeaseRightOfUseAsset>
    <cvm:BalanceOfTheFinanceLeaseLiability
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_120"
      unitRef="USD">13500000</cvm:BalanceOfTheFinanceLeaseLiability>
    <cvm:BalanceOfTheFinanceLeaseLiability
      contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_133"
      unitRef="USD">13800000</cvm:BalanceOfTheFinanceLeaseLiability>
    <cvm:CurrentBalance
      contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_134"
      unitRef="USD">600000</cvm:CurrentBalance>
    <cvm:CashPaidRelatedToFinanceLeases
      contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_122"
      unitRef="USD">600000</cvm:CashPaidRelatedToFinanceLeases>
    <cvm:CashPaidRelatedToFinanceLeases
      contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_123"
      unitRef="USD">500000</cvm:CashPaidRelatedToFinanceLeases>
    <cvm:CashPaidRelatedToFinanceLeasesInterest
      contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="-5"
      id="fid_124"
      unitRef="USD">300000</cvm:CashPaidRelatedToFinanceLeasesInterest>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionOneMember"
      decimals="INF"
      id="fid_75"
      unitRef="Pure">0.0845</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <cvm:MaturityYears contextRef="From2021-10-01to2021-12-31" id="fid_81">P6Y9M18D</cvm:MaturityYears>
    <cvm:FinancingLeaseContractualArrangement
      contextRef="From2021-10-01to2021-12-31_cvm_LandlordMember"
      decimals="-5"
      id="fid_100"
      unitRef="USD">11100000</cvm:FinancingLeaseContractualArrangement>
    <cvm:PaymentsMadeByLandlord
      contextRef="From2020-08-01to2020-08-31_cvm_LandlordMember"
      decimals="-5"
      id="fid_135"
      unitRef="USD">2400000</cvm:PaymentsMadeByLandlord>
    <cvm:PaymentsMadeByLandlord
      contextRef="From2021-10-01to2021-12-31_cvm_LandlordMember"
      decimals="-5"
      id="fid_136"
      unitRef="USD">1600000</cvm:PaymentsMadeByLandlord>
    <us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases
      contextRef="From2021-10-01to2021-12-31_cvm_LandlordMember"
      id="fid_89">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.</us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="fid_76"
      unitRef="Pure">0.0845</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <cvm:FinanceLeaseObligationsNetOfCurrentPortion
      contextRef="AsOf2021-03-31"
      decimals="-5"
      id="fid_91"
      unitRef="USD">200000</cvm:FinanceLeaseObligationsNetOfCurrentPortion>
    <cvm:FinanceLeaseObligationsNetOfCurrentPortion
      contextRef="AsOf2020-12-31"
      decimals="-5"
      id="fid_92"
      unitRef="USD">1900000</cvm:FinanceLeaseObligationsNetOfCurrentPortion>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1161">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2022&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,083,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,569,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,648,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,733,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,824,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,919,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,267,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation* &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,043,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,539,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,504,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_55"
      unitRef="USD">1083000</cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_56"
      unitRef="USD">2569000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_57"
      unitRef="USD">2648000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_58"
      unitRef="USD">2733000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_59"
      unitRef="USD">2824000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_60"
      unitRef="USD">2919000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_61"
      unitRef="USD">3267000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_62"
      unitRef="USD">18043000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_63"
      unitRef="USD">4539000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <cvm:NetPresentValueOfLeaseFinanceLeaseObligations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_64"
      unitRef="USD">13504000</cvm:NetPresentValueOfLeaseFinanceLeaseObligations>
    <cvm:NetBookValueOperatingLeaseRightOfUseAssets
      contextRef="AsOf2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="-5"
      id="fid_105"
      unitRef="USD">2000000.0</cvm:NetBookValueOperatingLeaseRightOfUseAssets>
    <cvm:NetBookValueOperatingLeaseRightOfUseAssets
      contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="-5"
      id="fid_137"
      unitRef="USD">2100000</cvm:NetBookValueOperatingLeaseRightOfUseAssets>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="-5"
      id="fid_140"
      unitRef="USD">2100000</us-gaap:OperatingLeaseLiability>
    <cvm:CurrentBalance
      contextRef="AsOf2021-09-30_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="-5"
      id="fid_139"
      unitRef="USD">100000</cvm:CurrentBalance>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="0"
      id="fid_114"
      unitRef="USD">91000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="0"
      id="fid_113"
      unitRef="USD">66000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-10-01to2021-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="-5"
      id="fid_104"
      unitRef="USD">6600000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-10-01to2020-12-31_cvm_OctoberOneTwothousandNineTeenMember_cvm_TransactionTwoMember"
      decimals="-5"
      id="fid_103"
      unitRef="USD">4800000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="fid_77"
      unitRef="Pure">0.0911</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cvm:OperatingLeaseMaturityYears contextRef="From2021-10-01to2021-12-31" id="fid_82">P9Y6M</cvm:OperatingLeaseMaturityYears>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1162">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Nine months ending September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;243,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;348,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,325,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,203,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,081,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,122,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_65"
      unitRef="USD">243000</cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_66"
      unitRef="USD">348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_67"
      unitRef="USD">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_68"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_69"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_70"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_71"
      unitRef="USD">1325000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <cvm:LesseeOperatingLeaseLiabilityPayments
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_72"
      unitRef="USD">3203000</cvm:LesseeOperatingLeaseLiabilityPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_73"
      unitRef="USD">1081000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <cvm:cfgh
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_74"
      unitRef="USD">2122000</cvm:cfgh>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1151">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;G.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;span style="text-decoration:underline"&gt;PATENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended December 31, 2021, the Company recorded approximately $31,000 in patent impairment charges. No patent impairment charges were recorded during the three months ended December 2020. During the three months ended December 31, 2021 and 2020, amortization of patent costs totaled approximately $14,000 and $13,000, respectively. Approximate estimated future amortization expense is as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;72,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;248,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <cvm:PatentImpairmentCharges
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_54"
      unitRef="USD">31000</cvm:PatentImpairmentCharges>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_52"
      unitRef="USD">13000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1163">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;72,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;248,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_43"
      unitRef="USD">35000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_44"
      unitRef="USD">38000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_45"
      unitRef="USD">30000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_46"
      unitRef="USD">28000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_47"
      unitRef="USD">24000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_48"
      unitRef="USD">21000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_49"
      unitRef="USD">72000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="fid_50"
      unitRef="USD">248000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1152">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;H. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;span style="text-decoration:underline"&gt;LOSS PER COMMON SHARE &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. For the years presented, the gain on warrant liabilities priced lower than the average market price during the period is excluded from the numerator and the incremental shares, determined using the treasury stock method, are added to the denominator in calculating diluted loss per share.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The following tables provide the details of the basic and diluted loss per-share computations:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three months ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Loss per share &#x2013; basic&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,782,606&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,022,643&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,077,961&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;38,670,247&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt"&gt;Basic loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.20&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.21&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Loss per share &#x2013; diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,782,606&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,022,643&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Gain on derivatives (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(25,114&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(164,073&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"&gt;Net loss available to common shareholders - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,807,720&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,186,716&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;43,077,961&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,670,247&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Incremental shares underlying dilutive - warrants and options (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,459&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;97,039&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Weighted average shares outstanding &#x2013; diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,083,420&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;38,767,286&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt"&gt;Diluted loss earnings per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.20&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.21&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:3%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:3%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;em&gt;(1) &lt;/em&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;em&gt;Includes Series CC and HH warrants for the three months ended December 31, 2021 and 2020.&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,477,966&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,517,160&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;302,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,629,216&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,819,660&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock contextRef="From2021-10-01to2021-12-31" id="fid_1164">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three months ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Loss per share &#x2013; basic&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,782,606&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,022,643&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,077,961&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;38,670,247&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt"&gt;Basic loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.20&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.21&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Loss per share &#x2013; diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Net loss available to common shareholders - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,782,606&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,022,643&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Gain on derivatives (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(25,114&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(164,073&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"&gt;Net loss available to common shareholders - diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,807,720&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,186,716&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Weighted average shares outstanding - basic&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;43,077,961&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,670,247&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Incremental shares underlying dilutive - warrants and options (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,459&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;97,039&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Weighted average shares outstanding &#x2013; diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,083,420&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;38,767,286&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt"&gt;Diluted loss earnings per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.20&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.21&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:94%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,477,966&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,517,160&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;302,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,629,216&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,819,660&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_21"
      unitRef="USD">-8782606</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_1"
      unitRef="USD">-8022643</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_22"
      unitRef="Shares">43077961</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_3"
      unitRef="Shares">38670247</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      id="fid_23"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      id="fid_5"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_24"
      unitRef="USD">-8782606</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_8"
      unitRef="USD">-8022643</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_25"
      unitRef="USD">-25114</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_10"
      unitRef="USD">-164073</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_26"
      unitRef="USD">-8807720</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_12"
      unitRef="USD">-8186716</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_27"
      unitRef="Shares">43077961</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_14"
      unitRef="Shares">38670247</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_28"
      unitRef="Shares">5459</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_15"
      unitRef="Shares">97039</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_29"
      unitRef="Shares">43083420</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_18"
      unitRef="Shares">38767286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      id="fid_511"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      id="fid_20"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2021-12-31_cvm_OptionsMember"
      decimals="0"
      id="fid_37"
      unitRef="Shares">10477966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2020-12-31_cvm_OptionsMember"
      decimals="0"
      id="fid_38"
      unitRef="Shares">6517160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2021-12-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_40"
      unitRef="Shares">151250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2020-12-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_42"
      unitRef="Shares">302500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      id="fid_39"
      unitRef="Shares">10629216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      id="fid_41"
      unitRef="Shares">6819660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-10-01to2021-12-31" id="fid_1153">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;J. &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M,G]=U^0Y"==?JSN'P45,TVI;UF PQ)!*TZ>-3'\6N4+"R+%T$+7A<ZB !*:
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MO@&N;X10YP/] \7N[?@_4$L#!!0    (  ^"2U0JAF]=G@8  (\9   8
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG5EM4^,V$/XKFLS-7#N3$$ORZQ68
M"4DZQS0%2D([_6@<A7C.MGRR#$=_?5=.B!-+%K1\ -MYM'YVL]IG5YR_</&M
MVC(FT8\\*ZJ+P5;*\LMX7"5;EL?5&2]9 9]LN,AC";?B:5R5@L7K9E&>C8GC
M^.,\3HO!Y7GS[$Y<GO-:9FG![@2JZCR/Q>L5R_C+Q0 /WA[<IT];J1Z,+\_+
M^(DMF7PH[P3<C0]6UFG.BBKE!1)L<S&8X"]3ZJH%#>+/E+U41]=(N?+(^3=U
M<[V^&#B*$<M8(I6)&/X\LRG+,F4)>'S?&QT<WJD6'E^_6?^U<1Z<>8PK-N79
M7^E:;B\&X0"MV2:N,WG/7[ZRO4.>LI?PK&I^HY<]UAF@I*XDS_>+@4&>%KN_
M\8]]((X68+=G =DO(!]=0/<+:./HCEGCUBR6\>6YX"](*#184Q=-;)K5X$U:
MJ*]Q*05\FL(Z>3F]O9G-;Y;S&;J:+"8WTSE:?IW/5TLT0@_+&?KIT\_G8PGO
M4>AQLK=YM;-)>FS.6'*&*!XBXA!L6#ZU+U^R$I8[IN5C\.[@(CFX2!I[M,_%
M6@A62#2I*B:K+Q:+]&"1-A;=/HMQM45QL4:)NF#?Z_0YSN 5E2E6.U-^8TIM
MJN=+&F GBG!P/GX^CHH!Z#N^@]WP #QAZQ[8NE:V#V?+,[2"/5[5XA5=I5EF
MY+DSXAV]WND0U!$^]C -/3,_[\#/L_*[9PF# #YFS,C+T][JN1$A'6[OH4Z8
M^0=FOI79G6!EG*X1^P%5LS+3\[47!X0&89>?#HNBT U[" 8'@H&5X+(NRRQE
M%:HKMD90U-']K$G,/"[J#93(6J3%DXEVH/$ACA\ ]0YO$\[QO= U$P\/Q$,[
M\2T7<B29R*'FEKQ*S7LGU-Z.(]@[VM;1<8Z97W3@%UGYK;B,,ZB_N\H1-Y7#
M1##27NSBT ^(CSL,#4"/!-@CV$P4.VT!=ZQ4?TV+N$@8RF"#,R24;"&^41EA
MX;VW>1)90CSB^]T$,"+]"$>]S(^D!UN9WY9,Q!(2]#]RQX:<Q!!WKTO=!/1\
M'/045-PJ"B;O% ;HHX1\;?::JO\E=#9RB HFC8R)'D-*(@=2N4O9A(0OQ?-[
M*@5N-0O;1>LNEBJ7$U[)JI\IU4/F!L=9NN=IP 5>Z/L]+%NMPG:QFEFJ 7Y?
MH@R0;L4X)=:*%+:KU*XB6+)25R _\@,<4.T[UI$J=%'D]P@I;O4*^Q]J=19I
M_)AFJ01IL/4[N-49;!>:29+P&AH<5,:O2JF-$="U D.9"(FV+PU 'T* :8__
MK:I@NZP 35$SNV!C72S"*(+-V&5IP'E0]?I2O)46;->66<V0Y(CE9<9?60])
M@UX$GJ/GDHXCOA=%/9$DK:H0NZK,F(">3(U8*"TJ*6I5X*!NO$EB"?H-8YB)
M.]$5@^"HFP0&E$L#&O8(-VE5A=A59=%H2=;N@(^1UK4B@+)+-=HZSH^@[O5L
M77(TI-@EY;3C.*)O9*O+!(4?5X^R 1C1 %J]'KZMG!"[G)RV'2?A!FU1*OZ1
MJ.LR@DD8.J[;3703DD+#0OV>3I2TDD/LDM-M0_ZO+R;I@9KF=C7* %23+G5Z
MVA+2:A2Q:]2MW#+Q;N[H\H.)YS@:S7=QIRQ;D2+VJ6J7Z>^QU <F'%*(T]'D
ML>=I0$:4>L?">\JT53UB5[TIS_-4-I5O-^[S0N4)*Y(^UKJR:6&U04YYMK)'
M0JOL+U>WT]^^WBYF\_OE9S3_X^%Z];?MX*25*F*7*AB -PPR?XTJR9-O0_3I
MS,'0 PCT'&<U&\$L.(2,0-4V%C"%QK6$N2[]AZU_02-G]/8XK2HERBJ"O):5
MA(N>J93H<J;%SP8Y/<UIQ8[:Q4Y]S[PP^XA&R-]YV>>I2X?$BX8.IHV+ZM8)
MAI"M=O]1+-&,)2Q_A#W[=EK6@):LE/O'^U.P(0([)6N./+-7XRF324Z!5C=\
M9IP3](P7M)5=:I?=R7J=JM((6UN=F8S2 B5QF<)6-]+59=0-@C *PK [@!JA
M+HE"KV_:H*WH4KOH0K]8YW4&D]%:G?VF26J<BJBNHB,7AN  NL:P2]>$Q2&.
M?!?W!?GHW-$NNKO2V>3IEF=K)JK/S?@IS3FA:Z:'J8==K]LFF)"^1UU"^D+<
MJBNUJ^OJ=C59H,7UY.IZ<;VZGB_1Y&:&WJ]8>Q=<[5"T9ZHR('NFJO'1:;GZ
M5\7OL7B"'A?4?P-+G;, PB!VI_^[&\G+Y@#]D4O)\^9RRV*(O@+ YQO.Y=N-
M.I,__ _F\E]02P,$%     @ #X)+5(HJ_XBG @  *PD  !@   !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R=EFMOFS 4AO^*A?9AD[I@(.12)4@MR=1)6Q8U
MNWQVX"18!<QLDW3[];,-94E#;LV'8)OSOGZ..=B,MHP_B01 HN<LS<782J0L
M;FU;1 ED1'18 ;FZLV(\(U)U^=H6!0<2&U&6VB[&/3LC-+>"D1F;\V#$2IG2
M'.8<B3++"/]S#RG;CBW'>AEXI.M$Z@$[&!5D#0N0/XHY5SV[<8EI!KF@+$<<
M5F/KSKD-':P%)N(GA:W8:2.=RI*Q)]WY'(\MK(D@A4AJ"Z(N&P@A3;63XOA=
MFUK-G%JXVWYQ_V225\DLB8"0I;]H+).Q-;!0#"M2IO*1;1^@3LC7?A%+A?E'
MVRK6[UHH*H5D62U6!!G-JRMYKA=B1^ <$[BUP+U4X-4"SR1:D9FT)D228,39
M%G$=K=QTPZR-4:ML:*X?XT)R=9<JG0S";[/)=+:83M#]W9>[63A%BX?I]/L"
MO9\3#KE,0-*(I!_01_0.V4@D:E2,;*FFU@9V5$]S7TWC'IEF E$'><X-<K'K
MM,C#T_(%%$J.V^2V2KC)VFVR=HV?=V76)ZR]QMHSUMTCUG-5AL YQ$@]N^CI
M!A6$HPU)2VA;M<JK;[ST&[<)< >K##>[:W,F: ^SVV!VK\.LGBPBI4P8IW\A
M;L.M//T=$K5=Z-\KXF-Q[<Q^P^R_B9D*4;;S^@<<KTE/1>Q!]AK(WIL@U18J
M),ECFJ_;2'MG24]%[)'V&]+^2=*099G:2"\IT_XE97HF:(]QT# .KF"\J$8'
M!^O4P[BU2B^)W*,>-M3#ZZF/5^GP@*/KN?X0.]XKX-9 W'<&7CNO@_^? OAZ
MXC,E6UM>P-T>V09N[YQD^C/B*^%KF@N4PDI)<:>O/'AU,E<=R0ISN"V95$>E
M:2;J:P:X#E#W5XS)EXX^+YOOH^ ?4$L#!!0    (  ^"2U2#[R'I* 0  *$-
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULC9=M;^(X$,>_BH7NQ:ZT
MV\1V2$)%D2BP=TA76A5Z^]HE!J)-8LXVT/OV-W'2!!(GVC<0)S/CW_S],/;X
M(N0O=>!<HX\TR=3#X*#U\=YQU/; 4Z;NQ)%G\&4G9,HT-.7>44?)662<TL0A
MKNL[*8NSP61LWKW(R5B<=!)G_$4B=4I3)O][Y(FX/ SPX//%:[P_Z/R%,QD?
MV9ZON7X[ODAH.564*$YYIF*1(<EW#X,IOI_A,'<P%O_$_**NGE&>RKL0O_+&
M,GH8N#D13_A6YR$8_)WYC"=)'@DX_BV##JH^<\?KY\_H/TSRD,P[4WPFDI]Q
MI \/@W" (KYCIT2_BLM?O$QHF,?;BD297W0I;(?! &U/2HNT= :"-,Z*?_91
M"G'E ''L#J1T($T'K\.!E@[4)%J0F;3F3+/)6(H+DKDU1,L?C#;&&[*)LWP8
MUUK"UQC\]&3VO)HO5NO%'*TWT\WB:;':K-'S#_3\LGB=;I;/JS7Z\K::OLV7
MF\7\*_J.WM9S].6/KV-'0^]Y#&=;]O18]$0Z>J+H263ZH- BBWATZ^\ =85.
M/M$?26_ .=_>(8J_(>(2;.&9_;Z[VX-#*R6IB4<[XCT?N60ZSO:(?\ B4US=
M]T3UJJB>B>IU1'WEBC.Y/2"613 ]S[#NCK"*M$W_(I)O(N7+]SSQW9!B/Q@[
MYVM=VG9##WN![U9V-ZC#"G78B_HGST"!Q)"R".9JK'2NR)G;8(M8PRL( @3$
M#1NP;3L**>&A;X?U*UB_%W8C-*"*UIC94/T60AAZE ;#!JK%+J#N"'>@!A5J
MT(M:3ZQ$*"M@T.KXNYW09MB'&%:(8?_00[U L"E'7,9G,^0HSF#T3_E4M2*'
M[6'UO>'(;P"WS4:4A+0#=U3ACOH5U0<N42:R[_4$V$,*5M)16S/J!B/:(&V;
M88)]MX,4N_7^[/:R+C/-)5?Z<X9^0QFWKOXRS@TH@<&E7H/4:NB[=-2Q_O%5
M+<&]K"LX=G3-T=*U,?="<BU1R6>Q!+W]T/<Z $D-2'H!GT04[^(M,R<(L4,7
M)B6SS]!9&>H6>!@$HPZ(NDY@^ELJ(79F<<+>$XZT0%N1I@"E#DSR@TA@)=EE
MI*W-NTM&FZ5+B._1C@SJFH2]WE)790"KYP:\I^#ANHS@_CKR.%TO9Z:*S)=_
MO\&QPZI#$2.XSLZ](TT-[%:X0X"Z>&"_5X"?YG3(H<Z=8?_8\QL1%(+CLM*0
M .PK?8K4!0#W5P"CB%6%]H;NP>84C'S<5*)M24,_<(D7=(A1[_VX?_/O&Z7V
M_@U\(?6(V^2S%(0P\ ,2-G=0Y^JPFW*Y-W< !2-PRG1Q>*S>5O>,J3E=-]X_
MYO</<XBNPQ27ER<F]U -4,)W$-*]"P!+%O>!HJ'%T1RIWX6& [IY/, =BLO<
M +[OA-"?C;R#ZE8V^1]02P,$%     @ #X)+5%,PMP2W!@  D2   !@   !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6RM6FUOVS80_BN$,6 M4-<B*5)2D01(
M;!4-MC99G:S81\6F8R&2Z$ITDO[[42^Q++[9V9(/B60_=WSNCB*?HW+RQ,N'
M:LV8 ,]Y5E2GH[40FT^32;58LSRI/O(-*^0W*U[FB9"WY?VDVI0L639&>39!
MGD<G>9(6H[.3YK/K\NR$;T66%NRZ!-4VSY/RUP7+^-/I"(Y>/OB>WJ]%_<'D
M[&23W+,Y$[>;ZU+>379>EFG.BBKE!2C9ZG1T#C_%F-0&#>+OE#U5>]>@#N6.
M\X?ZYG)Y.O)J1BQC"U&[2.2?1S9E659[DCQ^=DY'NS%KP_WK%^^?F^!E,'=)
MQ:8\^Y$NQ?IT%([ DJV2;2:^\Z<OK NH(;C@6=7\!D\MELH1%]M*\+PSEO=Y
M6K1_D^<N$7L&$%L,4&> CC7 G0%6#%!@,? [ U\U\"P&I#-H0I^TL3>)FR4B
M.3LI^1,H:[3T5E\TV6^L9;[2HIXH<U'*;U-I)\[F-^<W\=?XV\T<7'T&\YNK
MZ1]?KOZ<Q=_GOX/XK]O+FW_ N]MOY[>SRYMX]AZ,P>U\!M[]]OYD(N3HM8_)
MHAOIHAT)64:ZX2+)#&93M]F4Y[F<4'/!%P\&ZYG;^GRY3.L)F63@.DF7X\L"
M3)--:F82'_"U6&SS;98(M@0SMDH7J1@ZF<C<[PJ =@5 C5??XO4BR9)BP3Z
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MT5NPLM<ETI=2%%'L14IE(GVQ06IE++Z0XBO6<98L0*_?Q3UG'N0:^>[AO<Q
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M$A"9?#"V7@\")0XA?C<U=7:^0RU?C]4_8/6-6&=9DD 6 +-&WP%K6DAQ7Q:
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M7H18UD#K21KB)^\0?RFC+1!6KK#LI%H^P*7HE$-;NAOJ3(B&X[%KT=[BZ;0
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MEE2/6QY"^BD#^/M#EA6O/]0'#M?P9_\"4$L#!!0    (  ^"2U3@N_RH#PD
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MWI7*X,>OXY=J0]JKVJQ<U%;=%>"R.E8A-OE&H;IEF2G+IG*PZ76]41]@PSS
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MT+6Z6@<0\SVZ%\1XU'H/M>/TH0%I=![/324Y'Y^I+>Y86S8/8.R(_0C%K0]
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M@HG,?J5!X-YD^'C"5=7@@50A,9I:X#]#5#0V1%UXP_2I$T>:]!T;&'N[^ZC
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MAT@\^\R+1D0%E])'T6MT0%U"T@$X)CT@=GB$-^>' <E][P*"3*5S#A[;.>+
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M)L#3E$FQ0[53CG<:DD1;K\"-8YAMS8=FW2)/9T\'/+&9!J$178E&=K0FM./
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M1PZ ":4M_\W\=57%05ZFC#5@E675WU9'J;?J2"Y&B8L'I-O4Z&][M1_"X@T
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M.^B+P;OCT_[;#Z^U"<R<7*B_BU.;A+?-TY(G@_YNP^NW9LK<Z>CI>(P$C'T
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M-!!.9DZ@5SIF:-U[/.267SEK?1L/UJZFV K!+)L9#0,W9>(;11)9%@3,D8&
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M4%X'HAJ+-8)#9[>%4!+U%KI4'%HY*64+5.,K1]]X_'&25SL/0S+@I$>]DHY
M2YFAK=$X-E\7_!I[3F_O@UDJS,I_%J1%@7/X=E:-5I\>1^&#V\X\?+?\R@TN
M3)8IL81KOWL.E4WX%!A^X&+D/[\MM',Z]8^)X)".#/!^J;7;_J )J@^RUW\!
M4$L#!!0    (  ^"2U2Y8EE0\04  /<0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;-U8W5/C-A#_5W8R/-QU3&Q)MFPSP P)=&!:/HY K]<W)5$2
MS_DCM14X_ONN)-N8G'%YZD-?8DG[V]5J/Z4</Q?E]VHCI8(?69I7)Z.-4MLC
MUZT6&YF):EQL98Z455%F0N&T7+O5MI1B:9BRU*6>Q]U,)/GH]-BLW96GQ\5.
MI4DN[TJH=EDFRI>)3(OGDQ$9-0OWR7JC]()[>KP5:SF3ZG%[5^+,;:4LDTSF
M55+D4,K5R>B,'$UBC3> /Q+Y7'7&H$\R+XKO>G*U/!EY6B&9RH72$@1^GN14
MIJD6A&K\7<L<M5MJQNZXD?ZK.3N>92XJ.2W2K\E2;4Y&T0B6<B5VJ;HOGB]E
M?9Y RUL4:65^X=EB>3R"Q:Y2158SHP99DMNO^%';H<,0>>\PT)J!&KWM1D;+
M<Z'$Z7%9/$.IT2A-#\Q1#3<JE^3:*3-5(C5!/G4Z>[B=_G9Y^_OYQ?T,+KX\
M7CU\@T\/8I[*ZO.QJW 'C7,7M;2)E4;?D<;@NLC5IH*+?"F7;_E=U*Q5CS;J
M3>B@P'.Y& ,C#E"/D@%YK#TN,_+8QX\[(-5OI?I&JO^>5%4LOD.QU7%6.5"9
MZ;S(=Y6L0.1+6!099E$E3""N2Y$KN83Y"ZB-A"G21/[29^S!776Z'E5;L9 G
M(\S'2I9/<G1Z(S()Q0KN4I'#0Z%$"K.-0#+<6\CRISEF-MSN5*50TR1?PZT]
MQRM.YW:'X-:$1_1Q:3:JX"I?R%SG%UA;6&A-)"QR?,^#D#L1C>'&/0-*&-P4
M^>&7G4B35:*UZN$C3AB%#M87/:2>[[#(,^PDI$X0TYIIHBU=\X01<T)N42ST
M'!X3\ ES/,9K]+3K"\O$F>]X7BTZ8 Z) _ Y=1A^]T_VNAEPWVO9./&= ,<T
M,)__JQL\)T;31[4;?)Q_P T<S1]Q\"FZPR?_I1L&<CMH<SOX<&[;'I*HWF0=
M%-.?K+VRC^!A4TKYII("UD&9S679E$+]X[4ATE04&A!CB= <OJ'*'[)<)!72
MN5D/'-:A8MBM9**Y=98@P:<.X;S#O4U*I!Y"$ S9D[?VY/]NST/=2/?*(FZ$
M8]EGVD&) Z8]G)AMWH3:A=VF-G+69V1X:^6+;)L6+Q)3[0"80S$@:<SM..9H
MR]BDD.R@*(D<1B(]\B.'\\% #%O#A8.&.Y=E\B1,"J2)F"=IHA*)W>99E-K]
MMM$4V%'*IA/UF7)PCWY3?K4;N$U$7%753@+>-F13F_2*OC+ ;FLL;.--U[^:
MMW+;>&JI=V6RD-H=26D]8R3>RY4L)28[S/"\*/L&(I=$^I(9082ARV)M^C$&
M:KU.*?S2@!\?@;N$X"I:/V8.]YAVPACK%7>9MX?^$XA+F 9S(-06D0.(QS2
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M<[]C[COF_B?,&\P$SRBCQ+TX44"*.\HYY3L@/ ?DN353P@C/4)E'S8C&'+2
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M,*'AY6C@@6PF1^-H4;EN384VO>_,O1FV*"W [!="Z*-C#^C&]_P/4$L#!!0
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M;6E>"90VP)P70NBS81-T[\[X#U!+ P04    "  /@DM4[52R1*\#  ###P
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MD!:FEYG\R0!3"?(\H50< U6@^VV%_P!02P,$%     @ #X)+5+EKS.M4 @
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M252WT.3C!*:"*O=%51W;-<'I6FG!&K!1P I>_\E+4X<=@.$Y#, - .\#ND<
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M(8M:W5S*[P["E(%\/J=4;#MJ@N)+IO<?4$L#!!0    (  ^"2U268<KJ:P<
M -4E   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;+6:;6_;-A" _PIA
M;$ +M)9$D;)<) $2Y[5;DS1.EG7#/C R;0N5)8^B[738CQ\E,:(<B323=OW0
MV KO>+P[/CQ>M+?)V-=\3BD'CXLDS?=[<\Z7'QPGC^9T0?)^MJ2I^,TT8PO"
MQ5<V<_(EHV12"BT2![INX"Q(G/8.]LIGU^Q@+UOQ)$[I-0/Y:K$@[-L13;+-
M?L_K/3VXB6=S7CQP#O:69$;'E-\MKYGXYM1:)O&"IGF<I8#1Z7[OT/MP$90"
MY8C?8KK)&Y]!L92'+/M:?+F8[/?<PB*:T(@7*HCXL:8CFB2%)F''WU)IKYZS
M$&Q^?M)^6BY>+.:!Y'24)??QA,_W>V$/3.B4K!)^DVW.J5P0+O1%69*7_X--
M-1:[/1"M<IXMI+"P8!&GU4_R*!W1$/"01@!* 6@KX$L!WU8 20'T3"#4K0%+
M 6P[0R %@N<"H49@( 4&MC.$4B"T%1A*@6&9#E7\RN ?$TX.]EBV :P8+;05
M'\H,*J5%S..T2/8Q9^*WL9#C!^/;J]$OYU>_'I_<C,')Y[N+VR_@S3'E)$YR
M<$D8(T4RO@7OP=WX&+SYZ>V>P\6TA; 3R2F.JBF@9HIC&O6!&[X#T(5>A_C(
M+'Z9K?L ^EKQ8[/XX6HFQ*%6_,3&^$$I[G:(GYK%KR(N9@^UXF<6L_N>UOAS
M>_&NV2_,XF.Z%.)NU^R.2+,ZUV"=:[#4AS3Z;BA)XG_H!/ YRU:S.<A)0D$V
M!?F<,)IWN:=2&)0*"VZO#SRW^+?GK#L,\6M#?*,A]R4"A2%D39E .I@QDG(P
M(9R"*8D96)-D1;OLJ?0.&O;@?H"[K4&U-<AHS6D]8^D+GD5?0;8LCH(N"U#+
M(S#4.@37)F"C"=<LBRB=Y&#*L@6(\WQ%TJ@T)\H6"W$FE59U)2!N!\C'>(AU
M%@6U18'1HE&6YN*\BM,9.)PQ2L7YRG/PYR>Z>*#L+T,R#NH)!L8);C-.$D ?
M1=604Q"GD?#_!(B"84GBR=/SSIRL].)F!'S4#$&UMP8MS_@!TD8JK,T.[<WN
MLBYLYX<7MJP[[QB&AEKKAK5U0Z-UEUGZ_O-*[/)I+)PY+E/YJDQE<)V0U"J
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M_67)18F5[HJ5*S<"<&%%)74#STO<$A/F]+MV[%GTNWRK*&'P+)#<EB46OX9
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ME3ZG;7.M;U(0)D!_7W*NCATS07TW]_\ 4$L#!!0    (  ^"2U1N\M?L&0,
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M%7)MH+XO&).[B790WM/Z?P%02P,$%     @ #X)+5 ?%'XZ_ @  (@<  !D
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MX$%-.E%5RLCQ79[@>TA3&J.$GW?(ERA_U5!>5I27]91KN]<54*4VKTM65*C
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M0-H$<YX)H<^!G73MARK] %!+ P04    "  /@DM4.M[E6S@"  !M!0  &0
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M$D<Q3OH2ZW0Q^L,WX[+B5Q4*)9(#[9<=SS7P?YS//5;G![3;:K=**C>V"U7
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  /@DM4':0/)I0#  "U&0  #P
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MX_GOI#H,W[KI^''YV$0)YR/.%F[&=[]02P,$%     @ #X)+5&/6BA2; 0
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M9)4H9)4H9)4H9)7_2=8/K9=__9^X79-:E<W!GW4_XV=?4$L! A0#%     @
M#X)+5 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  /@DM4Y*?%P.T    K @  $0
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M965T-"YX;6Q02P$"% ,4    "  /@DM44S"W!+<&  "1(   &
M    @(%Z&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M#X)+5% [:K<R"   DA\  !@              ("!9R(  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    (  ^"2U3@N_RH#PD  "P6   8
M          " @<\J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    "  /@DM4 BK.'*()   -%P  &               @($4-   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #X)+5 J#UFIY#P  P"X
M !@              ("![#T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    (  ^"2U2ZEJ1>P@8   H3   9              " @9M-  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ #X)+5+6+E1QD
M P  [P<  !D              ("!E%0  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    "  /@DM4;9(,@\ +   &(P  &0
M@($O6   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  ^"
M2U3W7Z[!QP(  (,&   9              " @29D  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ #X)+5 VLEHR(!   X@H  !D
M         ("!)&<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    "  /@DM4@_^-DS("  #U!   &0              @('C:P  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  ^"2U1@$R*<< <  )P5
M   9              " @4QN  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ #X)+5+EB65#Q!0  ]Q   !D              ("!\W4
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  /@DM4:NM?
M2[\"  #*!0  &0              @($;?   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    (  ^"2U2,TYJT#P,  /P'   9
M  " @1%_  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M#X)+5$,HND=) @   P4  !D              ("!5X(  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    "  /@DM4# ^(UX@#   ]"   &0
M            @('7A   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    (  ^"2U1;=0Y3) (  (,$   9              " @9:(  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ #X)+5.U4LD2O P
MPP\  !D              ("!\8H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    "  /@DM49K8<^F@"  #"!@  &0              @('7
MC@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  ^"2U2Y
M:\SK5 (  ,T%   9              " @7:1  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ #X)+5"P$8^W !0  *R4  !D
M     ("! 90  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ^"2U0'Q1^.OP(  "('   9              "
M@72K  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ #X)+
M5!N$$JC5 @  7@@  !D              ("!:JX  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    "  /@DM4<,T0/,8"  !*"   &0
M        @(%VL0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   (  ^"2U2#&M4*L 4  /87   9              " @7.T  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ #X)+5-2$J+M) @  M 8
M !D              ("!6KH  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    "  /@DM4.M[E6S@"  !M!0  &0              @(':O
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  ^"2U1KKR&:
MC0,  ",,   9              " @4F_  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ #X)+5)V,'MZ% @  M08  !D
M ("!#<,  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  /
M@DM4O;X)2O\"  ")#P  #0              @ ')Q0  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    (  ^"2U27BKL<P    !,"   +              "  ?/(
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  ^"2U0=I \FE ,  +49   /
M          "  =S)  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  /@DM4
MM[W"2X$!   I%P  &@              @ &=S0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  /@DM48]:*%)L!  "4%P  $P
M        @ %6SP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +@ N 'D,
(   BT0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>372</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - OPERATIONS AND FINANCING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/OperationsAndFinancing</Role>
      <ShortName>OPERATIONS AND FINANCING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails4</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails</Role>
      <ShortName>LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails1</Role>
      <ShortName>LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cvm_10q.htm">cvm_10q.htm</File>
    <File>cvm-20211231.xsd</File>
    <File>cvm-20211231_cal.xml</File>
    <File>cvm-20211231_def.xml</File>
    <File>cvm-20211231_lab.xml</File>
    <File>cvm-20211231_pre.xml</File>
    <File>cvm_ex31.htm</File>
    <File>cvm_ex32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="365">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvm_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "contextCount": 115,
   "dts": {
    "calculationLink": {
     "local": [
      "cvm-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvm-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 379,
   "entityCount": 1,
   "hidden": {
    "http://cvm.com/20211231": 8,
    "http://fasb.org/us-gaap/2021-01-31": 14,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 27
   },
   "keyCustom": 84,
   "keyStandard": 288,
   "memberCustom": 34,
   "memberStandard": 10,
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://cvm.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://cvm.com/role/FairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - PATENTS",
     "role": "http://cvm.com/role/PATENTS",
     "shortName": "PATENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - LOSS PER COMMON SHARE",
     "role": "http://cvm.com/role/LossPerCommonShare",
     "shortName": "LOSS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://cvm.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://cvm.com/role/FairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - PATENTS (Tables)",
     "role": "http://cvm.com/role/PatentsTables",
     "shortName": "PATENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - LOSS PER COMMON SHARE (Tables)",
     "role": "http://cvm.com/role/LossPerCommonShareTables",
     "shortName": "LOSS PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31_us-gaap_PatentsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31_us-gaap_PatentsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31_cvm_IncentiveStockOptionPlansMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "role": "http://cvm.com/role/StockholdersEquityDetails1",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "role": "http://cvm.com/role/StockholdersEquityDetails2",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31_cvm_ConsultantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000026 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "role": "http://cvm.com/role/StockholdersEquityDetails3",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31_cvm_ConsultantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfFairValueOfWarrantLiabilitestabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:FairValueOfSeriesZwarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000027 - Disclosure - STOCKHOLDERS EQUITY (Details 4)",
     "role": "http://cvm.com/role/StockholdersEquityDetails4",
     "shortName": "STOCKHOLDERS EQUITY (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfFairValueOfWarrantLiabilitestabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:FairValueOfSeriesZwarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000028 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000029 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "role": "http://cvm.com/role/FairValueMeasurementsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvm:WeightedAverageRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000030 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "role": "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31_us-gaap_FairValueInputsLevel3Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvm:WeightedAverageRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31_srt_OfficerMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:OptionsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31_srt_OfficerMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:OptionsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000035 - Disclosure - PATENTS (Details)",
     "role": "http://cvm.com/role/PatentsDetails",
     "shortName": "PATENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:PatentImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000036 - Disclosure - PATENTS (Details Narrative)",
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "shortName": "PATENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cvm:PatentImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000037 - Disclosure - LOSS PER COMMON SHARE (Details)",
     "role": "http://cvm.com/role/LossPerCommonShareDetails",
     "shortName": "LOSS PER COMMON SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000038 - Disclosure - LOSS PER COMMON SHARE (Details 1)",
     "role": "http://cvm.com/role/LossPerCommonShareDetails1",
     "shortName": "LOSS PER COMMON SHARE (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000008 - Disclosure - OPERATIONS AND FINANCING",
     "role": "http://cvm.com/role/OperationsAndFinancing",
     "shortName": "OPERATIONS AND FINANCING",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY",
     "role": "http://cvm.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cvm_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "cvm_BalanceOfTheFinanceLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance of the finance lease liability"
       }
      }
     },
     "localname": "BalanceOfTheFinanceLeaseLiability",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalizable patent costs included in current liabilities"
       }
      }
     },
     "localname": "CapitalizablePatentCostsIncludedInCurrentLiabilities",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CashPaidRelatedToFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid related to finance leases"
       }
      }
     },
     "localname": "CashPaidRelatedToFinanceLeases",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CashPaidRelatedToFinanceLeasesInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid related to finance leases interest"
       }
      }
     },
     "localname": "CashPaidRelatedToFinanceLeasesInterest",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ClinicalServiceTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical service trial"
       }
      }
     },
     "localname": "ClinicalServiceTrial",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_CommonStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock price"
       }
      }
     },
     "localname": "CommonStockPrice",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ConsultantsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants One [Member]"
       }
      }
     },
     "localname": "ConsultantsOneMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_CurrentBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current balance"
       }
      }
     },
     "localname": "CurrentBalance",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_DecemberTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2020 [Member]"
       }
      }
     },
     "localname": "DecemberTwoThousandTwentyMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Deemed dividend after net loss to arrive at net loss available common shareholders"
       }
      }
     },
     "localname": "DeemedDividendAfterNetLossToArriveAtNetLossAvailableCommonShareholders",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_EquityBasedCompensationEmployeesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees, amount"
       }
      }
     },
     "localname": "EquityBasedCompensationEmployeesAmount",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_EquityBasedCompensationEmployeesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees, shares"
       }
      }
     },
     "localname": "EquityBasedCompensationEmployeesShares",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_ErgomedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "localname": "ErgomedMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ExerciseOfDerivativeLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of derivative liabilities"
       }
      }
     },
     "localname": "ExerciseOfDerivativeLiabilities",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_ExercisePricePer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants exercised"
       }
      }
     },
     "localname": "ExercisePricePer",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_ExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share"
       }
      }
     },
     "localname": "ExercisePricePerShare",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_ExpenseIncluedPrepaidExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expense inclued prepaid expenses"
       }
      }
     },
     "localname": "ExpenseIncluedPrepaidExpenses",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Expiration date",
        "verboseLabel": "Expiration date"
       }
      }
     },
     "localname": "ExpirationDate",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_ExpirationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obli",
        "label": "Expiration date description"
       }
      }
     },
     "localname": "ExpirationDateDescription",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized and unrealized (gains) and losses"
       }
      }
     },
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValueOfSeriesAaWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AA warrants"
       }
      }
     },
     "localname": "FairValueOfSeriesAaWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValueOfSeriesCcWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CC warrants"
       }
      }
     },
     "localname": "FairValueOfSeriesCcWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValueOfSeriesHhWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Series HH warrants"
       }
      }
     },
     "localname": "FairValueOfSeriesHhWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValueOfSeriesZwarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Z warrants"
       }
      }
     },
     "localname": "FairValueOfSeriesZwarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FairValueOfStockOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of stock option"
       }
      }
     },
     "localname": "FairValueOfStockOption",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nine months ending September 30, 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueRemainderOfYear",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinanceLeaseObligationsNetOfCurrentPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseObligationsNetOfCurrentPortion",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinancingCostsIncludedInCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "localname": "FinancingCostsIncludedInCurrentLiabilities",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_FinancingLeaseContractualArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement"
       }
      }
     },
     "localname": "FinancingLeaseContractualArrangement",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesAaWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series AA warrants"
       }
      }
     },
     "localname": "GainLossSeriesAaWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesBbWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series BB warrants"
       }
      }
     },
     "localname": "GainLossSeriesBbWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesCcWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series CC warrants"
       }
      }
     },
     "localname": "GainLossSeriesCcWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesHhWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series HH warrants"
       }
      }
     },
     "localname": "GainLossSeriesHhWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesWWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series W warrants"
       }
      }
     },
     "localname": "GainLossSeriesWWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesZWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series Z warrants"
       }
      }
     },
     "localname": "GainLossSeriesZWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GainLossSeriesZzWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains on Series ZZ warrants"
       }
      }
     },
     "localname": "GainLossSeriesZzWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_GrantPerformanceBasedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant performance-based stock options"
       }
      }
     },
     "localname": "GrantPerformanceBasedStockOptions",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_IncentiveStockBonusPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "localname": "IncentiveStockBonusPlansMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_IncentiveStockOptionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Option Plans [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionPlansMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_IssueDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue date"
       }
      }
     },
     "localname": "IssueDate1",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "cvm_LandlordMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "localname": "LandlordMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_LeaseLiabilitiesCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "LeaseLiabilitiesCurrentPortion",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_LeasesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesPolicyTextBlock",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_LesseeOperatingLeaseLiabilityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPayments",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Nine months ending September 30, 2022]",
        "verboseLabel": "Nine months ending September 30, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_MaturityYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Maturity years"
       }
      }
     },
     "localname": "MaturityYears",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_ModificationOfWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Modification of warrants 1]",
        "verboseLabel": "Modification of warrants"
       }
      }
     },
     "localname": "ModificationOfWarrant",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ModificationOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "localname": "ModificationOfWarrants",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ModificationOfWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Modification of warrants]",
        "verboseLabel": "Modification of warrants"
       }
      }
     },
     "localname": "ModificationOfWarrantsAmount",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value of the finance lease right of use asset"
       }
      }
     },
     "localname": "NetBookValueOfTheFinanceLeaseRightOfUseAsset",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetBookValueOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value operating lease right of use assets"
       }
      }
     },
     "localname": "NetBookValueOperatingLeaseRightOfUseAssets",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetOfDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of discount"
       }
      }
     },
     "localname": "NetOfDiscount",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NetPresentValueOfLeaseFinanceLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations"
       }
      }
     },
     "localname": "NetPresentValueOfLeaseFinanceLeaseObligations",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_NonQualifiedStockOptionSharesVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option shares vest"
       }
      }
     },
     "localname": "NonQualifiedStockOptionSharesVest",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option Plans [Member]"
       }
      }
     },
     "localname": "NonQualifiedStockOptionsPlansMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options issued"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_OctoberOneTwothousandNineTeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 1, 2019 [Member]"
       }
      }
     },
     "localname": "OctoberOneTwothousandNineTeenMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_OperatingLeaseMaturityYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease maturity years"
       }
      }
     },
     "localname": "OperatingLeaseMaturityYears",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_OptionsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[Options issued]",
        "verboseLabel": "Options issued"
       }
      }
     },
     "localname": "OptionsIssued",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_OptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "localname": "OptionsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_PatentImpairmentCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent impairment charges"
       }
      }
     },
     "localname": "PatentImpairmentCharges",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_PaymentsMadeByLandlord": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments made by landlord"
       }
      }
     },
     "localname": "PaymentsMadeByLandlord",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid consulting services paid with issuance of common stock"
       }
      }
     },
     "localname": "PrepaidConsultingServicesPaidWithIssuanceOfCommonStock",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromTheSaleOfCommonStockAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, amount"
       }
      }
     },
     "localname": "ProceedsFromTheSaleOfCommonStockAmount",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_ProceedsFromTheSaleOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares"
       }
      }
     },
     "localname": "ProceedsFromTheSaleOfCommonStockShares",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_ProceedsFromWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantsExercised",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in current liabilities"
       }
      }
     },
     "localname": "PropertyPlantEquipmentIncludedInCurrentLiabilities",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_RestrictedStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStocksMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities, warrants and other options"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfFairValueOfWarrantLiabilitestabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of warrant liabilites"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfWarrantLiabilitestabletextblock",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of gain and (losses) on derivative liabilities"
       }
      }
     },
     "localname": "ScheduleOfGainAndLossesOnDerivativeLiabilitiesTableTextBlock",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options, stock bonuses and compensation granted by the Company"
       }
      }
     },
     "localname": "ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_SeriesAaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AA [Member]"
       }
      }
     },
     "localname": "SeriesAaMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesBBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series BB [Member]"
       }
      }
     },
     "localname": "SeriesBBMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesCcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CC [Member]"
       }
      }
     },
     "localname": "SeriesCcMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesHhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series HH [Member]"
       }
      }
     },
     "localname": "SeriesHhMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesMMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "localname": "SeriesMMMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "localname": "SeriesNMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "localname": "SeriesNNMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesNWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N Warrants [Member]"
       }
      }
     },
     "localname": "SeriesNWarrantsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesRRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "localname": "SeriesRRMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesSSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "localname": "SeriesSSMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesTTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series TT [Member]"
       }
      }
     },
     "localname": "SeriesTTMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesUUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "localname": "SeriesUUMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesUUWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU warrants [Member]"
       }
      }
     },
     "localname": "SeriesUUWarrantsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesWWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series W Warrants [Member]"
       }
      }
     },
     "localname": "SeriesWWarrantsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "localname": "SeriesXMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesXWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X Warrants [Member]"
       }
      }
     },
     "localname": "SeriesXWarrantsMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "localname": "SeriesYMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_SeriesZMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Z [Member]"
       }
      }
     },
     "localname": "SeriesZMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_ShareIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.",
        "label": "Share issuance costs"
       }
      }
     },
     "localname": "ShareIssuanceCosts",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_SharesIssuableUponExerciseOfWarrantOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable upon exercise of warrant/options"
       }
      }
     },
     "localname": "SharesIssuableUponExerciseOfWarrantOptions",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_ShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term deposits"
       }
      }
     },
     "localname": "ShortTermDeposits",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_StockBonusPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "localname": "StockBonusPlansMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_StockOptionsVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options vest"
       }
      }
     },
     "localname": "StockOptionsVest",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "cvm_SuppliesUsedForRdAndManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for RD and manufacturing"
       }
      }
     },
     "localname": "SuppliesUsedForRdAndManufacturing",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_TotalFairValueOfDerivativeLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total warrant liabilities"
       }
      }
     },
     "localname": "TotalFairValueOfDerivativeLiabilities",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_TransactionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction One [Member]"
       }
      }
     },
     "localname": "TransactionOneMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_TransactionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Two [Member]"
       }
      }
     },
     "localname": "TransactionTwoMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_USTreasuryBills": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[U.S. Treasury Bills]",
        "verboseLabel": "U.S. Treasury Bills"
       }
      }
     },
     "localname": "USTreasuryBills",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvm_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "cvm_VolatilityRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility rate"
       }
      }
     },
     "localname": "VolatilityRate",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "cvm_WarrantExercisesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, amount"
       }
      }
     },
     "localname": "WarrantExercisesAmount",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvm_WarrantExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, shares"
       }
      }
     },
     "localname": "WarrantExercisesShares",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsExpiredDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expired during period"
       }
      }
     },
     "localname": "WarrantsExpiredDuringPeriod",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvm_WeightedAverageExercisePriceDerivativeInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Derivative instruments"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceDerivativeInstruments",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageFairValueDerivativeInstruments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Derivative instruments"
       }
      }
     },
     "localname": "WeightedAverageFairValueDerivativeInstruments",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvm_WeightedAverageRiskFreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average risk free interest rate"
       }
      }
     },
     "localname": "WeightedAverageRiskFreeInterestRate",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "cvm_WeightedAverageTimeToMaturityYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time to maturity year"
       }
      }
     },
     "localname": "WeightedAverageTimeToMaturityYear",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "cvm_cfgh": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of operating lease obligation"
       }
      }
     },
     "localname": "cfgh",
     "nsuri": "http://cvm.com/20211231",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r163",
      "r169",
      "r203",
      "r204",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r337",
      "r338",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r163",
      "r169",
      "r203",
      "r204",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r337",
      "r338",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r163",
      "r169",
      "r190",
      "r203",
      "r204",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r337",
      "r338",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Axis"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r163",
      "r169",
      "r190",
      "r203",
      "r204",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r337",
      "r338",
      "r348",
      "r349"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r123",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r15",
      "r124",
      "r125"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r221",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r218",
      "r219",
      "r220",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r56",
      "r134",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of patent costs"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r67",
      "r115",
      "r117",
      "r121",
      "r129",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r234",
      "r238",
      "r257",
      "r283",
      "r285",
      "r317",
      "r330"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r31",
      "r67",
      "r129",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r234",
      "r238",
      "r257",
      "r283",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date Axis"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type Axis"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r21",
      "r58"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r52",
      "r258"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]",
        "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r184",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right Axis"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Common stock price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r150",
      "r321",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r151",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "F. COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $.01 par value - 600,000,000 shares authorized; 43,259,013 and 43,207,183 shares issued and outstanding at December 31, 2021 and September 30, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Total expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r188",
      "r189",
      "r198",
      "r200",
      "r201",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Incremental cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r56",
      "r144"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Gain on derivative instruments"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative instruments, current portion"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeVariableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DerivativeVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases": {
     "auth_ref": [
      "r146",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Lease description"
       }
      }
     },
     "localname": "DescriptionOfLesseeLeasingArrangementsCapitalLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersCurrent": {
     "auth_ref": [
      "r11",
      "r278",
      "r328",
      "r344"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to employees"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r41",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r83",
      "r86",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r250",
      "r251",
      "r323",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "BASIC and DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r41",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r86",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r250",
      "r251",
      "r323",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted loss earnings per common share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "H. LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employees stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r37",
      "r38",
      "r39",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r105",
      "r130",
      "r181",
      "r183",
      "r218",
      "r219",
      "r220",
      "r230",
      "r231",
      "r249",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r339",
      "r340",
      "r341",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r252",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "D. FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r164",
      "r191",
      "r192",
      "r197",
      "r201",
      "r252",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level 1 (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r252",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r253",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Issuances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]",
        "negatedLabel": "Exercises"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Schedule of future minimum payments under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Total future minimum finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "negatedLabel": "Less: imputed interest on financing lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r269",
      "r271"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "[Finance Lease, Principal Payments]",
        "negatedLabel": "Payments on obligations under finance lease"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance lease right of use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent useful life",
        "verboseLabel": "Weighted average time to maturity"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]",
        "verboseLabel": "Nine months ending September 30, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r141",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class Axis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r135",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r138",
      "r303"
     ],
     "calculation": {
      "http://cvm.com/role/PatentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "[Finite-Lived Intangible Assets, Net]",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.",
        "label": "Patent costs, net"
       }
      }
     },
     "localname": "FiniteLivedPatentsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Net gain on warrant liabilities"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r44",
      "r56",
      "r128"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain on short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r56",
      "r325"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "[Gain (Loss) on Sale of Derivatives]",
        "verboseLabel": "Gain on derivative instruments"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfOngoingProject": {
     "auth_ref": [
      "r56",
      "r143"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned.",
        "label": "Loss on patent impairment"
       }
      }
     },
     "localname": "ImpairmentOfOngoingProject",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.",
        "label": "[Increase (Decrease) in Due to Officers and Stockholders]",
        "verboseLabel": "Due to employees"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToOfficersAndStockholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInMaterialsAndSupplies": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying amount of capitalized costs of materials, supplies, or both, which are not included in inventory.",
        "label": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "localname": "IncreaseDecreaseInMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "[Increase (Decrease) in Other Operating Liabilities]",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "[Increase (Decrease) in Receivables]",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental shares underlying dilutive - warrants and options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "G. PATENTS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r65",
      "r137",
      "r299",
      "r300",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Patents"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r50",
      "r53",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Share-based payments for services",
        "verboseLabel": "Non- Employees stock based compensation expense"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "negatedLabel": "Less imputed interest on operating lease obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r67",
      "r118",
      "r129",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r235",
      "r238",
      "r239",
      "r257",
      "r283",
      "r284"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r67",
      "r129",
      "r257",
      "r285",
      "r318",
      "r332"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r67",
      "r129",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r235",
      "r238",
      "r239",
      "r257",
      "r283",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r106",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "B. OPERATIONS AND FINANCING"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/OperationsAndFinancing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r34",
      "r35",
      "r39",
      "r40",
      "r57",
      "r67",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r81",
      "r82",
      "r94",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r129",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r251",
      "r257",
      "r322",
      "r335"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r78",
      "r83",
      "r84",
      "r95",
      "r98",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "totalLabel": "Net loss available to common shareholders",
        "verboseLabel": "Net loss available to common shareholders -basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r92",
      "r93",
      "r95",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net loss available to common shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [
      "r84",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net loss available to common shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "[Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Options Issued]",
        "verboseLabel": "Options issued"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "[Operating Expenses]",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r115",
      "r116",
      "r119",
      "r120",
      "r122"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease - liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid related to operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.",
        "label": "Other non-operating gains"
       }
      }
     },
     "localname": "OtherNonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "[Payments of Stock Issuance Costs]",
        "negatedLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "[Payments to Acquire Intangible Assets]",
        "negatedLabel": "Expenditures for patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name Axis"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Realized through sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r46",
      "r127"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from maturity of US treasury bills"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercises of warrants and options"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r34",
      "r35",
      "r39",
      "r51",
      "r67",
      "r73",
      "r81",
      "r82",
      "r115",
      "r116",
      "r119",
      "r120",
      "r122",
      "r129",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r233",
      "r236",
      "r237",
      "r240",
      "r241",
      "r251",
      "r257",
      "r326"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r145",
      "r285",
      "r327",
      "r333"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r145",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATIONS AND FINANCING"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r199",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r199",
      "r277",
      "r280",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party Axis"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r278",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "E. RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r223",
      "r298",
      "r350"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r183",
      "r221",
      "r285",
      "r331",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r130",
      "r218",
      "r219",
      "r220",
      "r230",
      "r231",
      "r249",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Common stock shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r206",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of future minimum payments under operating leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of total estimated future amortization"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r209",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Equity based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Total shares reserved under plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Remaining options/shares under plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r205",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Shares reserved for outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r185",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r12",
      "r319",
      "r320",
      "r329"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "U.S. Treasury Bills"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r64",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r30",
      "r37",
      "r38",
      "r39",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r105",
      "r130",
      "r181",
      "r183",
      "r218",
      "r219",
      "r220",
      "r230",
      "r231",
      "r249",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r339",
      "r340",
      "r341",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components Axis"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r105",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Stock Compensation Plan [Member]"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "401(k) contributions paid in common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock and options issued to nonemployees for service, shares",
        "verboseLabel": "Common stock issued for service, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r181",
      "r183",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Option exercises, shares",
        "verboseLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "401(k) contributions paid in common stock, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock and options issued to nonemployees for service, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r181",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Option exercises, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r67",
      "r126",
      "r129",
      "r257",
      "r285"
     ],
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "C. STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "I. SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Gain on derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "DILUTED",
        "verboseLabel": "Weighted average shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "[Weighted Average Number of Shares Outstanding, Basic and Diluted]",
        "verboseLabel": "Weighted average shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r83",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "BASIC",
        "verboseLabel": "Weighted average shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123397816&loc=SL2265659-115463"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(17))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r351": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r352": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r353": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r354": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r355": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r356": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001654954-22-001491-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-22-001491-xbrl.zip
M4$L#!!0    (  ^"2U3"&K(%^Q   &JQ   0    8W9M+3(P,C$Q,C,Q+GAS
M9.U=ZW/;-A+_?C/W/_#\Y=*9DV79::[)).U0#R>:VI(J47E]Z< D)&%*@0I
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M6=30C64_,[K/I94+[@[5BE6!KJ;J,,<Z5)V"+VJH%'/Z0Y7*]Y/GU^EM-YO
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MWTWOXIVB@I101E%UP>\#=AD:AS4?S5X0E_C!YH!)C"U?BT)!M?O<<_DXB@5
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MN)N^HM+"UJ@^BU+V M-$!N*[HPS$8=[!F(XZOWX<];OZQ/@WTO_[V)M^/LA
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MRG*+$>\R8;&C\/^>3!___']02P,$%     @ #X)+5)H8M2OY&0  3(,! !0
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ME0L67T[0[ZC6RU;K,JKS+SLR_NLC:KP>7#]:B(7SXL^SY\!&[?36L+")IBL
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M:C5H;>U=WAEZO"=)[CU)]?;.XSU)-,T:L7EQO"=)[)ZDBO8;CLFV.'KLMRG
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MZ*7O&'],X2#QR/TA(J^[#2S2J )J@"N!_W6>BIWCG\Z'H_/Q\,/7R/X&M08
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M-!IO.[[@':([+O6J560N@.NAY]?!?'DZ7YP-9DL=[)TXTO*JF&J2Y0Q,U<Z
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M9FG:M(PD([>U-'7@[6GHBT1.2T/36U)<SI#JY\XJ6OFJV6W#,O3C-G=FVZ@
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MRNTDU78<X. PAZD*<((01+3(=V/-3R0ZKPSE/*^NG*@=9S-E,9J8(QU.CT^
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M17^A'].?T/^9:.7UX_\#4$L#!!0    (  ^"2U0]1/[A)ST  "E" P 4
M8W9M+3(P,C$Q,C,Q7W!R92YX;6SM?6USX[B5[O=;=?^#[NR'FZVZ/<UW4JG-
M;JEM><85M^18\DPF7U @"=I,:-(A*7<[O_X"E"A1) B"+Q(A3S:UT]TV .)Y
M#EX.#@[.^:__^?X23-Y0G/A1^*<?Y!^E'R8H="+7#Y_^],,F^003Q_=_F"0I
M#%T81"'ZTP_O*/GA?_[[?_^O__H_GS[]]<O#W>0Z<C8O*$PG5S&"*7(GW_ST
M>4)^]14F*8H_?=J5_F7[G3].E!_5'R5K__,O,,&UHC"K@W\I[W]SC=N;1-[$
M(2UG527ELRQ]5B1%V1=:15[Z#<9H F/GV4^1DVYB&$Q<E/A/X01W?+(%],?)
MM?^*0C>&DS__.%GAGSSOV[B*7M]C_^DYG?S!^<\):7YR^VDQ7T^^;!(_1$DR
M647!AG0A^7^3V]#Y<3(+@LD#J9%,'E""XC?D_KAM+O##?_R1_,?&N":8X##Y
MX_?$_],/SVGZ^L?/G[]]^_;C-_7'*'["."3Y\U^_WJV<9_0"/_DA(=I!/^2U
M2"NT>O)T.OV<_38O6BGYW8Z#_!OJY[P[N'CB_S')/G<7.1FI'-4FM27(OS[E
MQ3Z1'WV2E4^J_./WQ/T!LS&9;/F(HP ](&]"_GQ\N-U_TWE[^=&)7CZ3GW^^
MBO!0Q%W,:CS'R/O3#_CWN%5%EI5MF_]Q5"9]?\4C,O%?7@,,[7/[[X4N"O'@
M^P(#POOJ&:$T:>P J]))>G2/1W>8/J/4=V#0J7O4%H;JZRK%TY2L ,G26[ZB
M.!M5R6,(-RZ>CBYOASF;Z=GKXE=6:>3\XSD*7+PPS?^Y\=-WWDZW;.443%_!
MY/DFB+[U([J^E9Y]QHNZC]N_C_'B&*:9+&>AN]J\O,#X'9.&UV;?PZ,Q3&>.
M$VW"%*_']U'@.SYJFH%#--T3W6%\XB_?^"&>:?@C#?UF5^H]KLNCL'$(UU7H
MV9,;Z,>_P&"#OB*8;.+M2&OH#+-.S_X\H("H)7@)3-_7,0P3Z&1":.A24[7>
M<_KEQ4\SG'@TX+E)1BG6O9J'/T?-GGV[GZWGB_6JH1^E4CV_>1<ER3V*";@H
M7#WC_:KA\_45^LZDC9V@?VXPO_,WCJ%;5[QW+WB6,\X5LUMC@Z](:V@'S7UM
MJ':*U8FK8QPU3[<F</60NW[?]0$OC+RL4<L.OE9P=:6IVH@:SS5*H1\D"Q@3
M#>&M:>T[Q:<&G^V[#[6>[J5ZI^J7W+5C\JE[IG3MF7+JGJE=>Z:>NF=:UYYI
MI^X9[YSF;^ 4.R#?9.6I>L+>\5+9JHT3G2Y:=KEM,Z?3-/A& G\#)^]ITT+>
MHH63]Y5W.'1H:1B=CD_Z],*#]H"7J89:@VN:? 0UUCM5OYHF0W/%^IZ]%M3-
M._R#HPKH.Y:#>S ?DFYR6/E3/R7EI.W_R9-/A^ND3Y.LY.0>/J');>A%\4OV
MZ>VU0MZI('*.^A&06XVH=(M NI'@?F1W%PER?GR*WCZ[R"<72?(_-?+73]N_
M9B3A?X+LVS,[26.\$N>M!=!&0?8-@,N4BGP^2[_F>"E(WQ_0DT^^&Z8+^(+H
MW:.7/.YE4:2SV)E$,58_L#CR%F'L' FR>@&T*_'Y-;MA^.0\^\%^#'AQ]%+'
MUHZ;J*&[10KQI\[+\A5&%,/@%H_K[W]&[RR:*T6Y>)9'X[D&VMF)SF?[&K=*
MY_>X!!>MR@BTTH"<G<T9[H%+>G$3P"<ZG:4B7'RJ(_!)A7)V0J\V,<%QXR<.
M#'Y#,)Z'+G%*J-D0:DMST:R-0',3P)%6WM4+#(+<]X*U[I8*<O&LC[;J4F&-
M1?$S"@*L![["D+FS'9?C(M@8CV *J)'XG;^@^ F?VGZ*HV_I,P?1-16X&#='
M8YP)<RR];;NH/:#7*"8'9^+PL&$N(W4UN,BWQM/BF$!'4^;P =./7.9665.4
MB^_IB.H=%=I(P_S&#_!)'O?C*8J9*TNI(-_19+PS(!77:(-YJQIMY7Z#?U:S
MCC"*\_$]QEFP$>/(K!.%E)OS0F$^QL<\)M;@&VO#W)H#R0U49A-,EILT\_DN
M^*=1MTUF/3XIC'&XY$<]V@3XRP;&*8J#]^WFSIX E<)\U(]QX&S -YX!BERZ
M^80A'L*KI?D8'^/HV81PI#7G-L3B)[><;PCK4G"GRK)6F[H:?-2/=RAE(QU1
M>5QL7NS#54R=YIB7XJ-YO)-H%=%H(]N)8CS#,FXR9_LKXH,5XPW'9=[5-%3D
M$\!XIU$NW"/)9 V_W[H89.861_K7//9KJ_#)88Q3*A?6D20P<UW,5++[X\X/
MD<QBGUJ<[_9GO),K Z,PK"OM6%=X61_O+I.!<5S6K_!?E_$Z^A9R<%XLS,?X
M&.?7!GSC\IWM.<OX/H[>_.TSVB;2*S7XF!_OS,I&.B[]]Q$^/0=_\U^;]!QZ
M>3[JQSBS-J,\_\4TZ5",8#W5QR7XR!WC>$I#<G8Z[R)B_WR.0N:9J%J*C]8Q
MCIYUB,Y.[0HYFQC+6%;L-7'VHU-;+<5'[1C'S3I$9Z=V'4-BJUR]O]A10.>U
M5(2/U#&.D%0LHPW6^7?G&89/J-Z[DEZ2C]\QCH8L9!6:_^MSI?]8K?['*7R!
MF<$T"L[!RN339!^X@/@&+Q?7\\5J?CWY,KN;+:[FD]7/\_EZU=<[V(.)G=&_
M23X]0?B:#9;/*$B3_"?9F/DDR;LH)_^Q^S'8]V[I[1[WXP4XVEI<&8[$N^H\
MM0%2354=8#)T!SE+$BR@9CC'Y8 $'==J/$I61N.PLZ0+T\?SB WNX-0[MGQV
M)F9>,96* ^AJFJ>*(:T:KAERJ4-S< X>3SPDW IYT(/_(&_\WF" R!.?] K&
M\3O>_K)7:_7BXJH.D*$9CBZ2^.I$0I5B.Y '%^7QI+IZCN)TC>*7V_ -)>E1
M\!+*2D\I#2S#\USC8F7&Q'1P;QYQ7=R^@T\>D(/PD+(#M$!I_9UCS@2C%M 4
M4_8JF_'%B(P+V\%C>CS1W<?H%?KN_/LKT10;948M#I!F2Z9]L<)B@SJX77>0
M4N6)(/X!6&U>7P,?)8]8-;^)X@<7+\A?8;CQ((FN2/<*PO4:JP%55DT'7IX<
M6H$[.&4/)H]\?;U&KT15I6TOI(OE8L!2%=NQ+I/O6C 'OVM!%&U.!1M -#64
M"]XRJ& .7MD8B(?P+]V[+0^U'<UZF48I#+*28\IQ>P1$=P@F*(OGNO3P!,^0
MUDN540E8MF,K0AV>6LF8!UK!17P\P>VB*89/[43'K 9<0S7URU43^, 5/,['
MU.HBW-GT_3X@4:I"EQSU7LFY8<&2'JL60.I4OV#A<6$K^*Z/NF;Z*;KSWTC
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M#4)./@0'?-]_=!>VOPC;[K@$]-4FCK.@9BS_IVVNFY;M@*EA(%'.]8.)Z'@
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MYX!M&<@1Q#+")6_J=#XM-P=OW7:[[.O6FIYB#6!T]; K0S4$99H(8[,XR>>
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M4K$4L$W)= 59]]KL1E00^:V"$$)HVH..RX&IZ5FV(,9\*KE,,91 ]!,$/8*
MDT8VBI<A6G^+TN=HD\#07>"CTQJAD!4_B*,BF"(D3P6QO-5IOQ7;6AM@N4 &
MC&U24#IP%U@2H)4$$K(559!S8KW^5"&=B25G><"PZ7=8I@%NE\7O<1E\MM*M
MJDNK #LOYU9:O1"BX\O9'C!,R3Q^BEX0D^RC(L#2)%.4A:-F+:[024>0LSE@
MA//B.>9;Q+E"[$L"6]9411#K1;<5HHHE9UF8-Z.EH.O7N^LT$OO^'L4.XGU8
MU-P.4$S3M069*PSC*U7/Z0A5A*@@QU>G?>3=MB7@3:?V5+0S/*?$.X,=/G5*
M,0="C;/(41$@FZKIBG8ETL1[+8I31",KRI:#7D8%(*ODAOCRR.;!)$)@BV7Z
MC.('S"9FXGD6NM<DZ5?T2E#N8M@Q5JS&ND"U%*V:@4)P\;6'URM61=UKU*67
M+X3T:7-4!)B6@<Q+V_]K4?2* M$8PJWP"#7[_-4F)JCNHYC\C,XV?WV ',<U
M+FUC[@:Q5YP&JIQV'_H" ](7NBR.RP#=L"U)D*-,&[YK8/3RN:Q;3+Y$T3]V
M;[+7ST<OLK-XVDOO,4&S)$'U:PUW"\!!4RAPBBS64M0>Y,$'<BAI[<9#I0=[
MOTRZB!JK <? G[K +8(?63\?!OIZ!)/G>^B[NU"^ZZC8@QJ%EET':+*FRX*D
ME6BU7O'!RH4PH#6<_>4\Z'(78>1U@6))IBAAUX832@5>+IQ18V<>$FS^ F.?
M7$<V)/O=5637 Y)F*=*EZ5WMH.7B&S4,YC5*G-C/0G&3""_D!0$9;?BP.R-1
MZI^V.:BOX*N?PJ!VG=P#;]T80"[T;-&NU;D%W1UO+OT!;Q&VJT5NIR!NT,3?
MF3AR''K#.A"Q:P+)<3U-D%@I[8]"G.!RL0QX_,\?8GV%+OKRGE_1T05!+PM<
M&UGVI:V&S7!RL@<T#5SA KX#@Q6*WWP'K?'Z&]3H$I220+4LR;C ,<X$D],\
M=@1&/\5J_AMR\6Z(YYV/]\7L^(6/8=XFN/,]=A3&QMH 0=.R!'&4Z'!MQ@\P
M%ZAUJ8_"CRWJC->]U"NF_<M63W5,5Y"H>_UNS2J0<A$/:(LX,HD<?;UD#ZF/
MB,A9'SBNH6D7:,7K %&(W)@UCWYY)]3!^#*59=42)&)9OQE5Q=0O.>-@#^!Q
MWV8A/N)C/H/&:SEJ<2!-#=6YT(V.C:B2S?%L#Y_O,0P2+:,^7Y->?MM\/UMG
M[YH%R,Q4TAG(/<_\NQ-L7#P=?HHB]YL?!,U/E]NT E1-M?7*=; 8*B4);A"G
M_K^R0;'/W[:/=WF#I0B#FFBBC0H9=^- GR*$!+D\Z23;EJIJ>V8N/=AH.RY:
MI97JT2Y0;65:-6'\O@9>+2F7'GVT'0T\N:O:-P=DP_5$413'&F%E+BX]'&D'
M](T)LKHT"&PH2?\>7&4V+CT^:7O\C5FX.K0'=-F6['\/KF,R+CU@:0?X3>F>
M.K0'H*F;U0@"O\.Q523CTB.8MCSO1$% +H"YTXKU;!O(MNZ8@G@@C7;(9!$S
M6IS3TX^_!=7'LYE"7 _8KJ9J@MPIGV7<%$$?_'+;C8DT(IX<HR29/S90,J,P
M&DV62B'B+8Y@LU3@U-(&?!ZUE<GMRROT8V(#OWJ&\5.=)VE-8:!IMBI?XD3,
MV:2X?;"1BO#8L[B+D*?WQ[CKQQN['M!<US %N9(>0)CM0)<?=)YM;;R+DN0>
MQ20.:!2N\&A#C'L<L[PZWBU7J\G]_"$+5KM<3%8_SQ[F(MSJS&$<8ED1:!FH
MYM6PK@8PH66H%3?+<X+!H^\VQ!)#1%@W>*QNX[1N<'=W-[=1F,S>,.7$8W8=
M%83Y' 5X8"5?8.([]=@'^@"P/1W*@GBD-LJ3.EV'9D*$];KTKGRQ(=$BEE[6
MZ62Y21.\)I&%K6&0M&H&0-6U17E(T&TH=,-[Z5<D9:X:!@6U.#!U51$E_&@W
MX;-Q]8H6<")!7?O!AHS6UAM=J2)0D*MX%[V(\R(4(?+ T893W5C2R/E'ASV\
MN2& +,EU!#D[\0JL><MN ?S2#?>/88Q@X/\+N3]!/R3@E^'A_13C'-90$9BN
M9!B"1(GL-3)X@?8*LW#V=6!'P1 KP:XI(#FR*PL2G^1,:T$9>J\0#F=0U,L*
M)XG$TC00NK4'/%U3JP^++G T],3?U=(MR@:!9T*<^1?#H'!,369I&OOV)MW-
M#!@$R]?ML39T?R7&;>9[DAZ- L/43$<0"U^O@34$";TB9IQVP=EQ43GIMEYI
MZAH"EN*ZL +] D="5^"%$!V7N;C4L-;ZV F0I[KP(RP*30 K 4'&M_'+-"._
MU<[(/Y$_AIG?@9HAC9KALV,Z.<^Q#21(/*-&=JDSIP;0A\@<Y^JNK AB3:OA
MF2V3*A11,L>%J>^2-1:?Y5?((9%%?91LKVF1N[V[>7G=I+NKUXI%]YW>0$,>
MNM-]%!BRHSB"6,W;#)5S<")$6C9Z/WGRL#35!! #]00Y<Y]#GBT&$H6E$P2X
MVYW4F$E>BD4 E!2]JB^()#$*<<>TUV(Z0>RZQ_ -)5@=?L#_C7V''(Z(-8[%
M-[,*@+IJB)*4OCO_?!B%"%?7<UEH2D@_2/- A;)5S0@ES/O^7(4ZQ3Y:8J#L
M>5)_VMS]AOS'A@GZ[_\/4$L#!!0    (  ^"2U2/] R?P\L   $8"P +
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M//B"7(H!G\;0O4P@>G46&K/911&R\?:*2E*.P7JIT=== X6DU%*'8XGVJ=G
MGTK,:]E(I"7@9V6VG>"@(I?W9I.!97QVOHC-W'W&&'T*H=GZ,1SC'6X2B)(_
MQCK\Y3&4-WOR)U/*2_@B=98O#"AWLK@P+)O66<8&;)/T%]^U:M(?[,-;Z+,A
MXT+8O]_O8V(08M]60B]@-AK_?>.-$/@T<$0Z?_9:;_:V0?^KFIN&"Q+0_=FD
M+-JFA@$1(@UFTG!,AM^E"19NO(X)C12A93,W!*7/^2_26'6DD6Z 3:0:!IA(
MF&!$4^EO3T=#">RC ?$?@'>&ME(1PT_Y,J8"?8LI8FB%HA"L*/P84X&2!I^"
MXL%'IS89$JJ&\@6)IL4=Z3.\#^@H.1Y(3F=L8<8^R+6Y8]5=GONKNCA+G"+[
MLK^&+Y)J:M+G BX1Y@Y@@(\'_X4%X./T2?@.3L)_#:9:'3H'.D?5<:6Z(FGJ
MS$DLB[<!!1/RCYN>;<-Z6,(8)0TXZ)YS=O4G>II+W."7GT@=2PHSQ\=0"+(5
M6]AS:"%+ %0FNNL"ML!5&J+RAA<8QDPB+\2>26T4:'A-)SCP-ZJKLG3H$M?,
MWX%(G%J.N^1Y/'KPI9)21AX!:'L&"V7V<GWI,^Y1]6NA6#CW'W#'N@.35Z<P
M\I=$N,E>S4ULZN&\0W8ASI?S+.598IF=D%Q(+9\Y!#=LHB0 =:ID@%8CDCH$
MMQ)KN@$D" 9;!H3$_E6"'<W%?N!,@(U@%#N03$#4R50U9ZA0X&T@AE&!/DO/
MMO7JCH-/ST&_$#HUC8RPG2FV8$:V^+^?:H6"\G75!.G'^:_!8V\>\#^7@P=6
M3B]X$;*$_^R*J09/ZB9C<#"3<X5 2T95XV5BG+0661^+/62=;)Y[<"!H712Z
M_D0&ENM:DX]G21<+BNX0-VR?(MA@?Z  6>T6%[*:8U0,Q<XDL]UJ',P6O>->
M!W_/9'()ED?93=C[9\N>Q3@]]"%*D*'_$/5_X@3Q.A\]TZT)E.W>)M!C\IZA
M.13Z[%=?GN]M;@GAAB[QVG-TDSC.KK7HNP2NTB@S2.R=F5*R%6\I'#JR@F7]
M2E?59(O:M3KYV$LW(O;W:(VABZFX6/-<'\7YJ=0[!;%N6M2C]!QF),.P[)!#
M3.$RV-DXEC'#P5]U&!JM;UR-A7;OB^Y0-6&JYE!7#;2IL0H.'\9SL)IJ:XZ$
MJ7Y=6Y5(*WY6O\09O.?"HPH]*F<,)G+H^WP&4E+'!K84_(:% -IZ)^)+EL$I
M\)>3*N#HX?H_*#)6'F@(?/=*AD@[% <K\QS:YA4B-+N+(/<32=MF)KFIFMW'
MYK'9=ZQSB9WLE[J>2P4V0$1LY59;B>?WN"T!]G.M1U+:ZVN36QJ=A65%U<E2
MCY"W.8YY<Q\&^0CB%X]?FMY$LUR-#'7PA<XD_P?GE[-VY_9,P@X/=,"@)4:I
M*!>J9;E:K 4:)YC?JFSVH6W[+1G8GFK/I (]>EK()!'Z5DU^L$_&BIX7N_36
M6%[Q^]J<[L ;,D36L(N.'J(&A+]/!V-[OFU;!+3ZK7_W<^W.3:O39W;+V;;"
MZ]-4?2:Y@4W4[SEU!'"YE%3C59TYG[81A:DGU??;><*GD^JJ(&G\T37=F1KJ
M[!(,>%K"2IO.@' ZN^HWKN]:>":V"?,!RO2DM*I!>7&(@MUZ:#SVI;9TV^XT
M.LUVXTX"@=M]O/>/Z&6^^*UL] ^R\H)U57\3!W>M:=)1G;9+)E+^/*O(F;\_
MB=B-JT=9$M_+YN'[&YN%4'@ D;G)*;]4]NI( K*G^\[5!/PZ4(??GVW+,[7<
M$$^77OXT'!(R&J5&V15AZ!2DU3=5&MMH=?\T<-"K,35B8N3Q6C54<TC BR7$
M=235E=XT2I$^>Z;J:;I+-%;EU2-3UW]$\1_Y=J&F;JQON%EI2J B1] <T7]2
M%#JI<C4?>WB$[.VX5I2_P\Z]--+7G1)V]FM>>>G"]TA0R,:R&&\E '(]=I:-
MBH(38?F28'G>7W[J+$_^=F-9/HSMCRT#?"\'2^7RU:\2:^(M),"&$J!\2A+@
M4-[)!SF.4)@,1ZO-AZ;JC*5;PWH5YL.FPJ,BA ?'[\ST>)\04(D)J([EPK=<
M2YI+JMNPA&HNLU;DQT]/"M4X@J200KR:,/O@9KW@9U(*Y\N\N*_IW*NF^DP%
MR"='NM&=H<=ZL*(5TS!58^;HU!J:2QR40JSJ$Y]Y)(YG+,=;3D30%)13DC1"
M/*3.CT5?/!3Y$ \PG7]A ;8.-@:>1D9^AS\8P>\H+@P+;[1Q)'5@>:Z$5SD0
M5WK4G>\G(P2X39,(&^$@A4#)%P(E/H1 B49(P)<P'"H 'FQK2#2/7J0E&/SH
MM/RAO),[<F3(G$$Q4,BD4S#D63E<FS%E3+F0(*W@M ,FQ[ZU<L'DS'6'7Y_,
M2-O1GFH0ZH;["<](SRQ4VT\.;2=(M3?13D9WGU1!PZ&\DP]R[%NB5'R!4N%#
MH,!T6C_&^D!W3T8XB%H'#M_)!SF.,)7HZ,]G5ST81G5/R7O/HB8AJS.-!W18
M<.ELS<  %HN<L)'>'":,)=Y&0R9]OI!,(ES##ME1(F!-$.PWS;53YL$'.0#!
M<C?_]$!A&7BT\)>S^AD'G+WE:4EZ$B3N,C__M.2&\.!L$YI=9*%>ZT:Z;MPU
M.LV6U/NMU>KW]GJ$*WCAZUAW"04JN91,Z]56$U!OL0,&XDI#5)_-:50(:10>
MZ4OU1&%V*Q9;G.Z*!=LLTC2^=URL7,[T>.Q-J]FZOVX]8OWM^F.R@C4Y)F.O
M]=#WZ:C(<7=D\B8 5NC^E'KC]GH+.IT#D,6;^>\?H5^-N"AN,T8?UNVOQ=Q#
MX^:FW?DUNLZOIR-0!*WYD#E'":Y#U%:?GSJ-IYMVOW7SSAUG)R,B3MP=R"Z>
MZ]\O(L'N$]>YC-V2H"%,YF@8C?:-ANR7+C8]ZZ5SG>5E(H&>'<6RBR'^@)<?
MO:@&"QSO?_]B1HY7M/'S^<<J &ZMO6G[X9A&G1BN'>G:7[52]2RN:^=2XV?/
MR3VKZO02-[UA:OB?UGS'&VY3M6UL2/Z[:GADP^:=2J1UYU/OYNRJ6)7S2EVN
MYZLQ?3NYHZ= TC*2:BN0I-1S125;)%5DI:+(^5)<!]@#DJQ9U[XRR?ITWCN7
M^C91'<^>2=>Z8? J4_=F"*3 /?5MY' /[P3L$WO2-E^(X]+#R8O,\C]B6QHP
MUUH^R7'''B<Z<NKP*BO;".?WX;6Y+*[(^7)>+M;*W&'M (S<1S(DH!L'!A$B
M.'T>R6\C@AOL8AUG3J(.<8.K27?DE7))KF,W=\X8Y41'3A]PA6V$\@D![@",
MY >;3%5=D\B/*?:+$>(Y?6XI;B.>??JT&'D^R";50E&NUOCCDQ,=.7VHE;81
MS(E"K5ZOR24.H78 QG+/FTX-/(SGT2L0+5MZ_#]U,OUZ0\/$\%5O!)OIV?1&
M+2Z ?,PL5-Y$6@]?)I<!V9Z :K>6_:@U3.T^2JQ=6:D@*Y6J7,7F IPQTXF.
MG#[H*IO([;1!IU3D<JW$'>@.P*BF<:><2^P);/'4<G3>LGGO'+GAAJ<VFF<2
M+)?/5S87]$%4\<:G[:X\EI?K>66C/&%LH=DIB5R!VY6XW5Q7K,=M0ID6'J#*
MX_G=DV+7=RRD8UON*8Y\2B3FVN2DM9Y]RU4-:;A0\<G#SO$,T03\M*V*'1J4
M*A^,JY7R<JU2E0N5/'>.V8F.G#K**EO5/"2#LK)<J.;E<H$_E G;CF^\']MR
M3W'D4R(Q_[8=NT^!2 91'2)1=8$-9CSX11AZ&:G@K4JJ?(+=(;T>\=7=T9-#
MJ&+>.518D OE@ERIB"00)R.GC[FMJJK2P5REGI?K1V0$9B>T_1MNS&<AMO?(
M0EN56H4D2Y*)"K*2+\EY#LO&3W3D]$&W5=%56J K5^1\51P;VUYP/]@6D,2=
MT6(K/(X[Q6,C,GS3Y03!Q\P[&R7AYP6+C%0/AFJZ#5-K!=3J?,#H*<J%NH('
M>+GCG1,=.7W0;91!3QETX-G)Y8JHE]U!8*O89Q<HZ+B.$-/9<,Q6S1; -865
MW^DO1&.T<GZU+6?GJJE"J<IE8N)$1TX?;%OU8T@:;-6R# J".[#Q;T??'$+A
M*_^E@VD4#=8J6]4M!)1DF>6.90[CDLM'5#XH@,H+4*M;E3YL!M1CK<\6A1%\
M6T+'MMQ3'/F42,R_B<F*7GE,IBWIQB+,6+.\@4'F6B')[G?O#9>,+MZNK0RE
MRL[-ENIRI9J7J\7WH[#+JK<H#,;C@=QVC64^!#GJZ-?E>N7]3"T/D./IQLC]
M@U^8 L>[T8+$/,N3[*R]NW;CNGW7[K=;/:G1N9%Z_6[SG[]U[T -]3Y)K7\]
MM?M_\K"3 K*GL-&"Q#Q+I6/: P&V4]AH06*>Y4EV5DYP:8^AJP/=T%V=<'-S
MCX#HT6^T(#%W4F@_/2B#)LW25)UABV8>MBUF9$ZOD*EN5<8<[/4#V^H/'MW/
MR_EZ0:X5Q(&3@T3.5K7(22.G@D'P/']'3+DVVT*!:7M$]%'/D%6V*D+VZ7,W
M-ZL_R"VU>EVN*Z(,F9.1TX?;5F7(R<.M7)<+^0,O1-Z/+7OC$<FU)#*9&M:,
MP'<X@>PQ,\MV!<8>Z5O=T4@?$MOIVCW7&GX?6X8&OWVTCQ48-,H&120G1?TC
MQEUMNWKAU'!7J)3E>ET8TKM(:V+K+ZJKOQ!)-QW7]NBM?7+8VW)JV93FG$#Z
MF)EIJX*_.=V2,WH*<KXNXAB<C)P^WK:J]DL#;Z5B52[6%.X0=P!&-FU?$LU:
MO9'8G,#8?Z$X7T59;J,&27AY *7O6TY[8+3=N>@6NQX4MZ^X%:<"3QJU&W58
M2@^UE7I-KNQ0)\[]J4!10242VV)D0>+#-D47[\*(F*0\[!_/0$U ,V]5^)"<
MXU:4B\6B7!+! EY&3A]I6Q5*)(FT>K&*%[)RAS1AZ?&-^6-;[BF.?$HD/@!+
M;_%F#&L  ZDHBUD?2.RVSG4,DC\ ?U@OU_-;M5R/WEH0Z.A9 HV;"G*MILBE
MDLC\<S)R^KC;JNMZ6K@KTEM:BA5Q:_H.TGSYR@PASSG@J\)610"+MQDDR5ER
MO9:7BR7^<K,G.G+ZP-NJ&B UX!5D&%,N*@=^E<9^[/.N.R8VOQ%8D4VED;2M
M:G4I22/AM"2,];*L*.\+=AZRJ0*UO*"VOE6E[VFC5D2&^3:6CFVYISCR*9&8
M:\LSTAF86\.3/WPFH)"W"A1$=/'.&K@F%PN*7*CQ%VP[T9'3Q]A6,8$D,%:7
MB\7R1GVHN1;"PJ@3&E^,+$A\T$9=TYI,=)<>!Z67\Z(FT,UG8@Z%@;<55F^[
MG7ZNU_Y/ZU*BHTKT#[>-^_;=GY?2\KC2?>/QUW;G$@GQ58I1U_YD5BCM?'[E
M<8U8RS!"Y8:I-:,T3NC",2[(=8HC<PS1577+L8;E*4!4F)>'PRS'L-Q3'/F4
M2,R_>2GNDSAQB)[HR*=$X@.H@GRPR8C8-L$QK>%W6?K'*K.UO%U+PO#%M,_5
M@VICQRO5)=KOJN&1!V+WQJI-HJ9JNW.[:*P^T$><LZOSF,:74]667O!5N943
MWJX]U^*$V= -SQU;-NRPMD-(-YA]05%B<_<._5Q2PS&^2FO6LE4L.FXM;<?Q
M/K2.MRO(2?X:=/IN&B:Q/-=QX0?P47A@09YE70)EZ%LUI5U$!>7#5"Y5/RD:
M'S.Z/B#PCP==7+L23(ECA @(]YX&KRM;U5ZRMZ:MOJ6<M!J JQ3X>_--4'M7
MF/;>5(.O7LM6!0MOUO)A[5W"PT)U68GIMX]J>Z7A4=\Z5KDP[^[<'/C@Y)6J
MG*^]G?Q:"T127>F&#,ED0&RIF)<EG#E]J$>FKO]GA?U9EN ]4S+$'G_&C!,9
M?\S:95=A%*-:MNFY6)#+=7&NAY.1TS_7LY4/F"3*E&J!.Y0=0$"BH6DZ[I5J
M2%-5UW*Z*0W5J>ZJ!B>0/5YFJ=57=;F)O^,DI-0#$*IM-AF9=F^>7Y5K=?@W
M1LESL/FG.'+Z@%L5OXB_Y21IP)7D0KTFEROBGI-=!/5PZ$T\ WU"V.61/M1=
M3F#KO_"D3JY]7LUCJZ(XL4+]D;BJ;A*MI=HF.%!.A,HWC,@[LIODP'1_.<L!
MWQ4J<KV*KNC[IYS7GF?;YE*]+P*7O.%RE?\7*_NSP&6^)N?K%;F4?]]P3QJ7
MHOZ);U/GV)9[BB.?$HFYMA\C9R:=R"58GR3RMZ>[G(5>3TI;K\X<;96)B5YM
MUJ(TW=5'*^?E(OQ;*A_&]0<"L-P =E6Z+=:Z3!"P%;E<+,F%POLQ!1X *^Q.
M892<QD8+$G,G3_9C=W;[C3OIKMVX;M^U^^U63VIT;B3^J_&7E&81UJ-9WL @
MN\4=_K&=CGXS7#)*>E51ZWM-/!JFEIS*KM3E2C6_4=>%995=%#;F\8!Q52OQ
M][I]) K&:EFN 2#K.]SWM@\P"OM1&!>GL=&"Q#S+$Y#<!DS._.6L'N[0.[;D
M[F?^HP;EPOG_(0'U8<,H/4)@DUQX@VNA4M&(Z1!-&M%[ '0:]U1=0H_TGR\M
M_L(=6-H,_ZN"@DMTA^D;@]<-+!NT%:6H;CY?*O2%]-5OUNZ#0%%^!@T)&)RJ
M&A;7HO:"E[+IQM+L+(K?\70PMN?S64_MLS76QL  )$2B1E*_]>]^KMVY:77Z
MK"=#'$F*&PTYW^]/4_69Y 8V4;_GU!&\XU)2C5=UYGRZV@2N_MO(Y.J;*HUM
MU.\_@9$ _@<E@C62L)$# N#;A0HOP@?3!L'&4(CLGT%&;HK0X(IKO^%< KBJ
MKOH<3DK3G:FASBXEW31TDYQ1J]%QK;.K9NLNUVNVI6;W\:'[V.BWNYUO%_B>
MS5'"V2XTN\A)O18ZQ8U^ZQZXJB=U;Z7N0XNMKW>H*^O_]MAJ2??PPM]Z4@M6
M>2/=M)JM^^O6X^+A /A!.=1%?G[J-)YNVOW6S9<MY%2*%D36=M)88W922)9"
MUC93YC:IV.*LK='C99OD<G2!2(K")#--[MJ6^7R%$AW4,?LE;IMC<W GP[_'
M1FN%5UKO4Y#L/6"Q/RUQPE&BD]GT#6,(Z2<6Y_<)DA]3C/<XESSLSPE#0VPZ
M5_S(004 $PN/Q"&J/1Q37U\C+\2PIAB+Y6'[8D9.,I.:Y,GJI3[+M[ XEKQ7
M<DK>M=:=,6+[WS"UF_GNMYC4W#F++RNUHIRO5+D[R\?5R+R"J1P+)B4")B5#
M,)7E4KXD5RO\]8DX@!/\OQ(3+"&#2E=5F^BF#DZ9BFU5^.()42A-.:^RJQCW
MZ0R,UUB@\@=YKX!\)Q<VN *7AP)J 61N@%S=586D!.2B7,Q7Y'SY"$\"[/'$
MF/7&S1;,R"$SUG;5*F$8Q>>^G2]3J\FU$K!@59P<$]#="KKU7?5(@M"M%A6Y
MGC]"S2%J@+/BE>,,+Y[HR*=$8OXMT7FJQ[ <SNQ/_L#Y\5Y!]:+R87.R;0ZM
M";D#>GVX4=#FEN6AMZHZ3C#E/VS@)0JF36T]T5_J@$<^)05^HB.?$HGYM]%^
M5753 K&O$5M_H>%<23<=U_8F[-#-_O>09[!^/(Q2+.QJLMV$%$,:HI+MFO._
M=<BNG1ZOBI627*[SU^SW1$=.'X+%70V]U" (;"'7BOQ!D.NR N9SNV-BPPZ8
MN7D&Z!F((T1Y!A[3SJ5>E&H=RPQIAOSD($/M'!V?NT[@-U7K6UP6()QP?D3S
MSO5>*2#J*E_(RQ7EP*7R7JSL-A["(8X;).-E^ YG=;0GE=5<(\-WKO,*:,R"
M7GYN<W<;:"Z_"]6BK!1+XA* $T;ESD5;Z:&RHLC%#6Z($U< '-G(IQ2_.]&1
M3XG$_!N/(*UI EWB8;MXQF42BG;G@DR@4K+ISEIA.V?K0"V\XX31SL61R<*H
M*H-#(]<J[SL/^S#)LA.A]Y:FCV (2B5K)+VJMJURE]\Z*6<GQV.-KD !-RYO
M:>ORH^'+Y#+*Z-W1'SZ;?UP=E^5J=?N^YYGZNA';]#@9@QO\'Z<C=*(CGQ*)
M^3?40E]7?5%U@W;?I:VA)Q/0#<Y8M8E_?0 /V[E29Q_210]K-/#.I4D+3DPC
MH&3?:E(Z1F^!N%8=?9BAM[SV,H@#]:"/$WP[%R5E#SZE . KO5]AD33XA'DH
M;(?3V&A!8F$>+IB'4V(O6(4\;)_ Z2ELM" Q=Z)H/^TQKQN]=I-V;[MIWSWU
M6S<\[-L'$SK)MS)<8^''U[9NX%ZV5-O4S6?G@=@]%/[4CL?&AKKAN42+FNWM
MSNVBX?Y O^%$['?EO+!%_\(#]1'Y1T-\W>4&_E[B:,ASF2P])NDNU.@I;+0@
M\<E;2M1I^X-.B6B2"F.ISV3!<7,DRW,=%\PHD.$\[*< [BELM" Q=[)I/UVX
MJ1?'PU[Q#,J/'V0L[5Q7&VB/!E,>'6\R('9WQ SW[EQW[)K,\3V JU)15JI5
MN5[9POP_!6@<,RAWKM+-"I3%FERI*G*AQ-]U'5S;G4RV\QV7.R)&*N_<=W %
M(_FQFS?\]$'Y7BO*I6V"?:< CF.&Y<X=#+.#)4CX:J4J%VH'WE9!1"J%JRA&
M%B1.(QH07@I9C\XJS<N28Z=^X0XL;8;_Q8+"1/<GDT7U" 'JNO &6E)M:M@*
M0I-&NJF:0UTU8 ZJ2VC?QW,Z*[K.8&8#R]:(35$"&N]2H<ND"WXS+1]8BO(S
MZ%_ ]5354$NB H27LDU<<Q5M</OV=#"VY[NT'D$+KL52A>K  '1%3BE)_=:_
M^[EVYZ;5Z=.MB[NA^ZJTT9!STGV:@J&0&]A$_9Y31_".2TDU7M69\^EJ$Q;P
MWT8F5]]4:6RCB?"3:PW/KOJ4"-9(:J(E0\\LJO B?# 3:*X'063G##)R4P1%
M>#%L/A23[[B0Z=ZF#I,)D*JZZG,X*4UWIH8ZNY1TT]!-<D;-4?*W>W;5;-WE
M>LVVU.P^/G0?&_UVM_/M M^S.4!XVX9>O]%OW0,?]:3NK=3K=YO__*U[!\S7
M^R2U_O74[O]YL$O[_-1I/-VT^ZV;+UOP;XK:.FN;9*SM^TKFS.T_L<5BBP]W
MQ6*+Q18?^(J%?CT^FHHM/O4M?C>2/W>K,G+>7-LRGZ\:X(%BI%TUP ]C?\IP
M3X-9!'O+YPRRY:3#V)/]ST!096D&J1L.![ ';W$1'P_=I5]3(#OG4*MD+:W9
M^7V)'N#G=?_W/X,C4,L/JJ[EVB:O.[S_&1P!C1O#H3?Q#-4E&J^[O/\9""TO
MM/R>M7PA:\' ULVJHZ2U!(AMMBC$Q7'"HC&Q/-,5>!!X\)T!=:J[[\1M!"!.
M"! W9*0/=2$A!"#\A?8MCN0#3WFNO1>Y[B\;<\*5Q6+3Q::+33^VI8M-Y_H0
MPU[:K5PW[AJ=9JLG-?I2M]GO7K<>I;PLX1E,'C:0)]1N'2U_[\AA/E]=ZF/6
M<+HC>OQ5J>>*RE_^ <._(LVH[PD>+EP^@<@B8&W'\;"%V4=.O1:4JIRO;7'_
M]RD 87GD_;;%6WF"M:XDA*9(U_/6WY[NSG:] [Q4+,A*M2#0='AH N%4W0A.
M\[HH3,6V33_8ECJTJB6Y4*_)Y0I_9Z&Y&IG3'IZ K]I&^'HDKJJ;1 LZ=Z8,
MK'ESSU*^)N?K%;F4WT* B8ZO*0FC^CJPI"=FRA6Y7 1)4^!/RHB."WS[!\>V
MW%,<69#XZ$<6)#[ZD06)CW[D4R(Q_U%E_RIEB?P@]E!W"&<7</*'SP3:UU5C
MV]?%=%5\/Q"(=V/[)&P%% SNOM@YN)RORU6ES)T7=:(CIX_'C7LX[X9'5N.Y
MJUN?K_/7(_=$1TX?B?&-F]<A<:.8=@JH+%?E:ED@DY.14X]J*OGX6\UB>LYN
M& [?%)/_([:EJ<YX+1QS HA\C)RZB*S$]SY>TY(['>%7+Y>XPQS7UY)0;XME
M.*2!B@TZA]9D2DQ'I03.260R-:P9$1Y88DR4XV MISAR^D*PD*S'PMCR&KFR
M&6'*5L"10B\?^LCI0[*8GNNR"SPWU^9%N5 IR(4Z?VGS$QTY?6>F$'^OR\><
M&2%$CWWD](7HUE>'G[)XY#^Y5%+RG[]_H22U]8&'N^9(4U!VDFZ&M\6ROD]<
M /R862O^'O:=3.:%VCUVE.'&LT$K/!!;M_QKE +VNR8F&>GN@Z&:'TA)5>6*
MR$CQ,G+Z8$TP0_H.6']7#8\D@U6J+JK\Z8D3'3E]E&Z?-]W^!$;ZB"T7Y%*U
M+E#+Q\@9.'])9[(2P:OP! ]IY-1E:W7GFV>SDYKE,G\6*?\I,$H?234UR9HR
MAU"GQ,++ZV GPRP8TD5RB/VB#PDGJ#]F?MLXK9R0>\C^?FO9/4;B#]4KUF1%
M7/_,R\CI8S7![-\F6B,)J+*ZB9H *2<CIP_2E/*!V0*V5)#K K2\C)R^;UA,
M.C&8 %R%9WA((Z<O6+?.$68L,HLR; IW<.0_6=BE[J XB)8A*V6=$Z0?,CH[
M02WR1[J@5>2RPA^KG>C(Z<,UXZQ@4FBE>J'"7ZSP1$=.'Z=[S LFBME"7:Y6
MA7SE9.0,O+]]9 8W0*SP  ]IY-3E:RV5W&#2DK-6Y$_C'T!V$"U[FA%4S2$!
M,CNN< 3%>;C#'CE]S5V*3]^NT]QK#\11-FS[7-A$)A0:^7!'3KU#<+VV?4IV
MX]-O[V%QEW[!9;F^C4-^Z*V"#P]J:T1=?&+U8V?7A+P[II$SD'>E70ZJ':8D
MXS]SU"&N9%@.9X[".]<M<L 1"5P(N=*UB+V$\92$T"FB8(W6WCZT^&[N!MB^
M;0ZM";D#WD]%7PL0"Q!'01R?+U\'XJT2.P+0 M I 'J-&;M]1GVSA,\:).]@
MY-;D:JT@5Y3WC]:NQ?>!>O$"JPRK&V?5CQ6,XA8AON,*Q[;<4QQ9D/CH1Q8D
M/OJ1!8F/?N13(C'_$?CHW?0WK6;K'B^G+W)Y._V2LU*$)6B6-S (M_[4FRDF
M4T6WZIK6;2OHD[O0OER7E?S[%]HO^U5%$<1:A>0D[PC. I7Y_'+CEYUAF=SU
MY<6"7*Z_7P8O8'FTL*S7\QNA<OMC',D@M%J5:W7XMR:$YPF@='6,M%[8"*9;
M'-I( I^1:I5"1:Y74<O7/@;4XPCE'Q+H5F.NN YSZ0F]<EXNPK^E#9JP\2#S
MJ ]WX0XL;8;_58$*B0Y"WQB\;F#9L,%T4<#?ETJ4H 89L0'H4-+RZ_U]492?
M@:P IJD*.LU\1@+ (&SZL:YH^JF&K+VRL<:X"1QK&!4D6"'K.$/FZEAL\4EN
M\;M:8$A P-L+$[WM=OJY7OL_K4N)SE2B?[AMW+?O_KQ\(U:D^\;CK^W.I;04
M.OHJQ8[BN+9E/E_-[>EO%_Z?,MS38!;!WO(Y@VPYZ3#V9/\S$%19FL'J&'9"
MAL,![,%;7"170!/(SCG4*EE+:Q:3DWKL0A<^]W__,S@"M8S!K5S;Y'6']S^#
M(Z!Q8SCT)IZAND3C=9?W/P.AY866W[.6+V0M&-BZ6=I66DN V/I7(2Z.$Q;L
MDD6!!X$'WQE@J4\!" $(MM ;,M*'NI 0 A#^0OL61_)A\Y++8SQ2LY0^WE\V
MYI0*4<2FBTT7FRXV76QZ1IJ;Q\,2W6:_BV<EV%$)A8<-Y FU6T?+-R@PCR_E
M57)*/5=4,C_W4*S)U:(BY\NBS_K:D9.LBTRR)TPY_KS"]G!*K#"R6*O*1:4@
MX'2 <,HOWVVY D[[.FB@Y.5\M217JOSU-N=JY/W":^4! <!7?+7V,K[V=D*@
M6,MCYWP08.\?93GTTP"<H&4-6$KKP)*>F,G7Y6JA E*FQ)V4$3UX^'80CFVY
MISBR(/'1CRQ(?/0C"Q(?_<BG1&+^P\H/M@7#:HXT@N<D=TPD1S6(9(W AJ>%
M^0XKS-__7O(,V@1"@DI\5]V=+V,*"(OOZ8])#ZC:'46^X8>2=X]!YV5%4?!?
M[MRM$QTY XS&=]--#:.L/'3G@(! )T<C9X#.^M;HW/@ZL9216I3+I;JXEIZ?
MD=-':S[^/MJ/W4BV"TS%+66'-'(&P-SX5M!L!6293P')_^W(?ZBVK9JN1/S[
MJ3F[\>PXF2C^:M.=+66?AL$5X\['O;>R,([Y&3D#0&Y_ >I6@/R@?!>%;+R,
MG $4XZ]!3<1/2Q:6M;J<%T*2EY'31F:]$N^2[7ZQV::(%"[8(8V<@83<^,K(
M5&5?@4.MS']&C56Q20/5(1HFT:;$=%1*X)Q$)E/#FA'A@F50M:KD$\ZH,<)>
M(UV;$;*V II^U">;U[,6MO/-#KV2];A0EW".[#W4?4C*1R G\,8QWM; +<6D
M5ZK0NRK*A7I%+A;JW-D8)SIR^OY5O./_,?]J%Y *?^N01DY?B!9V2GEE(AX5
M_L0C_QFODI+__/T+):FM#SS<-4>:@K*3=%/4-6;,6PEFPA8.C;%#]#>>#7KA
M@=BZI3$_*N"_:V*2D>X^&*KYD9/V<KG"WX&R$QTY [0FF"9[!ZV_JX9'D@$K
M4Q@5 5,^1LX IBFET#*&;"DO5XJB*0 G(Z?O_\7'*G;W_Q*!JW &#VGD#&3K
MULFW/4C-:IX[0/*?F:/TD513DZPI\PEU2BS)M6!?S# YAW21'&*_Z$/"">R/
MFN$2S--MY"&RO]]:=H_1^*-UE"7A('(R<@9@33"]MXG>2 *KHL22KY$S0&E*
M6<&,$5N0BZ+\DI>14W</EQN'9>(>OH-6X1P>TLCI"];BUIG"S$5FB4-%SW_*
ML$L]0G%&+DM>RCHS2#]DA':"*NF/=.$N"_.$GY$SP&O&N<&DX$HU0WF+SKBG
M )>C!NH>LX.)@K90!&NF)H#+Q\CI.X#[R ]N %CA!![2R!G(UU0RA$E+SG)>
MY BW]P/O+4T?P1"4Y-9(>F6'*H4_F!1;Y3A8RRF.G(%83/B\9905NR/_=+,X
MSW'P(V> Q.V3M!L?BML<E=M<72(NWN)DY S N7UN]OU3<$)6'N?(Z<.QM'$?
MTE.4@OPGKF@R@A8RJN:0 "D=X:P(9^7 1TX]U%B+S^.O"S6N]54H%[9])FPB
M#PJM>[@C9] FIK1]\GMC%^4],.[0'B:?K\K $J)'#+]@6RWKXO/6'VN[(03>
M,8V<A<#;."E]!**,_SQ'A[B283F<N0K7W<>;UF/NNMOO=^\OI3S,UK$,7?O*
M#4^\,\,/.1</C9N;=N?7Z,OWL7"!@BQ1L%IMEY-S48+\,W!]VQQ:$W('K)^*
MPA88%AB.8#B^4F(=AK>J1!-X%GA. <_KS-CMD]R;U:BM@?(.1FY5KA<K<FV#
MUE5K 7Z@7KP JP_6C?/@QXK&7?,WQRG$N8%_B/)C6^XICBQ(?/0C"Q(?_<B"
MQ$<_\BF1F/\(_'7CKM%IMGI2HR_=M)JM^^O6HU3,RQ):Y3QLX4I_J@A+T"QO
M8!!N':HW4TRH6&ZI=K/A=$<['?N-]"'[2'/JNERM5&5E@S.2RXY54<2Q5D%Y
M&S?S'SS ,E^I)01+_&AL&1JQ'7:[P<[-J.O5C9I4"E@>+RR5<GXC6&Y_]CP1
MB);R-;F05V3@'@'3XX?IFC!IN; 13K<X:YX$0.?ATV(-]'RU $BM?@RIQQ'.
M/R34K0%=<1WHTA-[A9I<*Y9!.;]_V(('J4?]N MW8&DS_*\*9$AJ$(F.$K[K
MMMOIYWKM_[0N)?HRB?[AMG'?OOOS4EI^G73?>/RUW;E$?^ZK%*'\D !-;=B*
M'B&P+RY\R[60TAHQ\4;8D6ZJYE!7#1A7=<D$'G?.DYI)U,.,GQ5;NK\!D<VF
M.QM,8&#9 #1*7!!TEPK=6+K%;T;W\: H/P.<@8NF*FAS\QF!!R]E9(MUP\^B
M'#B>#L;VG/CK'?BS-;)A8(!S'TFG2?W6O_NY=N>FU>DS6L5M2GFC(><4^C15
MGTEN8!/U>TX=P3LN)=5X56?.IZM-(A#^V\CDZILJC6UDS9^ O\^N^I0(UDAJ
MHF"@70=4>!$^F#8S; ""R,X99.2F" K+@%%!]]5#F?Q.."9-COF&<PF JKKJ
M<S@I37>FACJ[E'33 ,/@C$KWX>CLJMFZR_6:;:G9?7SH/C;Z[6[GVP6^9G-X
M<+8)S2ZR4*]U(_7ZC7[K'MBI)W5OI6:C]YMT>]?]HW>H*^O_]MAJ2??PPM]Z
M4@M6>?,F&I>G=P8LAN4.:Y&?GSJ-IYMVOW7S90L!E:('DW6T<*PQ$R\D2R'K
M^'?F3J+8XJPS"\?+-LE5+04B*0J3S!2Y:UOF\U6!GO[P?XG;YM@BI)/AWV.C
MM<(KK?<I2/:>MMN?ECBEL.VI;CK_V7\^S]^E$D]--E:_\24ARR'4!]L:Z6XB
M]<PUN5HKR!5EBQMW#S3T?@" B#\FMT&->X* V+S ?1_%[)E(-6:W-+3_>HY+
M@]H8]K8)D&:H&P2^R^0=_)53D;?O"J;CU,0G.O(ID9AK8ZM(IXS29Z@Z8\G#
M%)QN2M:4V*JKF\\2RND7W=6)<\G#9@K4GL)&"Q)S)YBRMI>88+HA4["1=-9N
M'K-,ZL2"0?]'_\##'O(,UB2J<.)/R&[@3D8IUS"U1H1NNY;FU&KH1X@;Q3@9
M.0/T;=P*.@/TE<N*7*D=> O>_9B7]#Q&;J"B<3E59\S]!2I(CG^?)R>(/F9>
MJL3WL=Y D@?MY;HC6F4)[!3TLX[<R-JUFX:J3W:^F;60K\G%O+C+C).1,\#C
MSC<%9X/'4DVN5/BS-0[ 9F?UUQ(3]T-K,B6F(^SUC+@JOFWR!E*>ZNAKI%DS
M0K*=S[?)A4I!+M2WR "= @".&GH;7_^;.O3J%;FHU+F#W@%8ZNP(++P1%"NE
MIJT//!?DN&M))27_^?L7:6JH0I)GP$Y;)_*Q'W3D"'-S3KV^U9I,#6M&R#4Q
MR4AW'X"&._O!!;E<+G/'7"<Z<@9 W+J (",@EO(;':'G6LKOQT+_5<44'XCY
ML66[.9?8$TDW7XA?F, )L@^?I]94Y50V;OR[;"PA[; FIVNVYR3[<(%.);^%
M1#_T6JW#0]+>[]DZ -,5F0*%VE3%HZ&2/IFJNHW<P0D6#A^%:\39SFG"=DBF
M[JAK/EMXY[MM_9<,=[XFL:C(U7J1.[/@1$<^30FX7[-.([;^HKKZ"P&SSG%M
M3YAU&9EUU9V3;'.SKJ<:I#NZ"6GX<>.N6"G)Y6U"L<+ XPE3.R?*TL14O5B0
M:\5T,74 1F?TGF=L3/+J9R(Y@>?A,\;>]?Z)CIR^SU#=.E^T\F)U<:-ZID+O
M<]L<VD1UR)<+V%SZ$YX9 , 05YP2.*D2\A,=^91(S+T5QM2.C@T$W<O:U#V[
M>B1# I;NP!"5I<(0._"1,S#$XG-1FU1B^G; C6\%M,T(Y^U<7P">9;' 7R4P
M]X;96SGX8).IJFL2^8%55? .3C!]U-P4?P'F)JF0-]SDTZ_%R+>SEU,JR>42
M?Y[.B8Z<1<APYWLM4\)@)!8-TKU:2[?8X  MUIXWG1HZ?)<>P,>C48__ITZF
M7V_HH5=XE3>"C?)LW7SF!,;'S4#Q!P]W$N+WJDML'=BB86H!F1.HUY'SQ2TJ
MG$5&1[CV!VC2GET%_'3Q.0@U?L%8HZ&K ]T0;4E.#K(G.O(ID?@ S;?&< B3
M<AT\W8[!#QZVD6>\)F&CU78^ZOC61@OH]\#(]V'SK%PHROGR%BZWL,_XB>#4
M=C[(F!:P:$RT4CWP$XU\Q$2!(K9'YC%13F!]U RU<T_B6(9"\MW-[?]=>:I>
MEBO;!*). 0M'C<*=&R&GB<)\J2@KAY[MXL,(O_$('E,G_@E3(=DSX*F=CS&^
MY2D@7]_JCD;ZD-@T5AJYTG/G+CY*759*H@D))R-G ,CX[.M.0CX-0.85N<IA
ME[,#M..[[IC8T3@P)QCW7_C.]5 <L%T"%UAMP(^['PQ]PX^4XMV@,7D"ME>A
M)-?KVU\9GA>7VY\TI'=N2IL!I&D7S??C1#Q >E</XSB9BQL>.LZ<THF.?$HD
M3MF&3>HVSG[KW_U<&V\+[U]*%31MHQ=TTHOCV>UW[]['PL.FGZAUL"8M6=^Y
M!0 0O0DT?["M%UTCVO7L"8@/-D) ^D9(^0_G)TMR32G+]0TB(VLMA0/-6@JH
M^E#=N;- AE MRK5"5:[5/VC49EA&?$Q*55@OI[#1@L1'8*!^+,A*+UUN-GJ_
M2;=WW3]ZTNUC]UYJ=WYO]?H@4Z5&L]_^O=UOMWJBW/:4,'NB(Y\2B;G.]+-;
MD\'.A'$U1QK!@Q)8DYZ--XQ8(^FI)[D82_7LF330#8,SIY@_Z"80 *_'UT=N
M=L4\I2-^@[4D^XT86M^Z]RG:(T/\[P?BWQ4LNY45A;^+>TYTY*-I/\&U]>:+
M2<\>CE4\YP^2<6ICS!"D)!X@)7][^E3T0L[F8$(]OM!P$_GHWXW8MQI#H)A-
M'GPBXC4);L/46@$==\X/5F4EY:Z- EBI 6OG1BWI ZLHYTMUN5;80O$>V\E^
M)H1IHP1-!X.&L#M._7[T0\OAK2VHB(/[?+5SRY8W?-4V7=5\U@<&:=!NB#N7
M)A7D:NG]NVU$=N; 4?G&K#VXRIR(J7MD&IU;6^+8EGN*(Y\2B5.VVO93F3/U
M<]_28"9]]LMTOOC7J(DZ'4[4ZQJ;;^<.3RMJ']H!Y3]<^X!!S'Q!+A3>O\2(
M!VM!@)H;3R:OQ!>?[5[1DQRJHQ4]FX8*]EK1(PQ;8?6(D06)#S5U'EO1<]ON
M-#I-4=%SNI@]T9%/B<2'D*I>J.C1'<=3S2'!O/607AP/8UG#[SQL)L^H/9SJ
MB1,=.?5BK+RR<[.Z:#%6VV? [JA)V8^VNMBYQJ HE\MUN<QA$1;7!ILO&?V4
M(LI"*@3GTI'#%/(!\]2Z,,K.#>L"ZG5'E(4"OFHBY78NK2C(M6UXZ4#SOD<*
MI9V[SJ4!I6I=+FUPDFX?,;:]&9_D![&'NE\U&=S?2ZLFK2GNCI"X&5@Q._>1
MBUHQ_FVPK8"@.QLP^:I<X-!Z.=&1,X#?SEWCTH!?59'K^?=KOX3MO,9V-B5K
M ,/0:Z(=V%^-V-)(-ZD9;6#O)4ZP+?*7BXRX<[NX6T;<.Z3M@ZV;0WVJ&@$>
M=K:\2\"*ROOM&D49YA%#<N=V;ZE LE#(RQ61.A=6T#$G,$YTY%,B\5'6A,[K
M0*/5H<SN%#6A_.OZ?-*]VVX#TB=8/E<H5^2R,$J/'ZAK<)ITX[;D<(K9OV*A
M+A?J[]]^QD/ULK!KA=%S&ALM2,R=/-E+26BGU9?:G>9CJ]%KP0\2+1%M=&[8
M#ZU_/;5_;]R!O=OC83MYQFT2BGSG.TQ1B^._V+CA134PI/1('-?6AR[1\(.&
MJ2W^(?+D [%U2WM['<'0\#0P EH_AF/5?":/JDM:HQ$9[MYN1%9*=;E:X>_F
MRA,=.0-([UR0=AB0KLC%<EXN5]\_G,>UZA&FK+!SQ,B"Q =MRJXT767INO5K
MN]/!@T[=6^FA]=CNWO"PIR*4M6PN+)7:-ISNB%J]2CU75.),!+ "EG1_PVVJ
MMCT#-?^[:G@[7[)>K,A*19'SI0_&5D]!#@H0+X"X' MB90\@SI<Q.2#7E2.\
M!$[8K,*@$2,+$A^KS=J"OQZ&M5J$U6B6-S#(;BGE?VRGM=\,EY#:KJRP/5>&
MI]*S/:MR7JG+]?SVUQ$7A>UY1)"LKK DLX=D(2_7P!TJU;9/Y.\#DL*2%&;&
M:6RT(#'/\@3$MP&3,W\YJZ=1D!K1)D,0]L3^NF+J%^[ TF;X7Q645*+[D\FB
M>H0 =5UX@VNA2M2(B<6U?C&M:L <5)?0LQ3G=%9TG<',!I:M$9NB!/3@I4*7
M21?\9EH^L!3E9U"]@.NIJF'&$#4BO)1M8BP.SJ(\,9X.QO9\E]8CZ&R-'3,P
M %V1.-5B"3)6(,?M5F6C(>>D^S15GTEN8!/U>TX=P3LN)=5X56?.IZM-6,!_
M&YE<?5.EL8TVPT^N-3R[ZE,B6".IB4:,B>TJ5'@1/I@)-->#8+ET.SU0S&7
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M1&'(4H.!Z@\4OKODZ5$#8.F+M%2)YL'44'U&_#^LM]W-W\LJ?[7V+L+2SEU
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M$^J]A_L4>6IDH<?-"E[@Q<_$9M%16]582 !G2>^6\0<-QJ/Y$6O@!4V1/?^
M#2W6,2W)44?$]54P.D<6YA=I-8WE^H4EL(4.IO_H5X:X][:DV=ZS0WNF8*T<
MP\V;L?VH;E@AC#WLJ,OH^GO%W+@W&Q9\W\;>&;1&45(Q:N(!4O*E\_S/# .T
MPC ("R]M&CW.,6'C!GWX/IN_%&N*[-<U,Z1.8?/8X1#_6^S8CK_#4P.@$F[Q
M%SE\%;Z[5#NO_"Q'!L8_5@KGU9_#E2Q?A".ZD&54[9)71+G+^G*7D[;F^-'
MM.]H<%-8Q-WFSD01MMD>KK>+.L_!^8&%&#&KGG=TVH*&QGW][&NH%]4A.XCC
M.\E!FI:US2(NVDJ1!MOT-J&ASIK4#B/Y$YH"H)%5%OX>>Q/:/!3M._@F/7N
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MDSD,4"\H);E8$U#G9&1A$A_ZR.D+JQK/&CA!LSA?+<CE>H$[T<1G:)@9P[2
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MM#PX%G"G;RQ <H;O;>! T1Q*I-@)P&\,\B8DWJ1P#*:W92'1U] .K&\6X%K
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ME2!Z-5OW0THA4K_VYF/WO=9]K]?KW5G_>0GOX:AJBS5]84%7[A7&<T-0KWP
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M5PE,SA8W] N.^<G43DX2_///K@<L_0EX\2I-W>(,;Y4F;V8)H5P)VRT\!.J
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MTP([@OS@'NF^_%^R@EP$:Z>6HNHH"\!G>-ED/\LLU(Q7Q+RCR/LDUXG.Z>"
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M"A4VBPJ:GL:%659?5F0HKG=L*>U"^W&'>"_0<#CD:)C F?2F3G>2<;+3HU=
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M") ;D1OR%;#HTXM\;@,@T&O-.?'R7E&S:[ETISV<4YNGU@I%(;KBH40_66K
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M,U DG@Q DI&.$[#!B#2>%ZQ>0Y?HEXO>S1V0"J 2_/AB8@7NA"D8D0*H*S?
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M B7/)'\DLP!)@225(%OF/8&.3'!GWP<CU)&Y"U5!M=G&%,A'^#7\$$T_O'#
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M>888^8?SX.J[1]5&C*JJ\!59:+5PU950$R<G)A-0^ '1)HXLJYF7ZO%+,PE
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M+'[=[5C;N[%!WXLWCX*Q_?'_ U!+ P04    "  /@DM4-G+A4W,(  !Z90
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M,4&M8B@<ZR5P\]RIMVY+@NV91D?;:D=MO7)KTZ5F0,: #X%K22EN=R8H^B+
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M@JO3>'9IP<FCBNSYHHM_'*7_?U!+ P04    "  /@DM4E^*(6<8#  "]#0
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M;3JOO'4=A]RTUBFO\9QU[=.IPE?J%7CEBZ[_#/#K.6C_7[7^ E!+ 0(4 Q0
M   (  ^"2U3"&K(%^Q   &JQ   0              "  0    !C=FTM,C R
M,3$R,S$N>'-D4$L! A0#%     @ #X)+5#5I6Y([#P  D;,  !0
M     ( !*1$  &-V;2TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ #X)+
M5)H8M2OY&0  3(,! !0              ( !EB   &-V;2TR,#(Q,3(S,5]D
M968N>&UL4$L! A0#%     @ #X)+5/PYPR7I40  %18$ !0
M ( !P3H  &-V;2TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ #X)+5#U$
M_N$G/0  *4(# !0              ( !W(P  &-V;2TR,#(Q,3(S,5]P<F4N
M>&UL4$L! A0#%     @ #X)+5(_T#)_#RP   1@+  L              ( !
M-<H  &-V;5\Q,'$N:'1M4$L! A0#%     @ #X)+5#9RX5-S"   >F4   P
M             ( !(98! &-V;5]E>#,Q+FAT;5!+ 0(4 Q0    (  ^"2U27
MXHA9Q@,  +T-   ,              "  ;Z> 0!C=FU?97@S,BYH=&U02P4&
2      @ " #S 0  KJ(!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
